<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>NO334858B1 - 
  Human CDR-seeded antibodies and antibody fragments thereof, DNA, recombinant vector, transformant and method of preparation thereof, as well as therapeutic and diagnostic agent, drug and method for immunological detection
 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/NO334858B1/en">
    <meta name="description" content="
   
    SUMMARY A human CDR-grafted antibody that specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but which shows no reactivity to human platelets or its antibody fragment; a human CDR-seeded antibody that specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) and exhibits cytotoxicity on cells expressing CCR4 or its antibody fragment; and drugs, therapeutic agents, and diagnostic agents containing at least one element selected from these antibodies and antibody fragments as active ingredient.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Human CDR-seeded antibodies and antibody fragments thereof, DNA, recombinant vector, transformant and method of preparation thereof, as well as therapeutic and diagnostic agent, drug and method for immunological detection
 
       ">
    <meta name="DC.date" content="2004-03-01" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    SUMMARY A human CDR-grafted antibody that specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but which shows no reactivity to human platelets or its antibody fragment; a human CDR-seeded antibody that specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) and exhibits cytotoxicity on cells expressing CCR4 or its antibody fragment; and drugs, therapeutic agents, and diagnostic agents containing at least one element selected from these antibodies and antibody fragments as active ingredient.
   
 
   ">
    <meta name="citation_patent_application_number" content="NO:20040976A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/0b/f7/d9/1cc06285a6d9c7/NO334858B1.pdf">
    <meta name="citation_patent_publication_number" content="NO:334858:B1">
    <meta name="DC.date" content="2014-06-23">
    <meta name="DC.contributor" content="Kenya Shitara" scheme="inventor">
    <meta name="DC.contributor" content="Kazuyasu Nakamura" scheme="inventor">
    <meta name="DC.contributor" content="Emi Hosaka" scheme="inventor">
    <meta name="DC.contributor" content="Akiko Shimizu" scheme="inventor">
    <meta name="DC.contributor" content="Masamichi Koike" scheme="inventor">
    <meta name="DC.contributor" content="Kyowa Hakko Kirin Co Ltd" scheme="assignee">
    <meta name="DC.relation" content="WO:2000042074:A1" scheme="references">
    <meta name="citation_reference" content="ANDREW ET AL., J IMMUNOL 2001, 166:103-111, &quot;C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential&quot;., Dated: 01.01.0001" scheme="references">
    <meta name="citation_reference" content="IMAI ET AL., INT IMMUNOL, 1999, 11:81-88, &quot;Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine&quot;., Dated: 01.01.0001" scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Human CDR-seeded antibodies and antibody fragments thereof, DNA, recombinant vector, transformant and method of preparation thereof, as well as therapeutic and diagnostic agent, drug and method for immunological detection
 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Norwegian</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA164711496" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SAMMENDRAG Et humant CDR-podet antistoff som spesifikt reagerer med den ekstracellulære region av human CC kjemokinreseptor 4 (CCR4) men som ikke utviser noen reaktivitet med humane blodplater eller dets antistoffragment; et humant CDR-podet antistoff som spesifikt reagerer med den ekstracellulære region av human CC kjemokinreseptor 4 (CCR4) og som utviser cytotoksisitet på celler som uttrykker CCR4 eller dets antistofffragment; og medikamenter, terapeutiske midler og diagnostiske midler inneholdende minst ett element valgt fra disse antistoffer og antistoffragmenter som aktiv bestanddel.</span>SUMMARY A human CDR-grafted antibody that specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but which shows no reactivity to human platelets or its antibody fragment; a human CDR-seeded antibody that specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) and exhibits cytotoxicity on cells expressing CCR4 or its antibody fragment; and drugs, therapeutic agents, and diagnostic agents containing at least one element selected from these antibodies and antibody fragments as active ingredient.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/00"><a id="link" href="#" class="style-scope state-modifier">A61P11/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the respiratory system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61P11/02"><a id="link" href="#" class="style-scope state-modifier">A61P11/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Nasal agents, e.g. decongestants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C07K16/2896"><a id="link" href="#" class="style-scope state-modifier">C07K16/2896</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/00"><a id="link" href="#" class="style-scope state-modifier">A61P11/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the respiratory system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/06"><a id="link" href="#" class="style-scope state-modifier">A61P11/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Antiasthmatics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P17/00"><a id="link" href="#" class="style-scope state-modifier">A61P17/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for dermatological disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P29/00"><a id="link" href="#" class="style-scope state-modifier">A61P29/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/02"><a id="link" href="#" class="style-scope state-modifier">A61P35/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents specific for leukemia</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/08"><a id="link" href="#" class="style-scope state-modifier">A61P37/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Antiallergic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K14/00"><a id="link" href="#" class="style-scope state-modifier">C07K14/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K14/435"><a id="link" href="#" class="style-scope state-modifier">C07K14/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K14/705"><a id="link" href="#" class="style-scope state-modifier">C07K14/705</a></state-modifier>
                  <span class="description style-scope classification-tree">Receptors; Cell surface antigens; Cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K14/00"><a id="link" href="#" class="style-scope state-modifier">C07K14/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K14/435"><a id="link" href="#" class="style-scope state-modifier">C07K14/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K14/705"><a id="link" href="#" class="style-scope state-modifier">C07K14/705</a></state-modifier>
                  <span class="description style-scope classification-tree">Receptors; Cell surface antigens; Cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K14/715"><a id="link" href="#" class="style-scope state-modifier">C07K14/715</a></state-modifier>
                  <span class="description style-scope classification-tree">Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K14/7158"><a id="link" href="#" class="style-scope state-modifier">C07K14/7158</a></state-modifier>
                  <span class="description style-scope classification-tree">Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/2866"><a id="link" href="#" class="style-scope state-modifier">C07K16/2866</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/00"><a id="link" href="#" class="style-scope state-modifier">G01N33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/48"><a id="link" href="#" class="style-scope state-modifier">G01N33/48</a></state-modifier>
                  <span class="description style-scope classification-tree">Biological material, e.g. blood, urine; Haemocytometers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/50"><a id="link" href="#" class="style-scope state-modifier">G01N33/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/53"><a id="link" href="#" class="style-scope state-modifier">G01N33/53</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/574"><a id="link" href="#" class="style-scope state-modifier">G01N33/574</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor for cancer</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/57484"><a id="link" href="#" class="style-scope state-modifier">G01N33/57484</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/57492"><a id="link" href="#" class="style-scope state-modifier">G01N33/57492</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/00"><a id="link" href="#" class="style-scope state-modifier">G01N33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/48"><a id="link" href="#" class="style-scope state-modifier">G01N33/48</a></state-modifier>
                  <span class="description style-scope classification-tree">Biological material, e.g. blood, urine; Haemocytometers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/50"><a id="link" href="#" class="style-scope state-modifier">G01N33/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/68"><a id="link" href="#" class="style-scope state-modifier">G01N33/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/6863"><a id="link" href="#" class="style-scope state-modifier">G01N33/6863</a></state-modifier>
                  <span class="description style-scope classification-tree">Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K2039/505"><a id="link" href="#" class="style-scope state-modifier">A61K2039/505</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies comprising antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/20"><a id="link" href="#" class="style-scope state-modifier">C07K2317/20</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by taxonomic origin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/24"><a id="link" href="#" class="style-scope state-modifier">C07K2317/24</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/50"><a id="link" href="#" class="style-scope state-modifier">C07K2317/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by immunoglobulin fragments</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/56"><a id="link" href="#" class="style-scope state-modifier">C07K2317/56</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/565"><a id="link" href="#" class="style-scope state-modifier">C07K2317/565</a></state-modifier>
                  <span class="description style-scope classification-tree">Complementarity determining region [CDR]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/70"><a id="link" href="#" class="style-scope state-modifier">C07K2317/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/73"><a id="link" href="#" class="style-scope state-modifier">C07K2317/73</a></state-modifier>
                  <span class="description style-scope classification-tree">Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/732"><a id="link" href="#" class="style-scope state-modifier">C07K2317/732</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibody-dependent cellular cytotoxicity [ADCC]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/00"><a id="link" href="#" class="style-scope state-modifier">G01N2333/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/435"><a id="link" href="#" class="style-scope state-modifier">G01N2333/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature from animals; from humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/46"><a id="link" href="#" class="style-scope state-modifier">G01N2333/46</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/47"><a id="link" href="#" class="style-scope state-modifier">G01N2333/47</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving proteins of known structure or function as defined in the subgroups</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/4701"><a id="link" href="#" class="style-scope state-modifier">G01N2333/4701</a></state-modifier>
                  <span class="description style-scope classification-tree">Details</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="G01N2333/4719"><a id="link" href="#" class="style-scope state-modifier">G01N2333/4719</a></state-modifier>
                  <span class="description style-scope classification-tree">G-proteins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/00"><a id="link" href="#" class="style-scope state-modifier">G01N2333/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/435"><a id="link" href="#" class="style-scope state-modifier">G01N2333/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature from animals; from humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/705"><a id="link" href="#" class="style-scope state-modifier">G01N2333/705</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/715"><a id="link" href="#" class="style-scope state-modifier">G01N2333/715</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="G01N2333/7158"><a id="link" href="#" class="style-scope state-modifier">G01N2333/7158</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 21 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">NO334858B1</h2>
                  <p class="tagline style-scope patent-result">Norway</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Granted patent</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/0b/f7/d9/1cc06285a6d9c7/NO334858B1.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;antibody&quot;,&quot;amino acid&quot;,&quot;region&quot;,&quot;chain&quot;,&quot;seq&quot;]" data-before="20010831"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/NO334858B1"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NO334858B1/no"><a id="link" href="#" class="style-scope state-modifier">Norwegian</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Kenya Shitara"><a id="link" href="#" class="style-scope state-modifier">Kenya Shitara</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Kazuyasu Nakamura"><a id="link" href="#" class="style-scope state-modifier">Kazuyasu Nakamura</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Emi Hosaka"><a id="link" href="#" class="style-scope state-modifier">Emi Hosaka</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Akiko Shimizu"><a id="link" href="#" class="style-scope state-modifier">Akiko Shimizu</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Masamichi Koike"><a id="link" href="#" class="style-scope state-modifier">Masamichi Koike</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2002</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7504104B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US10/231,452</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR100959248B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020047002852A</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PT1449850E/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PT02770179T</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN100430420C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CNB02820882XA</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2002338015B8/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2002338015A</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP4052515B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2003523494A</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DE60238503D1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">DE</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DE60238503T</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP1449850B9/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP02770179A</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MXPA04001894A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MXPA04001894A</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ATE490277T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AT02770179T</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2003018635A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/JP2002/008828</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2356190T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES02770179T</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2458627C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA2458627A</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BRPI0212266B8/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BRPI0212266</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK1449850T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK02770179.6T</div>
                <div class="style-scope application-timeline">Filing date: 2002-08-30</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2004</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CO5560582A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CO04017609A</div>
                <div class="style-scope application-timeline">Filing date: 2004-02-27</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NO334858B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline" this="">NO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NO20040976A</div>
                <div class="style-scope application-timeline">Filing date: 2004-03-01</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2005</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HK1073851A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">HK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HK05106562.0A</div>
                <div class="style-scope application-timeline">Filing date: 2005-08-01</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2009</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7842797B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US12/395,214</div>
                <div class="style-scope application-timeline">Filing date: 2009-02-27</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2010</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8143058B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US12/903,780</div>
                <div class="style-scope application-timeline">Filing date: 2010-10-13</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2011</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CY1111193T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CY20111100175T</div>
                <div class="style-scope application-timeline">Filing date: 2011-02-14</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2012</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20120177643A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/428,739</div>
                <div class="style-scope application-timeline">Filing date: 2012-03-23</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2013</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8900584B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/867,693</div>
                <div class="style-scope application-timeline">Filing date: 2013-04-22</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2014</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US9051371B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US14/215,556</div>
                <div class="style-scope application-timeline">Filing date: 2014-03-17</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2015</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US10131711B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US14/703,469</div>
                <div class="style-scope application-timeline">Filing date: 2015-05-04</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2017</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US10590203B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US15/675,154</div>
                <div class="style-scope application-timeline">Filing date: 2017-08-11</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2019</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/FR19C1028I2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">FR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: FR19C1028C</div>
                <div class="style-scope application-timeline">Filing date: 2019-04-19</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CY2019022I2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CY2019022C</div>
                <div class="style-scope application-timeline">Filing date: 2019-04-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BE2019C006I2/fr"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">BE</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BE2019C006C</div>
                <div class="style-scope application-timeline">Filing date: 2019-04-25</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/LUC00116I2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">LU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: LU00116C</div>
                <div class="style-scope application-timeline">Filing date: 2019-04-26</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NL300985I2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">NL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NL300985C</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-06</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application NO20040976A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2004-03-01</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Kyowa Hakko Kirin Co Ltd"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Kyowa Hakko Kirin Co Ltd</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2004-06-01</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NO20040976L/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of NO20040976L</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2014-06-23</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NO334858B1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of NO334858B1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (15)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#nplCitations" class="style-scope patent-result">Non-patent citations (2)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (33)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=NO&amp;NR=334858B1&amp;KC=B1&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/NO/334858/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/NO334858B1">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Norwegian</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES337196101" lang="EN" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Teknisk område </span>Technical area</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den foreliggende oppfinnelse vedrører et humant CDR-podet antistoff eller antistoff fragment derav som spesifikt reagerer med den ekstracellulære region av human CC kjemokinreseptor 4 (i det etterfølgende referert til som "CCR4") men reagerer ikke med en blodplate og antistoffragementet derav. Det humant CDR-podet antistoff som spesifikt reagerer med den ekstracellulære region av CCR4, har en cytotoksisk aktivitet og en inhiberende aktivitet av cytokinproduksjon ved Th2 celler, og omfatter et spesifikt hypervariabelt område (complementarity determining region) (i det etterfølgende referert til som "CDR"), og antistoffragmentet derav. Den foreliggende oppfinnelse vedrører også et DNA som koder for antistoffet eller antistoffragmentet derav. Den foreliggende oppfinnelse ved-rører videre en vektor omfattende DNA-et. Den foreliggende oppfinnelse vedrører dessuten en fremgangsmåte for fremstilling av antistoffet eller antistoffragmentet derav ved anvendelse av transformanten. Den foreliggende oppfinnelse vedrører i tillegg et medikament,terapeutisk middel og et diagnostisk middel for behandling av CCR4-relaterte sykdommer,for cancertyper slik som blodcancertyper, f.eks. levkemi og lymfomatose. </span>The present invention relates to a human CDR-grafted antibody or antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (hereinafter referred to as "CCR4") but does not react with a platelet and the antibody fragment thereof. The human CDR-grafted antibody that specifically reacts with the extracellular region of CCR4, has a cytotoxic activity and an inhibitory activity of cytokine production by Th2 cells, and comprises a specific hypervariable region (complementarity determining region) (hereinafter referred to as "CDR "), and the antibody fragment thereof. The present invention also relates to a DNA which codes for the antibody or antibody fragment thereof. The present invention further relates to a vector comprising the DNA. The present invention also relates to a method for producing the antibody or antibody fragment thereof using the transformant. The present invention also relates to a drug, therapeutic agent and a diagnostic agent for the treatment of CCR4-related diseases, for cancer types such as blood cancer types, e.g. leukemia and lymphomatosis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">B akgrunns t ekni kk </span>Basic technology</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Forskjellige faktorer slik som eosinofiler, mastceller, IgE og lignende spiller en rolle i allergiske sykdommer slik som bronkialastma. Eosinofiler infiltrerer inn i et inflammatorisk sete og frigjør cytotoksiske basiske proteiner slik som MBP (major basic protein) eller lignende ved degranulering og de omgivende vev skades av slike cytotoksiske basiske proteiner. Mastceller bindes til et antigen immunkompleks med IgE som produseres av B-celler og frigjør histamin slik at en umiddelbar allergisk reaksjon induseres. Den allergiske reaksjonen kontrolleres ved biologisk funksjonelle molekyler slik som cytokiner, kjemokiner og lignende, som tar del i signaltransduksjon mellom celler. IL-5 induserer diffe-rensiering, overlevelse og degranulering av eosinofiler. IL- 4 induserer B-celle-aktivering og produksjon av IgE. Produsert IgE danner et immunkompleks med antigenet og bevirker degranulering av mastceller. Det er blitt funnet at IL-4, IL-13 og lignende også produseres av mastceller og bidrar til produksjonen av IgE ved B-celler ( Am. J. Respir. Crit. Care Med., 152, 2059 (1995), Immunol. Today, 15, 19 (1994)). Et elaborert cytokin-kjemokin nettverk er således tilstede blant inflammatoriske celler og ivaretar kompliserte balanser. </span>Various factors such as eosinophils, mast cells, IgE and the like play a role in allergic diseases such as bronchial asthma. Eosinophils infiltrate into an inflammatory site and release cytotoxic basic proteins such as MBP (major basic protein) or similar during degranulation and the surrounding tissues are damaged by such cytotoxic basic proteins. Mast cells bind to an antigenic immune complex with IgE produced by B cells and release histamine so that an immediate allergic reaction is induced. The allergic reaction is controlled by biologically functional molecules such as cytokines, chemokines and the like, which take part in signal transduction between cells. IL-5 induces differentiation, survival and degranulation of eosinophils. IL-4 induces B-cell activation and production of IgE. Produced IgE forms an immune complex with the antigen and causes degranulation of mast cells. It has been found that IL-4, IL-13 and the like are also produced by mast cells and contribute to the production of IgE by B cells (Am. J. Respir. Crit. Care Med., 152, 2059 (1995), Immunol. Today, 15, 19 (1994)). An elaborate cytokine-chemokine network is thus present among inflammatory cells and takes care of complicated balances.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cytokinene og kjemokinene produseres av hjelper-T-celler som uttrykker CD4 på celleoverflaten (i det etterfølgende referert til som "CD4+Th celler"). Det er faktisk blitt funnet at infiltrering av hjelper-T-celler er funnet i luftveis-inflammasjonssetet hos pasienter med bronkial astma, hvori et betydelig stort av T-cellene er aktivert og at alvorligheten og luftveis-hypersensitiviteten hos en astmapasient korrelerer med antallet aktiverte T-celler, såvel som at de aktiverte T-celler også er økt i det perifere blod ( Am. Rev. Respir. Dis., 145, S22 (1992)). </span>The cytokines and chemokines are produced by helper T cells that express CD4 on the cell surface (hereafter referred to as "CD4+Th cells"). Indeed, it has been found that infiltration of helper T cells is found at the site of airway inflammation in patients with bronchial asthma, in which a significant proportion of the T cells are activated and that the severity and airway hypersensitivity of an asthma patient correlates with the number of activated T -cells, as well as that the activated T cells are also increased in the peripheral blood (Am. Rev. Respir. Dis., 145, S22 (1992)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hjelper-T-cellene er klassifisert i Thl celler og Th2 celler, avhengig av typen cytokin som skal produseres derved ( Annu. Rev. Immunol., !_ &gt; 145 (1989)). Th2 celler produserer IL-4, IL-5, IL-13 og lignende. Cytokinene produsert av Th2 celler er Th2 cytokiner. </span>The helper T cells are classified into Th1 cells and Th2 cells, depending on the type of cytokine to be produced thereby ( Annu. Rev. Immunol., !_ &gt; 145 (1989)). Th2 cells produce IL-4, IL-5, IL-13 and the like. The cytokines produced by Th2 cells are Th2 cytokines.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er blitt funnet at en antigen-spesifikk T-celle-klon isolert fra en pasient med atopisk sykdom frigjør Th2 cytokiner når stimulert in vitro ( Proe. Nati, Acad. Sei., U. S. A., 88., 4538 (1991)), og Th2 celler er tilstede i bronkoalveolært lavage fluid (i det etterfølgende referert til som "BAL") og luftveisslimhinnen hos astmapasienter ( N. Engl. J. Med., 326, 298 (1992), Sur. J". Immunol., 23., 1445 (1993)). Ekspresjons-nivåer av IL-4 og IL-5 mRNA-er av Th2 cytokiner økes når mRNA ekspresjoner av forskjellige cytokiner i celler i BAL under-søkes ved anvendelse av en allergisk inflammasjon-dyremodell ( Clin. Immunol. Immunophathol., 75, 75 (1995)). Også når Th2 celler administreres intravenøst eller intranasalt til mus, induseres astmatisk informasjon i lungene på antigen-spesifikk måte (J". Exp. Med., 186, 1737 (1997), J". Immunol., 160, 1378 (1998)) og eosinofili observeres (J\ Immunol., 161, 3128 </span>It has been found that an antigen-specific T-cell clone isolated from a patient with atopic disease releases Th2 cytokines when stimulated in vitro (Proe. Nati, Acad. Sei., U. S. A., 88., 4538 (1991)), and Th2 cells are present in bronchoalveolar lavage fluid (hereafter referred to as "BAL") and the airway mucosa of asthmatic patients (N. Engl. J. Med., 326, 298 (1992), Sur. J". Immunol., 23 , 1445 (1993)).Expression levels of IL-4 and IL-5 mRNAs of Th2 cytokines are increased when mRNA expressions of various cytokines in cells in BAL are examined using an allergic inflammation animal model ( Clin. Immunol . Immunophathol., 75, 75 (1995)). Also when Th2 cells are administered intravenously or intranasally to mice, asthmatic information is induced in the lungs in an antigen-specific manner (J". Exp. Med., 186, 1737 (1997), J ". Immunol., 160, 1378 (1998)) and eosinophilia is observed (J\ Immunol., 161, 3128</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1998)). Ekspresjon av IL-5 observeres i luftveisslimet til astmapasienter og hudlesjonene til pasienter med atopisk dermatitt (J". Clin. Invest. , 87., 1541 (1991), J. Exp. Med., 173, 775 (1991)) og ekspresjonsnivået av IL-5 i slimet ved kronisk allergisk rhinitt korrelerer med ekspresjonsnivået av IL-13, og mengdene av totalt serum IgE og antigen-spesifikt IgE ( Therapeutics, 32., 19 (1988)). </span>(1998)). Expression of IL-5 is observed in the airway mucus of asthma patients and the skin lesions of patients with atopic dermatitis (J". Clin. Invest. , 87., 1541 (1991), J. Exp. Med., 173, 775 (1991)) and the expression level of IL-5 in the mucus in chronic allergic rhinitis correlates with the expression level of IL-13, and the amounts of total serum IgE and antigen-specific IgE ( Therapeutics, 32., 19 (1988)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kjemokin er en generell betegnelse for basiske heparin-bindende proteiner som induserer kjemotoksis og aktivering av leukocytt, og klassifiseres i underfamilier av CXC, CC, C og CX3C avhengig av posisjonen av cysteinrestene i den primære struktur. 16 kjemokinreseptorer er blitt identifisert så langt ( Curr, Opi. Immunol., H, 626 (1999)), og det er blitt vist av ekspresjon av hver kjemokinreseptor er forskjellig blant leukocyttene slik som Thl celle, Th2 celle eller lignende ( Cell Engineering, 17., 1022 (1998) ) . </span>Chemokine is a general term for basic heparin-binding proteins that induce chemotoxicity and leukocyte activation, and are classified into subfamilies of CXC, CC, C and CX3C depending on the position of the cysteine residues in the primary structure. 16 chemokine receptors have been identified so far ( Curr, Opi. Immunol., H, 626 (1999)), and it has been shown that the expression of each chemokine receptor is different among leukocytes such as Thl cell, Th2 cell or the like ( Cell Engineering, 17., 1022 (1998) ).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Human CCR 4 er en G protein-koblet syv-transmembran-reseptor klonet som K5-5 fra en human immatur basofil cellelinje KU-812. Transmembranregionene av CCR4 vurderes til å være posisjoner 40 til 67, posisjoner 78 til 97, posisjoner 113 til 133, posisjoner 151 til 175, posisjoner 207 til 226, posisjoner 243 til 270 og posisjoner 285 til 308 i aminosyresekvensen, de ekstracellulære regioner er vurdert til å være posisjoner 1 til 39, posisjoner 98 til 112, posisjoner 176 til 206 og posisjoner 271 til 284 i aminosyresekvensen, og de intracellulære regioner er posisjoner 68 til 77, posisjoner 134 til 150, posisjoner 227 til 242 og posisjoner 309 til 360 i aminosyresekvensen (J". Biol. Chem. , 270, 19495 </span>Human CCR 4 is a G protein-coupled seven-transmembrane receptor cloned as K5-5 from a human immature basophilic cell line KU-812. The transmembrane regions of CCR4 are considered to be positions 40 to 67, positions 78 to 97, positions 113 to 133, positions 151 to 175, positions 207 to 226, positions 243 to 270 and positions 285 to 308 in the amino acid sequence, the extracellular regions are considered to be being positions 1 to 39, positions 98 to 112, positions 176 to 206 and positions 271 to 284 of the amino acid sequence, and the intracellular regions are positions 68 to 77, positions 134 to 150, positions 227 to 242 and positions 309 to 360 of the amino acid sequence (J". Biol. Chem. , 270, 19495</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1995)). Først ble det rapportert at liganden av CCR4 er MIP-la (macrophage inflammatory protein-la) RANTES (regulated on activation normal T-cell expressed and secreted) eller MCP-1 (monocyte chemotactic protein) ( Biochem. Biophys, Res. Commun., 218, 337 (1996), WO 96/23068). Det er imidlertid funnet at TARC (thymus and activation-regulated chemokine) produsert fra stimulerte mononukleære celler fra humant perifert blod (i det etterfølgende referert til som "PBMC") og thymusceller ( J. Biol. Chem., 2 71, 21514 (1996)) spesifikt binder til CCR4 ( J. Biol. Chem., 272, 15036 (1997)). Det er også blitt rapportert at MDC (macrophage-derived chemokine) isolert fra makrofag (J\ Exp. Med., 185, 1595 (1997)), også kjent som STCP-1 (stimulated T cell chemotactic protein-1)
( J. Biol. Chem., 272, 25229 (1997)), binder til CCR4 sterkere enn TARC ( J. Biol. Chem., 273, 1764 (1998)). </span>(1995)). First, it was reported that the ligand of CCR4 is MIP-1a (macrophage inflammatory protein-1a), RANTES (regulated on activation normal T-cell expressed and secreted) or MCP-1 (monocyte chemotactic protein) (Biochem. Biophys, Res. Commun. , 218, 337 (1996), WO 96/23068). However, it has been found that TARC (thymus and activation-regulated chemokine) produced from stimulated human peripheral blood mononuclear cells (hereinafter referred to as "PBMC") and thymus cells ( J. Biol. Chem., 2 71, 21514 (1996 )) specifically binds to CCR4 ( J. Biol. Chem., 272, 15036 (1997)). It has also been reported that MDC (macrophage-derived chemokine) isolated from macrophage (J\ Exp. Med., 185, 1595 (1997)), also known as STCP-1 (stimulated T cell chemotactic protein-1)
( J. Biol. Chem., 272, 25229 (1997)), binds to CCR4 more strongly than TARC ( J. Biol. Chem., 273, 1764 (1998)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er blitt vist av CCR4 uttrykkes på CD4+Th celler som produserer cytokin og/eller kjemokin (J". Biol. Chem., 272, 15036 (1997)), og det er blitt rapportert at CCR4 uttrykkes selektivt på Th2 celler blant CD4+Th celler (J\ Exp. Med., 187, 129 (1998), J. Immunol., 161, 5111 (1998)). I tillegg er CCR4+ celler blitt funnet i effektor/hukommelses-T-celler (CD4+/CD45R0+),og når CCR4+ celler ble stimulert ble IL-4 og IL-5 produsert men IFN-y ble ikke produsert ( Int. Immunol., 11, 81 (1999)). Det er også blitt rapportert at CCR4+ celler tilhører en CLA (cutaneous lymphocyte antigen)-positiv og a4(38 integrin-negativ gruppe blant hukommelses-T-celler, og CCR4 uttrykkes på hukommelses-T-celler relatert ikke til tarmimmunitet men til systemisk immunitet av huden og lignende (Nature, 400, 776 (1999)). Disse resultatene an-tyder sterkt at når inflammasjon induseres, aktiveres hukommelses-T-cellene til å uttrykke CCR4 og migreres inn i det inflammatoriske sete ved MDC og TARC av ligander av CCR4, og akselererer aktivering av andre inflammatoriske celler. </span>CCR4 has been shown to be expressed on CD4+Th cells that produce cytokine and/or chemokine (J". Biol. Chem., 272, 15036 (1997)), and it has been reported that CCR4 is expressed selectively on Th2 cells among CD4 +Th cells (J\ Exp. Med., 187, 129 (1998), J. Immunol., 161, 5111 (1998)). In addition, CCR4+ cells have been found in effector/memory T cells (CD4+/CD45R0+ ), and when CCR4+ cells were stimulated, IL-4 and IL-5 were produced but IFN-γ was not produced ( Int. Immunol., 11, 81 (1999)). It has also been reported that CCR4+ cells belong to a CLA ( cutaneous lymphocyte antigen)-positive and a4(38 integrin-negative group among memory T cells, and CCR4 is expressed on memory T cells related not to intestinal immunity but to systemic immunity of the skin and the like (Nature, 400, 776 (1999 )).These results strongly suggest that when inflammation is induced, the memory T cells are activated to express CCR4 and migrate into the inflammatory site at MDC and TARC by ligands of CCR4 , and accelerates the activation of other inflammatory cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er nylig blitt funnet at CCR4 også uttrykkes i naturlige dreperceller ( Journal of Immunology, 164, 4048-4054 (200), Blood, 97., 367-375 (2001)) og blodplater ( Thrombosis Research, 101, 279-289 (2001), Blood, 96, 4046-4054 (2000), Blood, 97., 937-945 (2001)) i mennesker. </span>It has recently been found that CCR4 is also expressed in natural killer cells ( Journal of Immunology, 164, 4048-4054 (200), Blood, 97., 367-375 (2001)) and platelets ( Thrombosis Research, 101, 279-289 ( 2001), Blood, 96, 4046-4054 (2000), Blood, 97., 937-945 (2001)) in humans.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er kjent at en antagonist i TARC eller MDC som en ligand av CCR4, nemlig en CCR4 antagonist, inhiberer blodplateaggre- gasjon (WO 99/15666). Det er kjent at et slikt middel som modulerer funksjonen av CCR4 også innvirker på blodplate-funksj oner. </span>It is known that an antagonist in TARC or MDC as a ligand of CCR4, namely a CCR4 antagonist, inhibits platelet aggregation (WO 99/15666). It is known that such an agent that modulates the function of CCR4 also affects platelet functions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ekspresjon av CCR4 er funnet i blodplater. Adrian et al. </span>Expression of CCR4 has been found in platelets. Adrian et al.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">( Blood, 97., 937-945 (2001)) og Abi-Younes et al. ( Thrombosis Research, 101, 279-289 (2001), WO 00/42074, WO 00/41724) har f.eks. påvist ekspresjon av CCR4 i humane blodplater ved anvendelse av anti-CCR4 antistoffer. Et antistoff som har reaktivitet med CCR4 men som ikke er i stand til å binde til humane blodplater har hittil ikke vært kjent. </span>(Blood, 97., 937-945 (2001)) and Abi-Younes et al. (Thrombosis Research, 101, 279-289 (2001), WO 00/42074, WO 00/41724) has e.g. demonstrated expression of CCR4 in human platelets using anti-CCR4 antibodies. An antibody that has reactivity with CCR4 but is unable to bind to human platelets has not been known to date.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er også kjent at når et autoantistoff som er i stand til å binde til blodplater produseres, induseres autoimmun trombopeni ( Blood, 70., 428-431 (1987) , Transfusion Science, 19, 245-251 (1998)). Midler som har innvirkninger på trombo-cytopeni og blodplatefunksjoner er generelt ikke ønskelig som medikamenter fordi de ofte forårsaker alvorlige bivirkninger slik som blødning og trombedannelse. Siden antistoffer har lang blod-halveringstid, er et antistoff som innvirker på blodplatefunksjoner særlig vanskelig å utvikles som et medikament. Utvikling av anti-CD40 ligand-antistoffer som er blitt utviklet som midler for behandling av autoimmune sykdommer er f.eks. blitt suspendert på grunn frembringelsen av bivirkninger som vurderes og skyldes gjenkjennelse av antigen uttrykt på aktiverte blodplater (Nature Medicine, 6_, 114 </span>It is also known that when an autoantibody capable of binding to platelets is produced, autoimmune thrombopenia is induced (Blood, 70., 428-431 (1987) , Transfusion Science, 19, 245-251 (1998)). Agents that have effects on thrombocytopenia and platelet functions are generally not desirable as drugs because they often cause serious side effects such as bleeding and thrombus formation. Since antibodies have a long blood half-life, an antibody that affects platelet functions is particularly difficult to develop as a drug. Development of anti-CD40 ligand antibodies that have been developed as agents for the treatment of autoimmune diseases are e.g. has been suspended due to the production of side effects which are considered to be due to recognition of antigen expressed on activated platelets (Nature Medicine, 6_, 114</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2000), BioCentury, A8 of 18 (2002.06.20)). </span>(2000), BioCentury, A8 of 18 (2002.06.20)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er kjent at proteiner underkastes forskjellige modifi-ser ingsreaks joner etter translasjon. En av de kjente modifi-seringreaksjonene er en sulfatert reaksjon av tyrosinrester. </span>It is known that proteins undergo various modification reactions after translation. One of the known modification reactions is a sulfated reaction of tyrosine residues.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er blitt rapportert at mange proteiner sulfateres i tyrosinrester ( Chemistry and Biology, ZrR57-R61 (2000)). Tyrosinresten som sulfateres har det kjennetegn at mange sure aminosyrerester er tilstede i dens nærhet, og et protein som har en mulighet til å sulfateres og dets region er blitt foreslått ( Cell, 96., 667-676 (1999)). Hva angår CCR4, er 4 tyrosinrester tilstede nær N-enden, men der er ingen rapporter som viser at tyrosinrestene er sulfatert. </span>It has been reported that many proteins are sulfated at tyrosine residues (Chemistry and Biology, ZrR57-R61 (2000)). The tyrosine residue which is sulfated has the characteristic that many acidic amino acid residues are present in its vicinity, and a protein having an opportunity to be sulfated and its region have been proposed (Cell, 96., 667-676 (1999)). As for CCR4, 4 tyrosine residues are present near the N-terminus, but there are no reports showing that the tyrosine residues are sulfated.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som den aktuelle metode for behandling av Th2-medierte immunsykdommer, er de følgende blitt utviklet: (1) antagonister for cytokiner og kjemokiner slik som et humanisert anti-IL-5 antistoff (SB-240563: Smith Kline Beecham, Sch-55700 (CDP-835): Shehling Plough/Celltech), et humanisert IL-4 antistoff (US patent 5 914 110), en oppløselig kjemokinreseptor (J". Immunol., 160, 624 (1998)), etc:; (2) cytokin/ kjemokin produksjon-inhibitorer slik som en IL-5 produksjon-inhibitor (Japansk publisert ikke-gransket patentsøknad nr. 53355/96), en retinoid antagonist (WO 99/24024), splatast tosilat (IPD-1151T, produsert av Taiho Pharmaceutical), etc:, (3) midler som virker på eosinofil, mastcelle og lignende som endelige inflammatoriske celler, slik som et humanisert IL-5 reseptor antistoff (WO 97/10354), en CC kjemokinreseptor 3 (CCR3) antagonist (Japansk publisert ikke-gransket patent-søknad nr. 147872/99), etc.; (4) inflammatorisk molekyl-inhibitorer slik som et humanisert anti-IgE antistoff ( Am. J. Respir. Crit. Care Med., 157, 1429 (1998)), etc.; og lignende. Men de inhiberer kun en del av det elaborate nettverk blant cytokin, kjemokin og inflammatoriske celler. Th2-medierte immunsykdommer bør ikke helbredes ved hjelp av disse midlene. Anti-CD4 antistoffer har en aktivitet til å kon-trollere T-celler, og har effekter på steroid-avhengig alvor-lig astma. Siden CD4 molekylet generelt uttrykkes i forskjellige immunceller, mangler de imidlertid spesifisitet og har en ulempe med å ledsage sterk immunsuppresiv effekt (Int. Arch. Aller. Immunol., 118, 133 (1999)). </span>As the current method for the treatment of Th2-mediated immune diseases, the following have been developed: (1) antagonists for cytokines and chemokines such as a humanized anti-IL-5 antibody (SB-240563: Smith Kline Beecham, Sch-55700 (CDP -835): Shehling Plow/Celltech), a humanized IL-4 antibody (US patent 5,914,110), a soluble chemokine receptor (J". Immunol., 160, 624 (1998)), etc:; (2) cytokine/ chemokine production inhibitors such as an IL-5 production inhibitor (Japanese Published Unexamined Patent Application No. 53355/96), a retinoid antagonist (WO 99/24024), splatast tosilate (IPD-1151T, manufactured by Taiho Pharmaceutical), etc:, (3) agents that act on eosinophil, mast cell and the like as definitive inflammatory cells, such as a humanized IL-5 receptor antibody (WO 97/10354), a CC chemokine receptor 3 (CCR3) antagonist (Japanese published unexamined patent application no. 147872/99), etc.; (4) inflammatory molecule inhibitors such as a humanized anti-IgE antibody ( Am . J. Respir. Crit. Care Med., 157, 1429 (1998)), etc.; and such. But they only inhibit part of the elaborate network between cytokines, chemokines and inflammatory cells. Th2-mediated immune diseases should not be cured by these agents. Anti-CD4 antibodies have an activity to control T cells, and have effects on steroid-dependent severe asthma. However, since the CD4 molecule is generally expressed in various immune cells, they lack specificity and have a disadvantage of accompanying strong immunosuppressive effect (Int. Arch. Aller. Immunol., 118, 133 (1999)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For å inhibere alle disse, er det således påkrevet å kontrol-lere spesielt oppstrøms av den problematiske allergiske reaksjon, nemlig Th2 celler. </span>In order to inhibit all of these, it is thus required to control especially upstream of the problematic allergic reaction, namely Th2 cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den for tiden anvendte alminnelige metode for behandling av pasienter med alvorlige Th2-medierte immunsykdommer er steroidadministrering, men bivirkninger ved steroider kan ikke unngås. Der er også ulemper ved at tilstandene til hver pasient returnerer til den tidligere tilstand når steroid-administreringen innstilles, og ved at legemiddelresistens oppnås når steroidet administreres i lang tid. </span>The currently used general method for treating patients with severe Th2-mediated immune diseases is steroid administration, but side effects of steroids cannot be avoided. There are also disadvantages in that the conditions of each patient return to their previous state when the steroid administration is stopped, and in that drug resistance is achieved when the steroid is administered for a long time.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Intet humant CDR-podet antistoff og antistoffragmentet derav som kan påvise CCR4-uttrykkende celler og også har cytotoksisitet mot CCR4-uttrykkende celler er frem til nå blitt etablert. Intet terapeutisk middel som kan inhibere produksjon av Th2 cytokin har i tillegg vært kjent frem til nå. </span>No human CDR-grafted antibody and antibody fragment thereof that can detect CCR4-expressing cells and also has cytotoxicity against CCR4-expressing cells has so far been established. In addition, no therapeutic agent that can inhibit the production of Th2 cytokines has been known until now.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Selv om det er blitt rapportert at CCR4 også uttrykkes på cancercellene hos levkemipasienter ( Blood, 96_, 685 (2000)), har intet terapeutisk middel som utmatter levkemiceller vært kjent. </span>Although it has been reported that CCR4 is also expressed on the cancer cells of leukemia patients (Blood, 96_, 685 (2000)), no therapeutic agent that depletes leukemia cells has been known.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er generelt kjent at når et antistoff avledet fra et ikke-humant dyr, f.eks. et muse-antistoff, administreres til et menneske, gjenkjennes det som en fremmed substans og induserer et humant antistoff mot muse-antistoffet (humant-anti-muse-antistoff: i det etterfølgende referert til som "HAMA") i menneskekroppen. Det er kjent at HAMA reagerer med det administrerte muse-antistoff til å forårsake bivirkninger (J\ Clin. Oncol., 2, 881 (1984), Blood, 65_, 1349 (1985), J. Nati. Cancer Inst., 80., 932 (1988), Proe. Nati. Acad. Sei. U. S. A., 82., 1242 (1985) ) , til å akselerere forsvinning av det administrerte muse-antistof f fra kroppen (J\ Nucl. Med., 26., 1011 (1985), Blood, 65_, 1349 (1985), J. Nati. Cancer Inst., 80, 837 (1988)), og til å redusere terapeutiske effekter av muse-antistof f et (J". Immunol., 135, 1530 (1985), Cancer Res., 46, 6489 (1986)). </span>It is generally known that when an antibody derived from a non-human animal, e.g. a mouse antibody, is administered to a human, it is recognized as a foreign substance and induces a human anti-mouse antibody (human-anti-mouse antibody: hereinafter referred to as "HAMA") in the human body. HAMA is known to react with the administered mouse antibody to cause side effects (J\ Clin. Oncol., 2, 881 (1984), Blood, 65_, 1349 (1985), J. Nat. Cancer Inst., 80. , 932 (1988), Proe. Nati. Acad. Sei. U. S. A., 82., 1242 (1985) ), to accelerate the elimination of the administered mouse antibody from the body (J\ Nucl. Med., 26., 1011 (1985), Blood, 65_, 1349 (1985), J. Nat. Cancer Inst., 80, 837 (1988)), and to reduce therapeutic effects of mouse antibody (J". Immunol., 135, 1530 (1985), Cancer Res., 46, 6489 (1986)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For å løse disse problemene, er det blitt gjort forsøk på å omdanne et antistoff avledet fra et ikke-humant dyr til et humant CDR-podet antistoff ved anvendelse av genteknologisk teknikk. </span>To solve these problems, attempts have been made to convert an antibody derived from a non-human animal into a human CDR-grafted antibody using genetic engineering techniques.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane CDR-podede antistoff er et antistoff hvori aminosyresekvensen av CDR i den variable region (i det etter-følgende referert til "V region") avledet fra et ikke-humant dyre-antistoff podes inn i en passende posisjon av et humant antistoff (Nature, 321, 522 (1986)). Sammenlignet med antistoffer avledet fra ikke-humane dyr slik som muse-antistoffer og lignende, har disse humane CDR-podede antistoffer forskjellige fordeler for kliniske anvendelser hos mennesker. Det er f.eks. blitt rapportert at dets immunogenisitet ble redusert og dets blod-halveringstid ble lang sammenlignet med et muse-antistof f ved anvendelse av en ape ( Cancer Res., 56., 1118 (1996), Immunol., 85, 668 (1995)). Det er således forventet at de humane CDR-podede antistoffer har mindre bivirkninger i mennesker og deres terapeutiske effekter fortsetter i lengre tid enn antistoffer avledet fra ikke-humane dyr. </span>The human CDR-grafted antibody is an antibody in which the amino acid sequence of the CDR in the variable region (hereinafter referred to as "V region") derived from a non-human animal antibody is grafted into an appropriate position of a human antibody ( Nature, 321, 522 (1986)). Compared with antibodies derived from non-human animals such as mouse antibodies and the like, these human CDR-grafted antibodies have various advantages for human clinical applications. It is e.g. has been reported that its immunogenicity was reduced and its blood half-life was prolonged compared to a mouse antibody using a monkey (Cancer Res., 56., 1118 (1996), Immunol., 85, 668 (1995)). Thus, it is expected that the human CDR-grafted antibodies have less side effects in humans and their therapeutic effects continue for a longer time than antibodies derived from non-human animals.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Siden det humane CDR-podede antistoff fremstilles ved anvendelse av genteknologisk teknikk, kan dessuten molekyler i forskjellige former fremstilles. Når f.eks. yl underklasse anvendes som en tung kjede (i det etterfølgende referert til som "H kjede") konstant region (i det etterfølgende referert til som "C region") (H kjede C region refereres til som "CH") av et humant antistoff, kan et humanisert antistoff som har en høy effektorfunksjon slik som antistoff-avhengig celle-mediert cytotoksisk (i det etterfølgende referert til som "ADCC") aktivitet fremstilles ( Cancer Res., 56., 1118 (1996)) og en forlenget blod-halveringstid sammenlignet med et muse-antistoff forventes ( Immunol., 85_, 668 (1995)). I behandling særlig for å redusere antallet CCR4-uttrykkende celler, er også høyere cytotoksiske aktiviteter slik som komplement-avhengig cytotoksisk aktivitet (i det etterfølgende referert til som "CDC aktivitet") og ADCC aktivitet via Fc regionen (regionen i og etter hengselregionen av et antistoff tung kjede) av et antistoff viktige for de terapeutiske effekter. Disse resultatene viser derfor klart at humane CDR-podede antistoffer er foretrukne fremfor antistoffer avledet fra ikke-humane dyr slik som muse-antistoffer. </span>Furthermore, since the human CDR-grafted antibody is produced using genetic engineering techniques, molecules in various forms can be produced. When e.g. yl subclass is used as a heavy chain (hereinafter referred to as "H chain") constant region (hereinafter referred to as "C region") (H chain C region referred to as "CH") of a human antibody, a humanized antibody having a high effector function such as antibody-dependent cell-mediated cytotoxic (hereinafter referred to as "ADCC") activity can be prepared (Cancer Res., 56., 1118 (1996)) and a prolonged blood half-life compared to a mouse antibody is expected (Immunol., 85_, 668 (1995)). In treatment particularly to reduce the number of CCR4-expressing cells, higher cytotoxic activities such as complement-dependent cytotoxic activity (hereinafter referred to as "CDC activity") and ADCC activity via the Fc region (the region in and after the hinge region of a antibody heavy chain) of an antibody important for the therapeutic effects. These results therefore clearly demonstrate that human CDR-grafted antibodies are preferred over antibodies derived from non-human animals such as mouse antibodies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I samsvar med de nylige fremskritt i proteinteknikk og genteknikk, kan dessuten et enkel kjede antistoff (i det etter-følgende referert til som "scFv") ( Science, 242, 423 (1998)), et dimerisert V region-fragment (i det etterfølgende referert til som "diabody") (Nature Biotechnol. , 15., 629 (1997)), et disulfid-stabilisert V region-fragment (i det etterfølgende referert som "dsFv") ( Molecular Immunol., 32., 249 (1995)), et peptid inneholdende CDR ( J. Biol. Chem., 271, 2966 (1996)) og lignende, fremstilles som humane CDR-podede antistoffer. Antistoffragmentene er fremragende med hensyn til overgangs-aktivitet inn i målvev sammenlignet med komplette antistoff-molekyler ( Cancer Res., 52., 3402 (1992)). </span>Furthermore, in accordance with the recent advances in protein engineering and genetic engineering, a single chain antibody (hereinafter referred to as "scFv") (Science, 242, 423 (1998)), a dimerized V region fragment (in the hereinafter referred to as "diabody") (Nature Biotechnol. , 15., 629 (1997)), a disulfide-stabilized V region fragment (hereinafter referred to as "dsFv") ( Molecular Immunol., 32., 249 ( 1995)), a CDR-containing peptide (J. Biol. Chem., 271, 2966 (1996)) and the like, are prepared as human CDR-grafted antibodies. The antibody fragments are excellent with regard to transfer activity into target tissues compared to complete antibody molecules ( Cancer Res., 52., 3402 (1992)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er vurdert at disse fragmenter avledet fra humane CDR-podede antistoffer og antistoffragmenter derav er mer ønske-lige enn dem avledet fra antistoffer avledet fra ikke-humane dyr slik som muse-antistoffer, når anvendt i kliniske anvendelser for mennesker. </span>It is considered that these fragments derived from human CDR-grafted antibodies and antibody fragments thereof are more desirable than those derived from antibodies derived from non-human animals such as mouse antibodies, when used in human clinical applications.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som beskrevet ovenfor, kan diagnostiske og terapeutiske effekter forventes fra humane CDR-podede antistoffer og antistoffragmenter derav når anvendt alene, men det er også blitt gjort forsøk på ytterligere å forbedre effektene ved anvendelse av andre molekyler i kombinasjon. Cytokin kan f.eks. anvendes som et av slike molekyler. Cytokin er en generell betegnelse for forskjellige oppløselige faktorer som kontrollerer intercellulære gjensidige funksjoner i immun-reaksjoner. CDC aktivitet og ADCC aktivitet er f.eks. kjent som de cytotoksiske aktiviteter av antistoffer, og ADCC aktivitet kontrolleres ved effektorceller som har Fc reseptorer på celleoverflaten slik som monocytter, makrofager, NK celler og lignende ( J. Immunol,. 138, 1992 (1987)). Siden forskjellige cytokiner aktiverer disse effektorceller, kan de administreres i kombinasjon med et antistoff for å forbedre ADCC </span>As described above, diagnostic and therapeutic effects can be expected from human CDR-grafted antibodies and antibody fragments thereof when used alone, but attempts have also been made to further enhance the effects by using other molecules in combination. Cytokine can e.g. is used as one of such molecules. Cytokine is a general term for various soluble factors that control intercellular mutual functions in immune reactions. CDC activity and ADCC activity are e.g. known as the cytotoxic activities of antibodies, and ADCC activity is controlled by effector cells that have Fc receptors on the cell surface such as monocytes, macrophages, NK cells and the like (J. Immunol,. 138, 1992 (1987)). Since different cytokines activate these effector cells, they can be administered in combination with an antibody to enhance ADCC</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">aktivitet av antistoffet. </span>activity of the antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Omtale av oppfinnelsen </span>Mention of the invention</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den foreliggende oppfinnelse vedrører de følgende 1 til 59. 1. Et humant CDR-podet antistoff eller antistoff fragment derav som spesifikt reagerer med en ekstracellulær region av human CC kjemokinreseptor 4 (CCR4) men ikke reagerer med en human blodplate,og som omfatter hypervariabelt område (CDR) 1. CDR2 og CDR3 av en antistoff tung kjede (H kjede) variabel region (V region) som har aminosyresekvensene representert ved henholdsvis SEQ ID N0:1, 2 og 3, og CDR 1, CDR2 og CDR3 av en antistoff lett kjede (L kjede) V region som har aminosyresekvensene representert ved henholdsvis SEQ ID NO:5, 6 og 7. 2. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 1, som har en cytotoksisk aktivitet mot en CCR4-uttrykkende celle. 3. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 1 eller 2, som spesifikt reagerer med en ekstracellulær region av CCR4 valgt fra gruppen bestående av posisjoner 1 til 39, 98 til 112, 176 til 206 og 271 til 2 84 i aminosyresekvensen representert ved SEQ ID NO:48. 4. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 3,som spesifikt reagerer med en epitop tilstede i posisjonene 2 til 2 9 i aminosyresekvensen representert ved SEQ ID NO:48. 5. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 4, som spesifikt reagerer med en epitop tilstede i posisjoner 13 til 2 9 i aminosyresekvensen representert ved SEQ ID NO:48. 6. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 5, som spesifikt reagerer med en epitop tilstede i posisjoner 13 til 25 i aminosyresekvensen representert ved SEQ ID NO:48. 7. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 1 eller 2, som spesifikt reagerer med en CCR4-uttrykkende celle. 8. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 7, som har en høyere cytotoksisk aktivitet mot en CCR4-uttrykkende celle enn et monoklonalt antistoff produsert ved et ikke-humant dyre-hybridom. 9. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 2 til 8, hvori den cytotoksiske aktivitet er en antistoff-avhengig celle-mediert cytotoksisk (ADCC) aktivitet. 10. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 9, hvori ADCC aktiviteten er en aktivitet med indusering av apoptose av en CCR4-uttrykkende celle. 11. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 10, som har en aktivitet med utarming av en CCR4-uttrykkende celle. 12. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 7 til 11, hvori den CCR4-uttrykkende celle er en Th2-celle. 13. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 12, som har en aktivitet med inhibering av cytokinproduksjon av en Th2-celle. 14. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 13, hvori cytokinet er IL-4, IL-5 eller IL-13. 15. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 14, som tilhører et humant IgG antistoff. 16. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 15, som omfatter rammeverkregioner (FR-er) H kjede V region og L kjede V region av et humant antistoff. 17. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 16, som omfatter FR-er av H kjede V region og L kjede V region av et humant antistoff, og H kjede C region og L kjede C region av et humant antistoff. 18. Det humane CDR-podede antistoff eller antistoffragmentet derav ifølge et hvilket som helst av kravene 1 til 17, som omfatter (a) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:4; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; (b) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:4; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (c) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:4; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:13; (d) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:4; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (e) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:9; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (f) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:9; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (g) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:10; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (h) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:10; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (i) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:11; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (j) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:11; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (k) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:38; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; (1) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:38; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (m) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:38; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:13; </span>The present invention relates to the following 1 to 59. 1. A human CDR-grafted antibody or antibody fragment thereof which specifically reacts with an extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human platelet, and which comprises hypervariable region (CDR) 1. CDR2 and CDR3 of an antibody heavy chain (H chain) variable region (V region) having the amino acid sequences represented by SEQ ID NO:1, 2 and 3, respectively, and CDR 1, CDR2 and CDR3 of an antibody light chain (L chain) V region having the amino acid sequences represented by SEQ ID NO:5, 6 and 7, respectively. 2. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 1, which has a cytotoxic activity against a CCR4-expressing cell. 3. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 1 or 2, which specifically reacts with an extracellular region of CCR4 selected from the group consisting of positions 1 to 39, 98 to 112, 176 to 206 and 271 to 2 84 in the amino acid sequence represented by SEQ ID NO:48. 4. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 3, which specifically reacts with an epitope present in positions 2 to 29 of the amino acid sequence represented by SEQ ID NO:48. 5. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 4, which specifically reacts with an epitope present in positions 13 to 29 of the amino acid sequence represented by SEQ ID NO:48. 6. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 5, which specifically reacts with an epitope present in positions 13 to 25 of the amino acid sequence represented by SEQ ID NO:48. 7. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 1 or 2, which specifically reacts with a CCR4-expressing cell. 8. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 7, which has a higher cytotoxic activity against a CCR4-expressing cell than a monoclonal antibody produced by a non-human animal hybridoma. 9. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 2 to 8, wherein the cytotoxic activity is an antibody-dependent cell-mediated cytotoxic (ADCC) activity. 10. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 9, wherein the ADCC activity is an activity of inducing apoptosis of a CCR4-expressing cell. 11. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 10, which has an activity of depleting a CCR4-expressing cell. 12. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 7 to 11, wherein the CCR4-expressing cell is a Th2 cell. 13. The human CDR-grafted antibody or antibody fragment thereof as stated in one or more of claims 1 to 12, which has an activity of inhibiting cytokine production by a Th2 cell. 14. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 13, wherein the cytokine is IL-4, IL-5 or IL-13. 15. The human CDR-grafted antibody or antibody fragment thereof as stated in one or more of claims 1 to 14, which belongs to a human IgG antibody. 16. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 15, comprising framework regions (FRs) H chain V region and L chain V region of a human antibody. 17. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 16, comprising FRs of H chain V region and L chain V region of a human antibody, and H chain C region and L chain C region of a human antibody. 18. The human CDR-grafted antibody or antibody fragment thereof according to any one of claims 1 to 17, comprising (a) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:4; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8; (b) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:4; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (c) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:4; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:13; (d) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:4; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (e) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:9; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (f) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:9; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (g) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:10; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (h) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:10; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (i) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:11; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (j) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:11; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (k) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:38; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8; (1) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:38; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (m) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:38; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:13;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(n) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:38; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; </span>(n) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:38; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(o) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:39; og en </span>(o) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:39; and a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; </span>antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(p) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:3 9; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; </span>(p) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:39; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(q) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:39; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:13; </span>(q) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:39; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:13;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(r) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:39; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; </span>(r) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:39; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(s) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:40; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; </span>(s) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:40; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(t) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:40; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; </span>(t) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:40; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(u) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:41; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; eller </span>(u) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:41; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8; or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(v) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:41; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14. 19. Antistoffragmentet som angitt i ett eller flere av kravene 1 til 18, hvori antistoffragmentet er en antistoffragment valgt fra Fab, Fab&lt;1&gt;, F(ab')2, et enkel kjede antistoff (scFv), et dimerisert V region fragment (Diabody), et disulfid-stabilisert V region fragment (dsFv) og et peptid omfattende CDR. 20. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 27, som er produsert ved en transformant KM8759 (FERM BP-8129) eller KM8760 (FERM BP-8130). 21. Et DNA som koder for det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20. 22. En rekombinant vektor som omfatter DNA-et i samsvar med krav 21. 23. En ikke-human transformant som produserer det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 eller som kan oppnås ved innføring av den rekombinante vektor i samsvar med krav 22 i en vertcelle. 24. Ikke-human transformant som angitt i krav 23, hvori transformanten er KM8759 (FERM BP-8129) eller KM8760 (FERM BP-8130). 25. En fremgangsmåte for fremstilling av et antistoff som er i stand til å produsere det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20, som omfatter dyrking av transformanten i samsvar med krav 23 eller 24 i et medium for å danne og akkumulere det humane CDR-podede antistoff eller antistoffragmentet derav i kulturen; og utvinning av antistoffet eller antistoffragmentet fra kulturen. 26. Et humane CDR-podede antistoff eller antistoffragmentet derav hvori det humane CDR-podede antistoff eller antistoff-fragmentet derav som angitt i ett eller flere av kravene 1 til 20 er kjemisk eller genetisk konjugert med en radioisotop, et protein eller et middel. 27. Et medikament som omfatter minst ett valgt fra det humane CDR-podede antistoff og antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 og 26 som en aktiv bestanddel. 28. Et terapeutisk middel for behandling av CCR4-relaterte sykdommer, som omfatter minst ett valgt fra det humane CDR-podede antistoff og antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 og 26 som en aktiv bestanddel . 29. Det terapeutiske middel som angitt i krav 28, hvori den CCR4-relaterte sykdom er en cancer eller inflammatoriske sykdommer . 30. Det terapeutiske middel som angitt i krav 29, hvori canceren er en blodcancer. 31. Det terapeutiske middel som angitt i krav 30, hvori blodcanceren er levkemi eller lymfomatose. 32. Det terapeutiske middel som angitt i krav 29, hvori den inflammatorisk sykdom er akutt eller kronisk luftveis-over-følsomhet eller bronkialastma, atopisk hudsykdom, allergisk rhinitt eller pollinosis. 33. Det terapeutiske middel som angitt i krav 28, hvori den Th2-medierte immunsykdom er kronisk luftveis-overfølsomhets-astma, bronkial astma, atopisk hudsykdom, allergisk rhinitt eller pollinosis. 34. Et diagnostisk middel for CCR4-relaterte sykdommer eller Th2-medierte immunsykdommer, som omfatter minst ett valgt fra det humane CDR-podede antistoff og antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 og 26 som en aktiv bestanddel. 35. Det diagnostiske middel som angitt i krav 34, hvori den CCR4-relaterte sykdom er en cancer eller en inflammatorisk sykdom. 36. Det diagnostiske middel som angitt i krav 35, hvori canceren er en blodcancer. 37. Det diagnostiske middel som angitt i krav 35, hvori blodcanceren er levkemi eller lymfomatose. 38. Det diagnostiske middel som angitt i krav 35, hvori den inflammatoriske sykdom er kronisk luftveis-overfølsomhets-astma, bronkial astma, atopisk hudsykdom, allergisk rhinitt eller pollinosis. 39. Det diagnostiske middel som angitt i krav 34, hvori den Th2-medierte immunsykdom er kronisk luftveis-overfølsomhets-astma, bronkial astma, atopisk hudsykdom, allergisk rhinitt eller pollinosis. 40. En fremgangsmåte for immunologisk påvisning av CCR4 eller en celle som uttrykte CCR4 på celleoverflaten, som anvender det humane CDR-podede antistoff og antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 og 26. </span>(v) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:41; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14. 19. The antibody fragment as set forth in one or more of claims 1 to 18, wherein the antibody fragment is an antibody fragment selected from Fab, Fab&lt;1&gt;, F(ab')2, a single chain antibody (scFv), a dimerized V region fragment ( Diabody), a disulfide-stabilized V region fragment (dsFv) and a peptide comprising the CDR. 20. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 27, which is produced by a transformant KM8759 (FERM BP-8129) or KM8760 (FERM BP-8130). 21. A DNA encoding the human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 20. 22. A recombinant vector comprising the DNA in accordance with claim 21. 23. A non-human transformant which produces the human CDR-grafted antibody or antibody fragment thereof as stated in one or more of claims 1 to 20 or which can be obtained by introducing the recombinant vector in accordance with claim 22 into a host cell. 24. The non-human transformant as set forth in claim 23, wherein the transformant is KM8759 (FERM BP-8129) or KM8760 (FERM BP-8130). 25. A method for producing an antibody capable of producing the human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 20, comprising culturing the transformant in accordance with claim 23 or 24 in a medium for forming and accumulating the human CDR-grafted antibody or antibody fragment thereof in the culture; and recovering the antibody or antibody fragment from the culture. 26. A human CDR-grafted antibody or antibody fragment thereof wherein the human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 20 is chemically or genetically conjugated with a radioisotope, a protein or an agent. 27. A medicament comprising at least one selected from the human CDR-grafted antibody and the antibody fragment thereof as set forth in one or more of claims 1 to 20 and 26 as an active ingredient. 28. A therapeutic agent for the treatment of CCR4-related diseases, comprising at least one selected from the human CDR-grafted antibody and the antibody fragment thereof as stated in one or more of claims 1 to 20 and 26 as an active ingredient. 29. The therapeutic agent as set forth in claim 28, wherein the CCR4-related disease is a cancer or inflammatory diseases. 30. The therapeutic agent as set forth in claim 29, wherein the cancer is a blood cancer. 31. The therapeutic agent as set forth in claim 30, wherein the blood cancer is leukemia or lymphomatosis. 32. The therapeutic agent as set forth in claim 29, wherein the inflammatory disease is acute or chronic airway hypersensitivity or bronchial asthma, atopic skin disease, allergic rhinitis or pollinosis. 33. The therapeutic agent as set forth in claim 28, wherein the Th2-mediated immune disease is chronic airway hypersensitivity asthma, bronchial asthma, atopic skin disease, allergic rhinitis or pollinosis. 34. A diagnostic agent for CCR4-related diseases or Th2-mediated immune diseases, comprising at least one selected from the human CDR-grafted antibody and antibody fragment thereof as set forth in one or more of claims 1 to 20 and 26 as an active ingredient. 35. The diagnostic agent as set forth in claim 34, wherein the CCR4-related disease is a cancer or an inflammatory disease. 36. The diagnostic agent as set forth in claim 35, wherein the cancer is a blood cancer. 37. The diagnostic agent as stated in claim 35, wherein the blood cancer is leukemia or lymphomatosis. 38. The diagnostic agent as set forth in claim 35, wherein the inflammatory disease is chronic airway hypersensitivity asthma, bronchial asthma, atopic skin disease, allergic rhinitis or pollinosis. 39. The diagnostic agent as set forth in claim 34, wherein the Th2-mediated immune disease is chronic airway hypersensitivity asthma, bronchial asthma, atopic skin disease, allergic rhinitis or pollinosis. 40. A method for immunological detection of CCR4 or a cell that expressed CCR4 on the cell surface, using the human CDR-grafted antibody and antibody fragment thereof as set forth in one or more of claims 1 to 20 and 26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I den foreliggende oppfinnelse, inkluderer de CCR4-relaterte sykdommer cancertyper, inflammatoriske sykdommer og lignende. </span>In the present invention, the CCR4-related diseases include cancers, inflammatory diseases and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I den foreliggende oppfinnelse, inkluderer cancertypene blodcancertyper, særlig levkemi, lymfomatose og lignende. </span>In the present invention, the cancer types include blood cancer types, especially leukemia, lymphoma and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I den foreliggende oppfinnelse, inkluderer de inflammatoriske sykdommer akutt eller kronisk luftveis-overfølsomhet eller bronkial astma; atopiske hudsykdommer slik som atopisk dermatitt; allergisk rhinitt; pollinosis; og lignende. </span>In the present invention, the inflammatory diseases include acute or chronic airway hypersensitivity or bronchial asthma; atopic skin diseases such as atopic dermatitis; allergic rhinitis; pollinosis; and such.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I den foreliggende oppfinnelse, kan de Th2-medierte immunsykdommer være hvilken eller hvilke som helst immunsykdommer som Th2 celle er relatert til, og inkluderer akutt eller kronisk luftveis-overfølsomhet eller bronkial astma; atopiske hudsykdommer slik som atopisk dermatitt; allergisk rhinitt; pollinosis; interstitiell pneumoni; pulmonal fibrose; autoimmune sykdommer slik som systemisk lupus erythematosus; og lignende. </span>In the present invention, the Th2-mediated immune diseases can be any immune diseases to which Th2 cells are related, and include acute or chronic airway hypersensitivity or bronchial asthma; atopic skin diseases such as atopic dermatitis; allergic rhinitis; pollinosis; interstitial pneumonia; pulmonary fibrosis; autoimmune diseases such as systemic lupus erythematosus; and such.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane CDR-podede antistoff som spesifikt reagerer med CCR4 (anti-CCR4 CDR-podet antistoff) og et antistoffragment derav i henhold til den foreliggende oppfinnelse) i det et-terfølgende vil begge generelt refereres som antistoffet i henhold til den foreliggende oppfinnelse i enkelte tilfeller (er ikke begrenset, så lenge som det er et humant CDR-podet antistoff som spesifikt reagerer med den ekstracellulære region av human CCR4 men reagerer ikke med en human blodplate eller et antistoffragment derav. Betegnelsen "reagerer ikke med en human blodplate" betyr at antistoffet utviser hoved-sakelig ingen bindingsaktivitet overfor en human blodplate. Det betyr spesifikt av bindingsaktiviteten ikke vises når målt ved hjelp av et flow-cytometer. </span>The human CDR-grafted antibody that specifically reacts with CCR4 (anti-CCR4 CDR-grafted antibody) and an antibody fragment thereof according to the present invention) hereinafter will both be generally referred to as the antibody according to the present invention in some cases (are not limited, as long as it is a human CDR-grafted antibody that specifically reacts with the extracellular region of human CCR4 but does not react with a human platelet or an antibody fragment thereof. The term "does not react with a human platelet" means that the antibody shows essentially no binding activity towards a human platelet, meaning specifically that the binding activity does not appear when measured using a flow cytometer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre er antistoffet i henhold til den foreliggende oppfinnelse et antistoff som spesifikt reagerer med den ekstra cellulære region av human CCR4 og har en cytotoksisk aktivitet for CCR4-uttrykkende celler. </span>Furthermore, the antibody according to the present invention is an antibody that specifically reacts with the extra cellular region of human CCR4 and has a cytotoxic activity for CCR4-expressing cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den cytotoksiske aktivitet inkluderer CDC aktivitet og ADCC aktivitet. </span>The cytotoxic activity includes CDC activity and ADCC activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffet i henhold til den foreliggende oppfinnelse inkluderer videre antistoffer som spesifikt reagerer med foretrukket en region omfattende posisjoner 1 til 39, 98 til 112, 176 til 206 eller 271 til 284 i aminosyresekvensen representert ved SEQ ID NO:48, mer foretrukket en region omfattende posisjoner 2 til 29 i aminosyresekvensen representert ved SEQ ID N0:48 (SEQ ID NO:36), enda mer foretrukket en region omfat tende posisjoner 12 til 2 9 i aminosyresekvensen representert ved SEQ ID NO:48 (SEQ ID NO:37), og mest foretrukket en region omfattende posisjoner 12 til 25 i aminosyresekvensen representert ved SEQ ID NO:48. </span>The antibody according to the present invention further includes antibodies which specifically react with preferably a region comprising positions 1 to 39, 98 to 112, 176 to 206 or 271 to 284 in the amino acid sequence represented by SEQ ID NO:48, more preferably a region comprising positions 2 to 29 of the amino acid sequence represented by SEQ ID NO:48 (SEQ ID NO:36), even more preferably a region comprising positions 12 to 29 of the amino acid sequence represented by SEQ ID NO:48 (SEQ ID NO:37), and most preferably a region comprising positions 12 to 25 of the amino acid sequence represented by SEQ ID NO:48.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane CDR-podede antistoff representerer et antistoff hvori aminosyresekvenser av CDR av VH og VL i et antistoff avledet fra et ikke-humant dyr er podet til passende posisjoner av VH og VL av et humant antistoff. </span>The human CDR-grafted antibody represents an antibody in which amino acid sequences of CDRs of VH and VL of an antibody derived from a non-human animal are grafted to appropriate positions of VH and VL of a human antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane CDR-podede antistoff i henhold til den foreliggende oppfinnelse kan produseres ved konstruering av cDNA-er som koder for V regioner hvori aminosyresekvenser av CDR av VH og VL i et antistoff avledet fra et ikke-humant dyr, som spesifikt reagerer med CCR4, podes til FR av VH og VL i et humant antistoff, å innskyte dem henholdsvis i en ekspresjonsvektor for dyrecelle som har DNA som koder for CH og H kjede C region (i det etterfølgende referert til som "CL") av et humant antistoff for å konstruere en human CDR-podet antistoff ekspresjonsvektor, og deretter å innføre den i en dyrecelle for å uttrykke det humane CDR-podede antistoff. </span>The human CDR-grafted antibody of the present invention can be produced by constructing cDNAs encoding V regions in which amino acid sequences of CDRs of VH and VL in an antibody derived from a non-human animal, which specifically reacts with CCR4, grafted to the FR of VH and VL in a human antibody, inserting them respectively into an animal cell expression vector having DNA encoding the CH and H chain C region (hereinafter referred to as "CL") of a human antibody to constructing a human CDR-grafted antibody expression vector, and then introducing it into an animal cell to express the human CDR-grafted antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som metoden for å velge FR aminosyresekvenser av VH og VL av et humant antistoff, kan det anvendes en hvilken som helst metode så lenge som de er avledet fra humane antistoffer. Eksempler inkluderer FR aminosyresekvenser av VH og VL i humane antistoffer registrert i databaser slik som Protein Data Bank og lignende, eller aminosyresekvenser som er felles i hver undergruppe av FR av VH og VL i humane antistoffer (Seguences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). </span>As the method for selecting FR amino acid sequences of VH and VL of a human antibody, any method can be used as long as they are derived from human antibodies. Examples include FR amino acid sequences of VH and VL in human antibodies registered in databases such as the Protein Data Bank and the like, or amino acid sequences common to each subgroup of FR of VH and VL in human antibodies (Sequences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et hvilket som helst CH i antistoffet i henhold til den foreliggende oppfinnelse kan anvendes, så lenge som det tilhører humant immunglobulin (i det etterfølgende referert til som"hig"). En hlgG klasse, og hvilken som helst av yl, y2, y3 ogY4 underklasser som tilhører hlgG klassen kan foretrukket anvendes. En hvilken som helst CL i det humane CDR-podede antistoff kan også anvendes, så lenge som det tilhører hig, og dem i k klasse eller A klasse kan anvendes. </span>Any CH in the antibody of the present invention can be used, as long as it belongs to human immunoglobulin (hereinafter referred to as "hig"). An hlgG class, and any of the yl, y2, y3 and Y4 subclasses belonging to the hlgG class can preferably be used. Any CL in the human CDR-grafted antibody can also be used, as long as it belongs to hig, and those in k class or A class can be used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffet i henhold til den foreliggende oppfinnelse inkluderer humane CDR-podede antistoffer eller antistoffragmentene derav som omfatter antistoff HV CDR1, CDR2 og CDR3 omfattende aminosyresekvensene representert ved henholdsvis SEQ ID N0:1, 2 og 3, og/eller VL CDR1, CDR2 og CDR3 omfattende aminosyresekvensene representert ved henholdsvis SEQ ID NO:5, 6 og 7. </span>The antibody according to the present invention includes human CDR-grafted antibodies or the antibody fragments thereof comprising antibody HV CDR1, CDR2 and CDR3 comprising the amino acid sequences represented by SEQ ID NO:1, 2 and 3, respectively, and/or VL CDR1, CDR2 and CDR3 comprising the amino acid sequences represented by SEQ ID NO:5, 6 and 7 respectively.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foretrukne eksempler inkluderer humane CDR-podede antistoffer hvori VH i antistoffet omfatter aminosyresekvensen representert ved SEQ ID NO:4 eller 38 og/eller VL omfatter aminosyresekvensen representert ved SEQ ID NO:8. </span>Preferred examples include human CDR-grafted antibodies wherein VH of the antibody comprises the amino acid sequence represented by SEQ ID NO:4 or 38 and/or VL comprises the amino acid sequence represented by SEQ ID NO:8.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mer foretrukne eksempler inkluderer: </span>More preferred examples include:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">et humant CDR-podet antistoff som omfatter VH av antistoffet omfattende en aminosyresekvens hvori minst en aminosyrerest valgt fra Ala i posisjon 40, Gly i posisjon 42, Lys i posisjon 43, Gly i posisjon 44, Lys i posisjon 76 og Ala i posisjon 97 i aminosyresekvensen representert ved SEQ ID NO:4 er substituert med en annen aminosyrerest, </span>a human CDR-grafted antibody comprising VH of the antibody comprising an amino acid sequence in which at least one amino acid residue selected from Ala at position 40, Gly at position 42, Lys at position 43, Gly at position 44, Lys at position 76 and Ala at position 97 in the amino acid sequence represented by SEQ ID NO:4 is substituted with another amino acid residue,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">et humant CDR-podet antistoff som omfatter VH i antistoffet omfattende en aminosyresekvens hvori minst en aminosyrerest valgt fra Thr i posisjon 28 og Ala i posisjon 97 i aminosyresekvensen representert ved SEQ ID NO:38 er substituert med en annen aminosyrerest, </span>a human CDR-grafted antibody comprising VH in the antibody comprising an amino acid sequence in which at least one amino acid residue selected from Thr in position 28 and Ala in position 97 of the amino acid sequence represented by SEQ ID NO:38 is substituted with another amino acid residue,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">et humant CDR-podet antistoff som omfatter VL i antistoffet omfattende en aminosyresekvens hvori minst en aminosyrerest valgt fra Ile i posisjon 2, Val i posisjon 3, Gin i posisjon 50 og Val i posisjon 88 i aminosyresekvensen representert ved SEQ ID NO:8 er substituert med en aminosyrerest, </span>a human CDR-grafted antibody comprising VL in the antibody comprising an amino acid sequence in which at least one amino acid residue selected from Ile in position 2, Val in position 3, Gin in position 50 and Val in position 88 in the amino acid sequence represented by SEQ ID NO:8 is substituted with an amino acid residue,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">et humant CDR-podet antistoff som omfatter VH i antistoffet omfattende en aminosyresekvens hvori minst en aminosyrerest valgt fra Ala i posisjon 40, Gly i posisjon 42, Lys i posisjon 43, Gly i posisjon 44, Lys i posisjon 76 og Ala i posisjon 97 i aminosyresekvensen representert ved SEQ ID NO:4 er </span>a human CDR-grafted antibody comprising VH in the antibody comprising an amino acid sequence in which at least one amino acid residue selected from Ala at position 40, Gly at position 42, Lys at position 43, Gly at position 44, Lys at position 76 and Ala at position 97 in the amino acid sequence represented by SEQ ID NO:4 is</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">substituert med en annen aminosyrerest; og VL i antistoffet omfattende en aminosyresekvens hvori minst en aminosyrerest valgt fra Ile i posisjon 2, Val i posisjon 3, Gin i posisjon 50 og Val i posisjon 88 i aminosyresekvensen representert ved SEQ ID NO:8 er substituert med en annen aminosyrerest, </span>substituted with another amino acid residue; and VL in the antibody comprising an amino acid sequence in which at least one amino acid residue selected from Ile in position 2, Val in position 3, Gin in position 50 and Val in position 88 in the amino acid sequence represented by SEQ ID NO:8 is substituted with another amino acid residue,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">et humant CDR-podet antistoff som omfatter VH i antistoffet omfattende en aminosyresekvens hvori minst en aminosyrerest valgt fra Thr i posisjon 28 og Ala i posisjon 97 i aminosyresekvensen representert ved SEQ ID NO:38 er substituert med en annen aminosyrerest; og VL i antistoffet VL omfattende en aminosyresekvens hvori minst en aminosyrerest valgt fra Ile i posisjon 2, Val i posisjon 3, Gin i posisjon 50 og Val i posisjon 8 i aminosyresekvensen representert ved SEQ ID NO:8 er substituert med en annen aminosyrerest, </span>a human CDR-grafted antibody comprising VH in the antibody comprising an amino acid sequence in which at least one amino acid residue selected from Thr at position 28 and Ala at position 97 in the amino acid sequence represented by SEQ ID NO:38 is substituted with another amino acid residue; and VL in the antibody VL comprising an amino acid sequence in which at least one amino acid residue selected from Ile in position 2, Val in position 3, Gin in position 50 and Val in position 8 in the amino acid sequence represented by SEQ ID NO:8 is substituted with another amino acid residue,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">og lignende. </span>and such.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den foreliggende oppfinnelse inkluderer antistoffer som omfatter aminosyresekvensen hvori en eller flere aminosyrer er delert, substituert, innskutt eller addert og spesifikt reagerer med CCR4 som beskrevet ovenfor, og antistoffragmentene derav. </span>The present invention includes antibodies comprising the amino acid sequence in which one or more amino acids are split, substituted, inserted or added and specifically react with CCR4 as described above, and the antibody fragments thereof.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I den foreliggende oppfinnelse betyr en eller flere aminosyre-delesjoner, -substitusjoner, -insertioner eller -addi-sjoner i aminosyresekvensen at en eller flere aminosyrer er delert, substituert, innskutt og/eller addert til en eller flere posisjoner i aminosyresekvensen. Delesjonen, substitu-sjonen, insertionen og/eller addisjonen kan bevirkes i den samme aminosyresekvens samtidig. Videre kan den substitu-erte, innskutte eller adderte aminosyrerest være naturlig eller ikke-naturlig. Den naturlige aminosyrerest inkluderer L-alanin, L-asparagin, L-asparaginsyre, L-glutamin, L-glutaminsyre, glycin, L-histidin, L-isoleucin, L-leucin, L-lysin. L-metionin, L-fenylalanin, L-prolin, L-serin, L-treonin, L-tryptofan, L-tyrosin, L-valin, L-cystein og lignende. </span>In the present invention, one or more amino acid deletions, substitutions, insertions or additions in the amino acid sequence means that one or more amino acids have been split, substituted, inserted and/or added to one or more positions in the amino acid sequence. The deletion, substitution, insertion and/or addition can be effected in the same amino acid sequence at the same time. Furthermore, the substituted, inserted or added amino acid residue can be natural or non-natural. The natural amino acid residue includes L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine. L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-cysteine and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I det etterfølgende vises foretrukne eksempler på aminosyrerester som er erstattet med hverandre. Aminosyrerestene i den samme gruppen kan erstattes med hverandre. </span>In the following, preferred examples of amino acid residues that have been replaced with each other are shown. The amino acid residues in the same group can be substituted for each other.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Gruppe A: </span>Group A:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">leucin, isoleucin, norleucin, valin, norvalin, alanin, 2-aminobutansyre, metionin, O-metylserin, t-butylglycin, t-butylalanin, cykloheksylalanin, </span>leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, O-methylserine, t-butylglycine, t-butylalanine, cyclohexylalanine,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gruppe B: </span>group B:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">asparaginsyre, glutaminsyre, isoasparaginsyre, isoglutamin-syre, 2-aminoadipinsyre, 2-aminosuberinsyre, </span>aspartic acid, glutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gruppe C: </span>group C:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">asparagin, glutamin, </span>asparagine, glutamine,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gruppe D: </span>group D:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">lysin, arginin, ornitin, 2,4-diaminobutansyre, 2,3-diamino-propinsyre, </span>lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diamino-propionic acid,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gruppe E: </span>group E:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">prolin, 3-hydroksyprolin, 4-hydroksyprolin, </span>proline, 3-hydroxyproline, 4-hydroxyproline,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gruppe F: </span>group F:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">serin, treonin, homoserin, </span>serine, threonine, homoserine,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gruppe G: </span>group G:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">fenylalanin, tyrosin. </span>phenylalanine, tyrosine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffragmentet i henhold til den foreliggende oppfinnelse inkluderer Fab, Fab&lt;1&gt;, F(ab')2, scFc, Diabody, dsFv, et peptid omfattende CDR, og lignende. </span>The antibody fragment according to the present invention includes Fab, Fab&lt;1&gt;, F(ab')2, scFc, Diabody, dsFv, a peptide comprising CDR, and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et Fab er et antistoffragment som har en molekylvekt på omtrent 50.000 og antigenbindende aktivitet, hvori omtrent en halvpart av N-ende siden av H kjede og hele L kjeden, blant fragmenter oppnådd ved behandling av IgG med en protease, papain (kuttet ved en aminosyrerest i posisjon 224 av H kjeden), er bundet sammen gjennom en disulfidbinding. </span>A Fab is an antibody fragment having a molecular weight of about 50,000 and antigen-binding activity, in which about half of the N-terminal side of the H chain and the entire L chain, among fragments obtained by treating IgG with a protease, papain (cut at an amino acid residue in position 224 of the H chain), are bound together through a disulfide bond.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fab-et i henhold til den foreliggende oppfinnelse kan oppnås </span>The Fab according to the present invention can be obtained</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ved behandling av et humant CDR-podet antistoff i henhold til den foreliggende oppfinnelse som spesifikt reagerer med CCR4, med en protease, papain. Fab-et kan videre fremstilles ved å innføre DNA som koder for Fab av antistoffet inn i en ekspresjonsvektor for prokaryot eller en ekspresjonsvektor for </span>by treating a human CDR-grafted antibody according to the present invention which specifically reacts with CCR4, with a protease, papain. The Fab can further be produced by introducing the DNA encoding the Fab of the antibody into an expression vector for prokaryote or an expression vector for</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">eukaryot, og innføring av vektoren i en prokaryot eller eukaryot for å uttrykke Fab-et. </span>eukaryotic, and introducing the vector into a prokaryote or eukaryote to express the Fab.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et F(ab')2er et antistoffragment som har en molekylvekt på omtrent 100.000 og antigenbindende aktivitet, som er noe større enn det Fab som er bundet via en disulfidbinding i hengselregionen, blant fragmenter oppnådd ved behandling av IgG med en protease, pepsin. </span>An F(ab')2 is an antibody fragment having a molecular weight of approximately 100,000 and antigen-binding activity, which is somewhat greater than that of the Fab bound via a disulfide bond in the hinge region, among fragments obtained by treatment of IgG with a protease, pepsin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">F(ab')2 i henhold til den foreliggende oppfinnelse kan oppnås ved behandling av et humant CDR-podet antistoff som spesifikt reagerer med CCR4, med en protease, pepsin. Videre kan F(ab')2-et produseres ved binding av Fab&lt;1&gt;beskrevet nedenfor via en tioeterbinding eller en disulfidbinding. </span>F(ab')2 according to the present invention can be obtained by treating a human CDR-grafted antibody that specifically reacts with CCR4, with a protease, pepsin. Furthermore, the F(ab')2 can be produced by binding Fab&lt;1&gt; described below via a thioether bond or a disulfide bond.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et Fab&lt;1&gt;er et antistoffragment som har en molekylvekt på omtrent 50.000 og antigenbindende aktivitet, som oppnås ved kutting av en disulfidbinding i hengselregionen av F(ab')2-et. </span>A Fab&lt;1&gt; is an antibody fragment having a molecular weight of approximately 50,000 and antigen-binding activity, which is achieved by cutting a disulfide bond in the hinge region of the F(ab')2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fab&lt;1-&gt;et i henhold til den foreliggende oppfinnelse kan oppnås ved å behandle F(ab')2-et som spesifikt reagerer med CCR4, med et reduksjonsmiddel, ditiotreitol. Fab&lt;1-&gt;et i henhold til den foreliggende oppfinnelse kan videre produseres ved å innskyte DNA som koder for et Fab&lt;1&gt;av et humant CDR-podet antistoff i henhold til den foreliggende oppfinnelse som spesifikt reagerer med CCR4 i en ekspresjonsvektor for prokaryot eller en ekspresjonsvektor for eukaryot, og å innføre vektoren i en prokaryot eller eukaryot for å uttrykke Fab1 et. Et scFv er et VH-P-V1 eller VL-P-VH polypeptid hvori en kjede VH og en kjede VL er forbundet ved anvendelse av en passende peptid-linker (P) av 12 eller flere rester og som har en antigenbindende aktivitet. </span>The Fab&lt;1&gt; according to the present invention can be obtained by treating the F(ab')2 which specifically reacts with CCR4, with a reducing agent, dithiothreitol. The Fab&lt;1&gt; according to the present invention can further be produced by inserting DNA encoding a Fab&lt;1&gt; of a human CDR-grafted antibody according to the present invention which specifically reacts with CCR4 into a prokaryotic expression vector or an expression vector for eukaryote, and introducing the vector into a prokaryote or eukaryote to express Fab1 et. An scFv is a VH-P-V1 or VL-P-VH polypeptide in which a chain VH and a chain VL are joined using a suitable peptide linker (P) of 12 or more residues and which has an antigen-binding activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">scFv-et i henhold til den foreliggende oppfinnelse kan produseres ved å oppnå cDNA-er som koder for VH og VL av et humant CDR-podet antistoff som spesifikt reagerer med CCR4 i henhold til den foreliggende oppfinnelse, og konstruere DNA som koder for scFv, å innskyte DNA-et i en ekspresjonsvektor for </span>The scFv according to the present invention can be produced by obtaining cDNAs encoding VH and VL of a human CDR-grafted antibody that specifically reacts with CCR4 according to the present invention, and constructing DNA encoding the scFv, to insert the DNA into an expression vector for</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">prokaryot eller en ekspresjonsvektor for eukaryot, og deretter å innføre ekspresjonsvektoren i en prokaryot eller eukaryot for uttrykke scFv-et. </span>prokaryote or a eukaryotic expression vector, and then introducing the expression vector into a prokaryote or eukaryote to express the scFv.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et diabody er et antistoffragment hvori scFv-er som har den samme eller forskjellig antigenbindende spesifisitet danner en dimer, og har en divalent antigenbindende aktivitet overfor det samme antigen eller to spesifikke antigenbindende aktiviteter overfor forskjellige antigener. </span>A diabody is an antibody fragment in which scFvs having the same or different antigen-binding specificity form a dimer, and have a divalent antigen-binding activity towards the same antigen or two specific antigen-binding activities towards different antigens.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Diabody-et i henhold til den foreliggende oppfinnelse, f.eks. et divalent diabody som spesfikt reagerer med CCR4, kan produseres ved å oppnå cDNA-er som koder for VH og VL av et antistoff som spesifikt reagerer med CCR4, å konstruere DNA som koder for scFv som har en polypeptid-linker av 3 til 10 rester, å innskyte DNA-et som koder for scFv som har en polypeptid-linker av 3 til 10 rester, å innskyte DNA-et i en ekspresjonsvektor prokaryote eller en ekspresjonvektor for eukaryot, og deretter å innføre ekspresjonsvektoren i en prokaryot eller eukaryot for å uttrykke diabody-et. </span>The Diabody according to the present invention, e.g. a divalent diabody that specifically reacts with CCR4 can be produced by obtaining cDNAs encoding VH and VL of an antibody that specifically reacts with CCR4, constructing DNA encoding scFv having a polypeptide linker of 3 to 10 residues , inserting the DNA encoding the scFv having a polypeptide linker of 3 to 10 residues, inserting the DNA into a prokaryotic or eukaryotic expression vector, and then introducing the expression vector into a prokaryotic or eukaryotic to express the diabody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En dsFv oppnås ved å binde polypeptider hvori en aminosyrerest av hver av VH og VL er erstattet med en cysteinrest via en disulfidbinding mellom cysteinrestene. Aminosyreresten som er erstattet med en cysteinrest kan velges basert på en vurdering av tredimensjonal struktur til antistoffet i sam svar med metoden vist av Reiter et al. ( Protein Engineering, 7, 697 (1994)). </span>A dsFv is obtained by binding polypeptides in which an amino acid residue of each of VH and VL is replaced by a cysteine residue via a disulfide bond between the cysteine residues. The amino acid residue that is replaced with a cysteine residue can be selected based on an assessment of the three-dimensional structure of the antibody in accordance with the method shown by Reiter et al. (Protein Engineering, 7, 697 (1994)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">dsFv-et i henhold til den foreliggende oppfinnelse kan produseres ved å oppnå cDNA-er som koder for VH og VL av et humant CDR-podet antistoff som spesifikt reagerer med CCR4 i henhold til den foreliggende oppfinnelse, og konstruere DNA som koder for dsFv, å innskyte DNA-et i en ekspresjonsvektor for </span>The dsFv according to the present invention can be produced by obtaining cDNAs encoding VH and VL of a human CDR-grafted antibody that specifically reacts with CCR4 according to the present invention, and constructing DNA encoding the dsFv, to insert the DNA into an expression vector for</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">prokaryot eller en ekspresjonvektor for eukaryot, og deretter å innføre ekspresjonsvektoren i en prokaryot eller eukaryot for å uttrykke dsFv-et. </span>prokaryote or a eukaryotic expression vector, and then introducing the expression vector into a prokaryote or eukaryote to express the dsFv.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et peptid omfattende CDR konstitueres ved å inkludere minst en region av H kjede og L kjede CDR-er. Flere CDR-er kan bindes direkte eller via en passende peptid-linker. </span>A peptide comprising CDRs is constituted by including at least one region of H chain and L chain CDRs. Multiple CDRs can be linked directly or via a suitable peptide linker.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Peptidet omfattende CDR i henhold til den foreliggende oppfinnelse kan produseres ved å oppnå cDNA som koder for CDR av VH og VL av et humant CDR-podet antistoff som spesifikt reagerer med CCR4, å konstruere DNA som koder for CDR, å innskyte DNA-et i en ekspresjonsvektor for prokaryot eller en ekspresjonvektor for eukaryote, og deretter ved å innføre ekspresjonsvektoren i en prokaryot eller eukaryot for å uttrykke peptidet. Videre kan peptidet omfattende CDR også produseres ved en kjemisk syntesemetode slik som en Fmoc-metode (fluorenylmetoksykarbonyl-metode), en tBoc-metode (t-butyloksykarbonyl-metode), eller lignende. </span>The CDR-comprising peptide according to the present invention can be produced by obtaining cDNA encoding the CDRs of VH and VL of a human CDR-grafted antibody that specifically reacts with CCR4, constructing DNA encoding the CDRs, inserting the DNA into a prokaryote expression vector or a eukaryote expression vector, and then introducing the expression vector into a prokaryote or eukaryote to express the peptide. Furthermore, the peptide comprising the CDR can also be produced by a chemical synthesis method such as an Fmoc method (fluorenylmethoxycarbonyl method), a tBoc method (t-butyloxycarbonyl method), or the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffet i henhold til den foreliggende oppfinnelse inkluderer antistoffderivater hvori en radioisotop, et protein, et middel eller lignende er kjemisk eller genetisk konjugert til antistoffet i henhold til den foreliggende oppfinnelse. </span>The antibody according to the present invention includes antibody derivatives in which a radioisotope, a protein, an agent or the like is chemically or genetically conjugated to the antibody according to the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffderivatene i henhold til den foreliggende oppfinnelse kan produseres ved kjemisk konjugering av en radioisotop, et protein eller et middel til N-ende siden eller C-ende siden av en H kjede eller en L kjede av et antistoff eller antistoffragment som spesifikt reagerer med CCR4, til en passende substituentgruppe eller sidekjede av antistoffet eller antistoffragmentet eller til en sukkerkjede i antistoffet eller antistoffragmentet ( Antibody Engineering Handbook, forfattet av Osamu Kanemitsu, publisert av Chijin Shokan (1994)) . </span>The antibody derivatives according to the present invention can be produced by chemical conjugation of a radioisotope, a protein or an agent to the N-terminal side or the C-terminal side of an H chain or an L chain of an antibody or antibody fragment that specifically reacts with CCR4, to an appropriate substituent group or side chain of the antibody or antibody fragment or to a sugar chain in the antibody or antibody fragment (Antibody Engineering Handbook, authored by Osamu Kanemitsu, published by Chijin Shokan (1994)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det kan videre produseres genetisk ved å forbinde et DNA som koder for antistoffet eller antistoffragmentet i henhold til den foreliggende oppfinnelse som spesifikt reagerer med CCR4 til et annet DNA som koder for et protein som skal bindes, å innskyte DNA-et i en ekspresjonsvektor, og innføre ekspresjonsvektoren i en vertcelle. </span>It can further be produced genetically by joining a DNA encoding the antibody or antibody fragment of the present invention that specifically reacts with CCR4 to another DNA encoding a protein to be bound, inserting the DNA into an expression vector, and introducing the expression vector into a host cell.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Radioisotopen inkluderer 131I,&lt;1&gt;25I og lignende, og den kan være konjugert til antistoffet ved f.eks. en kloramin T-metode. </span>The radioisotope includes 131I,&lt;1&gt;25I and the like, and it can be conjugated to the antibody by e.g. a chloramine T method.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Middelet er foretrukket en forbindelse med lav molekylvekt. Eksempler inkluderer anticancermidler slik som alkylerings-midler (f.eks. nitrogen "mustard", cyklofosfamid), metabolske antagonister (f.eks. 5-fluorouracil, metotreksat), antibiotika (f.eks. daunomycin, bleomycin, mitomycin C, daunorubicin, doksorubicin), plante-alkaloider (f.eks. vinkristin, vinblastin, vindesin), hormon-legemidler (f.eks. tamoksifen, deksametason), og lignende ( Clinical Oncology, forfattet av Japanese Society of Clinical Oncology, publisert av Cancer and Chemotherapy (1996)); antiinflammatoriske midler slik som steroidmidler (f.eks. hydrokortison, prednison), ikke-steroide legemidler (f.eks. aspirin, indometacin), immunmodulatorer (f.eks. aurotiomalat, penicillamin), immunsuppresive midler (f.eks. cyklofosfamid, azatioprin) og antihistaminmidler (f.eks. klorfeniramin-maleat, klemastin) ( Inflammation and Anti- inflammatory Therapy, Ishiyaku Shuppan (1982)), og lignende. Metoden for å konjugere daunomycin til et antistoff inkluderer en metode hvori daunomycin og en aminogruppe i et antistoff konjugeres via glutaraldehyd, en metode hvori en aminogruppe i daunomycin og en karboksylgruppe i et antistoff konjugeres via et vannoppløselig karbodiimid, og lignende. </span>The agent is preferably a low molecular weight compound. Examples include anticancer agents such as alkylating agents (eg, nitrogen "mustard", cyclophosphamide), metabolic antagonists (eg, 5-fluorouracil, methotrexate), antibiotics (eg, daunomycin, bleomycin, mitomycin C, daunorubicin, doxorubicin), plant alkaloids (e.g. vincristine, vinblastine, vindesine), hormone drugs (e.g. tamoxifen, dexamethasone), and the like (Clinical Oncology, authored by the Japanese Society of Clinical Oncology, published by Cancer and Chemotherapy (1996)); anti-inflammatory agents such as steroid agents (eg hydrocortisone, prednisone), non-steroidal drugs (eg aspirin, indomethacin), immunomodulators (eg aurothiomalate, penicillamine), immunosuppressive agents (eg cyclophosphamide, azathioprine ) and antihistamines (e.g. chlorpheniramine maleate, clemastine) (Inflammation and Anti-inflammatory Therapy, Ishiyaku Shuppan (1982)), and the like. The method of conjugating daunomycin to an antibody includes a method in which daunomycin and an amino group in an antibody are conjugated via glutaraldehyde, a method in which an amino group in daunomycin and a carboxyl group in an antibody are conjugated via a water-soluble carbodiimide, and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Proteinet er foretrukket cytokin som aktiverer immunceller. Eksempler inkluderer humant interlevkin 2 (i det etter-følgende referert til som "hIL-2"), human granulocyttmakro-fagkoloni-stimulerende faktor (i det etterfølgende referert til som "hGM-CSF"), human makrofag koloni-stimulerende faktor (i det etterfølgende referert til som "hM-CSF"), humant interlevkin 12 (i det etterfølgende referert til som "hlL-12"), og lignende. For å inhibere cancerceller direkte kan det også anvendes et toksin slik som ricin, difteriatoksin og lignende. Et fusjonsantistoff med et protein kan f.eks. produseres ved å forbinde et cDNA som koder for et antistoff eller antistoffragment til et annet cDNA som koder for proteinet, å konstruere DNA som koder for fusjonsantistoffet, å innskyte DNA-et i en ekspresjonsvektor for prokaryot eller en ekspresjonsvektor for eukaryot, og deretter å innføre den i en prokaryot eller eukaryot for å uttrykke fusjonsanti-stof f et . </span>The protein is preferably a cytokine that activates immune cells. Examples include human interleukin 2 (hereinafter referred to as "hIL-2"), human granulocyte macrophage colony-stimulating factor (hereinafter referred to as "hGM-CSF"), human macrophage colony-stimulating factor (in hereinafter referred to as "hM-CSF"), human interleukin 12 (hereinafter referred to as "hlL-12"), and the like. To inhibit cancer cells directly, a toxin such as ricin, diphtheria toxin and the like can also be used. A fusion antibody with a protein can e.g. produced by joining a cDNA encoding an antibody or antibody fragment to another cDNA encoding the protein, constructing DNA encoding the fusion antibody, inserting the DNA into a prokaryotic expression vector or a eukaryotic expression vector, and then introducing that in a prokaryote or eukaryote to express the fusion antibody f et .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metoder for å produsere det humane CDR-podede antistoff og antistoffragmenet derav som spesifikt reagerer med CCR4, metoder for å evaluere aktiviteten derav og metoder for å anvende dem forklares nedenfor. </span>Methods for producing the human CDR-grafted antibody and the antibody fragment thereof that specifically reacts with CCR4, methods for evaluating the activity thereof, and methods for using them are explained below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Framstilling av humant CDR-podet antistoff </span>1. Preparation of human CDR-grafted antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) Konstruksjon av humanisert antistoff-ekspresjonsvektor </span>(1) Construction of humanized antibody expression vector</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En humanisert antistoff-ekspresjonsvektor er en ekspresjonsvektor for dyrecelle som gener som koder for CH og CL av et humant antistoff er blitt innskutt i, og er konstruert ved kloning av hver av CH og Cl av et humant antistoff inn i en ekspresjonsvektor for dyrecelle. </span>A humanized antibody expression vector is an animal cell expression vector into which genes encoding CH and CL of a human antibody have been inserted, and is constructed by cloning each of CH and Cl of a human antibody into an animal cell expression vector.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">C regionen av et humant antistoff kan være CH og CL av et hvilket som helst humant antistoff. Eksempler inkluderer CH av y underklasse og CL av k klasse av et humant antistoff, og lignende. cDNA kan også anvendes. Som ekspresjonsvektor for dyrecelle kan det anvendes en hvilken som helst ekspresjonsvektor, så lenge som en C region av et humant antistoff kan innskytes og uttrykkes. Eksempler inkluderer pAGE107 ( Cytotechnology, 3., 133 (1990)), pAGE103 (J\ Biochem. , 101, 1307 (1987)), pHSG274 ( Gene, 27, 223 (1984)), pKCR ( Proe. Nati. Acad. Sei. USA, 78, 1527 (1981)), pSGI(3d2-4 ( Cytotechnology, 4, 173 (1990)), pSElUKlSedl-3 ( Cytotechnol, 13., 79 1993)) og lignende. En promoter og enhancer anvendt for en ekspresjonsvektor for dyrecelle inkluderer en SV4 0 tidlig promoter og enhancer ( J. Biochem., 101, 1307 (1987)), en Moloney muse-levkemivirus LTR promoter og enhancer ( Biochem. Biophys, Res. Comun., 149, 960 (1987)), en immunglobulin H kjede promoter ( Cell, 4_1, 479 (1985)) og enhancer ( Cell, 33., 717 (1983)), og lignende. </span>The C region of a human antibody can be CH and CL of any human antibody. Examples include CH of y subclass and CL of k class of a human antibody, and the like. cDNA can also be used. Any expression vector can be used as an expression vector for animal cells, as long as a C region of a human antibody can be inserted and expressed. Examples include pAGE107 ( Cytotechnology, 3., 133 (1990)), pAGE103 ( J\ Biochem. , 101, 1307 (1987)), pHSG274 ( Gene, 27, 223 (1984)), pKCR ( Proe. Nat. Acad. Sci. USA, 78, 1527 (1981)), pSGI(3d2-4 ( Cytotechnology, 4, 173 (1990)), pSElUKlSedl-3 ( Cytotechnol, 13., 79 1993)) and the like. A promoter and enhancer used for an animal cell expression vector include an SV4 0 early promoter and enhancer ( J. Biochem., 101, 1307 (1987)), a Moloney mouse leukemia virus LTR promoter and enhancer ( Biochem. Biophys, Res. Comun. , 149, 960 (1987)), an immunoglobulin H chain promoter ( Cell, 4_1, 479 (1985)) and enhancer ( Cell, 33., 717 (1983)), and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humanisert antistoff-ekspresjonsvektoren kan være enten av en type hvori et gen som koder for en antistoff H kjede og et gen som koder for en antistoff L kjede eksisterer på separate vektorer eller av en type hvori begge gener eksisterer på den samme vektor (tandem-type). Med hensyn til enkelheten av konstruksjon av en humanisert antistoff-ekspresjonsvektor, enkelhet av innføring i dyreceller, og balanse mellom ekspre-sjonsmengder av antistoff H og L kjeder i dyreceller, er en tandem-type av humanisert antistoff-ekspresjonsvektoren mer foretrukket (J". Immunol. Methods, 167, 271 (1994)). Tandem-typen av humanisert antistoff-ekspresjonsvektoren inkluderer pKANTEX93 (WO 97/10354), pEE18 (HYBRIDOMA, 17., 559 (1998)) og lignende. </span>The humanized antibody expression vector can be either of a type in which a gene encoding an antibody H chain and a gene encoding an antibody L chain exist on separate vectors or of a type in which both genes exist on the same vector (tandem type ). In view of the ease of construction of a humanized antibody expression vector, ease of introduction into animal cells, and balance between expression amounts of antibody H and L chains in animal cells, a tandem type of the humanized antibody expression vector is more preferred (J". Immunol. Methods, 167, 271 (1994)).The tandem type of humanized antibody expression vector includes pKANTEX93 (WO 97/10354), pEE18 (HYBRIDOMA, 17., 559 (1998)) and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den konstruerte humanisert antistoff-ekspresjonsvektor kan anvendes for ekspresjon av et humant CDR-podet antistoff i dyreceller. </span>The constructed humanized antibody expression vector can be used for expression of a human CDR-grafted antibody in animal cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2)Konstruksjon av cDNA som koder for V region av human CDR-podet antistoff cDNA-er som koder for VH og VL av et humant CDR-podet antistoff kan oppnås som følger. Først velges aminosyresekvenser av FR-er i VH og VL av et humant antistoff hvortil aminosyresekvenser av CDR-er i VH og VL av en antistoff avledet fra et ikke-humant dyre-antistoff er podet. Hvilken eller hvilke </span>(2) Construction of cDNA encoding V region of human CDR-grafted antibody cDNAs encoding VH and VL of a human CDR-grafted antibody can be obtained as follows. First, amino acid sequences of FRs in VH and VL of a human antibody are selected to which amino acid sequences of CDRs in VH and VL of an antibody derived from a non-human animal antibody are grafted. Which one or which ones</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">som helst aminosyresekvenser av FR-er i VH og VL av et humant antistoff kan anvendes, så lenge som de er avledet fra menneske. Eksempler inkluderer aminosyresekvenser av FR-er i VH og VL av humane antistoffer registrert i databaser slik som Protein Data Bank og lignende, og aminosyresekvenser som er felles for undergrupper av FR-er i VH og VL av humane antistoffer ( Sequences of Proteins of Immunologi cal Interest, US Dept. Health and Human Sevices (1991)), og lignende. For å produsere et humant CDR-podet antistoff som har potent aktivitet, velges foretrukket aminosyresekvenser som har høy homologi (minst 60% eller mer) med aminosyresekvens av FR-er i VH og VL av et mål-antistoff avledet fra et ikke-humant dyr. </span>any amino acid sequences of FRs in the VH and VL of a human antibody may be used, as long as they are derived from humans. Examples include amino acid sequences of FRs in the VH and VL of human antibodies registered in databases such as the Protein Data Bank and the like, and amino acid sequences common to subsets of FRs in the VH and VL of human antibodies ( Sequences of Proteins of Immunology cal Interest, US Dept. Health and Human Services (1991)), and the like. To produce a human CDR-grafted antibody having potent activity, amino acid sequences are preferably selected that have high homology (at least 60% or more) with amino acid sequence of FRs in VH and VL of a target antibody derived from a non-human animal .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aminosyresekvenser av CDR-er i VH og VL av antistoffet avledet fra et ikke-humant dyr podes deretter til de valgte aminosyresekvenser av FR-er i VH og VL av et humant antistoff for å designe aminosyresekvenser av VH og VL av et humant CDR-podet antistoff. De designede aminosyresekvenser omdan-nes til DNA-sekvenser ved å vurdere hyppigheten av kodon-bruk funnet i nukleotidsekvenser av gener av antistoffer (Seguence of Proteins of Immunological Interest, US Dept. Health and Human Services (1991)), og DNA-sekvensene som koder for aminosyresekvensene av VH og VL av et humant CDR-podet antistoff designes. Flere syntetiske DNA-er som har en lengde på omtrent 100 til 200 nukleotider syntetiseres, og PCR utføres ved anvendelse av disse. I dette tilfelle er det foretrukket i hver av VH og VL at 4 eller 6 syntetiske DNA-er er designet med tanke på reaksjonseffektiviteten av PCR og lengden av DNA-er som kan syntetiseres. Videre kan de enkelt klones inn i humanisert antistoff-ekspresjonsvektoren konstruert i punkt 1(1) ved innføring igjenkjennelsessekvensen av et passende restriksjonsenzym til 5' enden av de syntetiske DNA-er til stede på begge endene. Etter PCR klones et amplifisert produkt inn i et plasmid slik som pBluescript SK (-) (produsert av Stratagene) eller lignende, og nukletidsekvensene bestemmes til å oppnå et plasmid som har DNA-sekvenser som koder VH og VL av et designet humant CDR-podet antistoff. </span>Amino acid sequences of CDRs in VH and VL of the antibody derived from a non-human animal are then grafted to the selected amino acid sequences of FRs in VH and VL of a human antibody to design amino acid sequences of VH and VL of a human CDR graft antibody. The designed amino acid sequences are converted into DNA sequences by assessing the frequency of codon usage found in nucleotide sequences of genes of antibodies (Sequence of Proteins of Immunological Interest, US Dept. Health and Human Services (1991)), and the DNA sequences which codes for the amino acid sequences of VH and VL of a human CDR-grafted antibody are designed. Several synthetic DNAs having a length of about 100 to 200 nucleotides are synthesized and PCR is performed using these. In this case, it is preferred in each of VH and VL that 4 or 6 synthetic DNAs are designed in view of the reaction efficiency of PCR and the length of DNAs that can be synthesized. Furthermore, they can be easily cloned into the humanized antibody expression vector constructed in point 1(1) by introducing the recognition sequence of an appropriate restriction enzyme to the 5' end of the synthetic DNAs present at both ends. After PCR, an amplified product is cloned into a plasmid such as pBluescript SK (-) (manufactured by Stratagene) or the like, and the nucleotide sequences are determined to obtain a plasmid having DNA sequences encoding VH and VL of a designed human CDR graft antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3)Modifisering av aminosyresekvens av V region av humant CDR-podet antistoff </span>(3) Modification of amino acid sequence of V region of human CDR-grafted antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er kjent at når et humant CDR-podet antistoff produseres ved ganske enkelt å kode kun CDR-er i VH og VL av et antistoff avledet fra et ikke-humant dyr inn i FR-er i VH og VL av et humant antistoff, er dets antigenbindende aktivitet lavere enn den for det opprinnelige antistoff avledet fra et ikke-humant dyr ( BIO/' TECHNOLOGY, 9, 266 (1991)) . Hva angår årsaken, vurderes det at flere aminosyrerester i ikke bare CDR-er og også FR-er direkte eller indirekte relaterer til antigenbindende aktivitet i VH og VL av de opprinnelige antistoff avledet fra en ikke-humant dyr, og at de er forandret til forskjellige aminosyrerester av forskjellige FR-er i VH og VL av et humant antistoff. For å løse problemet, i humane CDR-podede antistoffer, blant aminosyresekvensene av FR-er i VH og VL av et humant antistoff, blir en aminosyrerest som direkte relaterer til binding til et antigen, eller en aminosyrerest som indirekte relaterer til binding til et antigen ved å interagere med en aminosyrerest i CDR eller ved å opp-rettholde den tredimensjonale struktur av et antistoff identifisert og modifisert til en aminosyrerest som finnes i det opprinnelige ikke-humane dyre-antistoff for derved å øke den antigenbindende aktivitet som er blitt redusert ( BIO/ TECHNOLOGY, 9, 266 (1991)). I produksjonen av et humant CDR-podet antistoff er det viktigst hvordan man effektivt kan identifisere aminosyrerestene som relaterer til den antigen-bindende aktivitet i FR, slik at den tredimensjonale struktur av et antistoff konstrueres og analyseres ved røntgen kry-stallografi ( J. Mol. Biol., 112, 535 (1977)), datamaskin-modellering ( Protein Engineering, 1_, 1501 (1994) ) eller lignende. Selv om informasjonen om den tredimensjonale struktur av antistoffer har vært anvendbar i produksjonen av et humant CDR-podet antistoff, er det ennå ikke blitt etablert noen metode for å produsere et humant CDR-podet antistoff som kan appliseres til noen antistoffer. Ulike forsøk må derfor for tiden være nødvendige, idet f.eks. flere modifiserte antistoffer av hvert antistoff produseres og forholdet mellom hvert av de modifiserte antistoffer og dets antistoffbindende aktivitet undersøkes. </span>It is known that when a human CDR-grafted antibody is produced by simply encoding only CDRs in the VH and VL of an antibody derived from a non-human animal into FRs in the VH and VL of a human antibody, its antigen-binding activity lower than that of the original antibody derived from a non-human animal (BIO/' TECHNOLOGY, 9, 266 (1991)). Regarding the cause, it is considered that several amino acid residues in not only CDRs and also FRs directly or indirectly relate to antigen-binding activity in VH and VL of the original antibody derived from a non-human animal, and that they are changed to different amino acid residues of different FRs in VH and VL of a human antibody. To solve the problem, in human CDR-grafted antibodies, among the amino acid sequences of FRs in VH and VL of a human antibody, an amino acid residue that directly relates to binding to an antigen, or an amino acid residue that indirectly relates to binding to an antigen by interacting with an amino acid residue in the CDR or by maintaining the three-dimensional structure of an antibody identified and modified to an amino acid residue found in the original non-human animal antibody to thereby increase the antigen-binding activity that has been reduced ( BIO / TECHNOLOGY, 9, 266 (1991)). In the production of a human CDR-grafted antibody, it is most important how to effectively identify the amino acid residues that relate to the antigen-binding activity in the FR, so that the three-dimensional structure of an antibody is constructed and analyzed by X-ray crystallography ( J. Mol. Biol., 112, 535 (1977)), computer modeling ( Protein Engineering, 1_, 1501 (1994) ) or the like. Although the information on the three-dimensional structure of antibodies has been useful in the production of a human CDR-grafted antibody, no method of producing a human CDR-grafted antibody that can be applied to any antibodies has yet been established. Various attempts must therefore currently be necessary, as e.g. several modified antibodies of each antibody are produced and the relationship between each of the modified antibodies and its antibody binding activity is investigated.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Modifiseringen av den valgte aminosyresekvens av FR-er i VH og VL av et humant antistoff kan utføres ved anvendelse av ulike syntetiske DNA for modifisering i samsvar med PCR. Hva angår det amplifiserte produkt oppnådd ved PCR, bestemmes nukleotidsekvensen i overensstemmelse med metoden som er beskrevet i punkt 1(2) slik at hvorvidt den tilsiktede modifisering er blitt utført bekreftes. (4) Konstruksjon av human CDR-podet antistoff-ekspresjonsvektor </span>The modification of the selected amino acid sequence of FRs in the VH and VL of a human antibody can be performed using various synthetic DNAs for modification in accordance with PCR. As regards the amplified product obtained by PCR, the nucleotide sequence is determined in accordance with the method described in point 1(2) so that whether or not the intended modification has been carried out is confirmed. (4) Construction of human CDR-grafted antibody expression vector</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En human CDR-podet antistoff-ekspresjonsvektor kan konstrueres ved å klone cDNA-er som koder for VH og VL av det humane CDR-podede antistoff konstruert i punktene 1(2) og 1(3) opp-strøms av genene som koder for VH og VL av det humane antistoff i humanisert antistoff-ekspresjonsvektoren som beskrevet i punkt 1(1). Når f.eks. gjenkjennelsesseter for passende restriksjonsenzymer er innført i 5&lt;1-&gt;enden av syntetiske DNA-er posisjonert ved begge ender blant syntetiske DNA-er anvendt i konstruksjonen av VH og VL av det humane CDR-podede antistoff i punktene 1(2) og (3), kan kloning utføres slik at de uttrykkes i en passende form oppstrøms av gener som koder for CH og CL av det humane antistoff i humanisert antistoff-ekspresjonsvektoren som er beskrevet i punkt 1(1). </span>A human CDR-grafted antibody expression vector can be constructed by cloning cDNAs encoding VH and VL of the human CDR-grafted antibody constructed in points 1(2) and 1(3) upstream of the genes encoding VH and VL of the human antibody in the humanized antibody expression vector as described in item 1(1). When e.g. recognition sites for appropriate restriction enzymes are introduced at the 5&lt;1-&gt;end of synthetic DNAs positioned at both ends among synthetic DNAs used in the construction of VH and VL of the human CDR-grafted antibody in items 1(2) and (3 ), cloning can be performed so that they are expressed in an appropriate form upstream of genes encoding CH and CL of the human antibody in the humanized antibody expression vector described in item 1(1).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(5) Transient ekspresjon av humant CDR-podet antistoff </span>(5) Transient expression of human CDR-grafted antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For å effektivt evaluere den antigenbindende aktivitet av </span>To effectively evaluate the antigen-binding activity of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">forskjellige produserte humane CDR-podede antistoffer, kan de humane CDR-podede antistoffer uttrykkes transient ved anvendelse av human CDR-podet antistoff-ekspresjonsvektoren som beskrevet i punkt 1(4) eller den modifiserte ekspresjonvektor </span>different produced human CDR-grafted antibodies, the human CDR-grafted antibodies can be transiently expressed using the human CDR-grafted antibody expression vector as described in item 1(4) or the modified expression vector</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">derav. En hvilken som helst celle kan anvendes som en vertcelle, så lenge som vertcellen kan uttrykke et humant CDR-podet antistoff. COS-7 celle (ATCC CRL16 51) anvendes generelt i betraktning av dens høye ekspresjonsmengde ( Methods in Nucleic Acids Res., CDV Press, s. 283 (1991)). Metoden for innføring av ekspresjonsvektoren i COS-7 celle inkluderer en DEAE-dekstran-metode ( Methods in Nucleic Acids Res., CRC Press, s. 283 (1991)), en lipofeksjonsmetode ( Proe, Nati. Acad. Sei. USA, 84., 7413 (1987)), og lignende. </span>hence. Any cell can be used as a host cell, as long as the host cell can express a human CDR-grafted antibody. COS-7 cell (ATCC CRL16 51) is generally used in view of its high expression level (Methods in Nucleic Acids Res., CDV Press, p. 283 (1991)). The method of introducing the expression vector into COS-7 cell includes a DEAE-dextran method ( Methods in Nucleic Acids Res., CRC Press, p. 283 (1991)), a lipofection method ( Proe, Nati. Acad. Sei. USA, 84 ., 7413 (1987)), and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter innføring av ekspresjonsvektoren, kan ekspresjonsmengden og antigenbindende aktivitet av det humane CDR-podede antistoff i kultur-supernatanten bestemmes ved enzym-immunanalyse (ELISA) ( Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 14 (1988), Monoclonal Antibodies: Principles and Practice, Academic Press Limited (1996)) og lignende. </span>After introduction of the expression vector, the expression level and antigen-binding activity of the human CDR-grafted antibody in the culture supernatant can be determined by enzyme-linked immunosorbent assay (ELISA) ( Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 14 (1988), Monoclonal Antibodies: Principles and Practice, Academic Press Limited (1996)) and similar.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(6)Stabil ekspresjon av humant CDR-podet antistoff </span>(6) Stable expression of human CDR-grafted antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En transformant som stabilt produserer et humant CDR-podet antistoff kan oppnås ved å innføre i en passende vertcelle human CDR-podet antistoff-ekspresjonsvektoren beskrevet i punkt 1(4). </span>A transformant that stably produces a human CDR-grafted antibody can be obtained by introducing into a suitable host cell the human CDR-grafted antibody expression vector described in point 1(4).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metoden for innføring av ekspresjonsvektoren i en vertcelle inkluderer elektroporering ( Cytotechnology, 3, 133 (1990)) og lignende. </span>The method of introducing the expression vector into a host cell includes electroporation (Cytotechnology, 3, 133 (1990)) and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En hvilken som helst celle kan anvendes som vertcellen som humant CDR-podet antistoff-ekspresjonsvektoren skal innføres i, så lenge som den kan uttrykke et humant CDR-podet antistoff. Eksempler inkluderer muse SP2/0-Agl4 celle (ATCC CRL1581), muse P3X63-Ag8.653 celle (ATCC CRL1580), CHO celle hvori et dihydrofolatreduktase (defr) gen er påvisbart ( Proe. Nati. Acad. Sei. U. S. A., 77, 4116 (1980)), rotte YB2/ 3HL.P2.Gll.16Ag.20 celle (YB2/0 celle; ATCC CRL1662) og lignende. </span>Any cell can be used as the host cell into which the human CDR-grafted antibody expression vector is to be introduced, as long as it can express a human CDR-grafted antibody. Examples include mouse SP2/0-Agl4 cell (ATCC CRL1581), mouse P3X63-Ag8.653 cell (ATCC CRL1580), CHO cell in which a dihydrofolate reductase (defr) gene is detectable ( Proe. Nati. Acad. Sei. U. S. A., 77, 4116 (1980)), rat YB2/3HL.P2.Gll.16Ag.20 cell (YB2/0 cell; ATCC CRL1662) and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter innføring av ekspresjonsvektoren, velges transformanter som stabilt uttrykker et humant CDR-podet antistoff ved dyrking i et medium for dyrecellekultur inneholdende et middel slik som G418 sulfat (G418; produsert av Sigma) eller lignende (J". Immuol. Methods, 167, 271 (1994)). Mediet for dyrecellekultur inkluderer PRMI1640 medium (produsert av Nissui Pharmaceutical), GIT medium (produsert av Nissui Pharmaceutical), EX-CELL302 medium (produsert av JRH), IMDM medium (produsert av GIBCO BRL), Hybridoma-SFM medium (produsert av GIBCO BRL), medier oppnådd ved å tilsette forskjellige additiver slik som FBS til disse mediene og lignende. Det humane CDR-podede antistoff kan produseres og akkumuleres i et kulturmedium ved å dyrke de valgte transformanter i et medium. Ekspresjonsmengden og antigenbindende aktivitet av det humaniserte antistoff i kultursupernatanten kan måles ved hjelp av ELISA eller lignende. Også, i transformanten, kan ekspresjonsmengden av det humane SDR-podede antistoff økes ved anvendelse av dhfr ampiifikasjonssystem eller lignende ( J. Immuol. Methods, 167, 271 (1994)). </span>After introduction of the expression vector, transformants stably expressing a human CDR-grafted antibody are selected by cultivation in an animal cell culture medium containing an agent such as G418 sulfate (G418; manufactured by Sigma) or the like (J". Immuol. Methods, 167, 271 (1994)).The medium for animal cell culture includes PRMI1640 medium (manufactured by Nissui Pharmaceutical), GIT medium (manufactured by Nissui Pharmaceutical), EX-CELL302 medium (manufactured by JRH), IMDM medium (manufactured by GIBCO BRL), Hybridoma-SFM medium (manufactured by GIBCO BRL), media obtained by adding various additives such as FBS to these media and the like. The human CDR-grafted antibody can be produced and accumulated in a culture medium by culturing the selected transformants in a medium. The expression amount and antigen-binding activity of the humanized antibody in the culture supernatant can be measured by ELISA or the like Also, in the transformant, the expression amount of the human SDR-grafted antibody can is increased by using the dhfr amplification system or similar (J. Immuol. Methods, 167, 271 (1994)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane CDR-podede antistoff kan renses fra kultursupernatanten av transformanten ved anvendelse av en protein A kolonne ( Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 8 (1988), Monoclonal Antibodies: Principles and Practice, Academic Press Limited (1996)). Hvilken eller hvilke som helst andre konvensjonelle metoder for proteinrensing kan anvendes. Det humaniserte antistoff kan f.eks. renses ved en kombinasjon av gelfiltrering, ionebytterkromatografi, ultrafiltrering og lignende. Molekyl-vekten til H kjeden eller L kjeden av det rensede humaniserte antistoff eller antistoffmolekylet som helhet betraktet bestemmes ved polyakrylamid-gel-elektroforese (SDS-PAGE; </span>The human CDR-grafted antibody can be purified from the culture supernatant of the transformant using a protein A column ( Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 8 (1988), Monoclonal Antibodies: Principles and Practice, Academic Press Limited (1996) ). Any other conventional protein purification method(s) may be used. The humanized antibody can e.g. is purified by a combination of gel filtration, ion exchange chromatography, ultrafiltration and the like. The molecular weight of the H chain or L chain of the purified humanized antibody or the antibody molecule as a whole is determined by polyacrylamide gel electrophoresis (SDS-PAGE;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nature, 227, 680 (197)), Western blotting { Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 12 </span>Nature, 227, 680 (197)), Western blotting { Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 12</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1988), Monoclonal Antibodies: Principles and Practice, Academic Press Limited (1966)) og lignende. </span>(1988), Monoclonal Antibodies: Principles and Practice, Academic Press Limited (1966)) and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2.Fremstilling av antistoffragment </span>2.Preparation of antibody fragment</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffragmentet kan fremstilles basert på det humaniserte antistoff beskrevet i punkt 1 ved anvendelse av genteknikk eller proteinteknikk. Antistoffragmentet inkluderer Fab, F(ab')2Fab&lt;1&gt;sdFv, diabody, dsFv, et peptid omfattende CDR, og lignende. </span>The antibody fragment can be produced based on the humanized antibody described in point 1 using genetic engineering or protein engineering. The antibody fragment includes Fab, F(ab')2Fab&lt;1&gt;sdFv, diabody, dsFv, a peptide comprising CDRs, and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1)Fremstilling av Fab </span>(1) Production of Fab</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fab kan fremstilles ved å behandle IgG med et proteolytisk enzym papain. Etter papainbehandlingen, når de opprinnelige antistoff er en IgG underklasse som har en protein A-bindende aktivitet, kan ensartet Fab utvinnes ved å separere det fra IgG molekyler og Fc fragmenter ved passering gjennom en protein A kolonne ( Monoclonal Antibodies: Principles and Practice, (1995)). Når det opprinnelige antistoff er et antistoff av IgG underklasse som ikke har noen protein A-bindende aktivitet, kan Fab utvinnes ved ionebytterkromatografi i en fraksjon eluert ved en lav saltkonsentrasjon ( Monoclonal Antibodies: Principles and Practice, tredje utgave (1995)). I tillegg kan Fab også fremstilles ved genmanipuleringsteknikker ved anvendelse av Escherichia coli. </span>Fab can be prepared by treating IgG with a proteolytic enzyme papain. After the papain treatment, when the original antibody is an IgG subclass that has a protein A-binding activity, uniform Fab can be recovered by separating it from IgG molecules and Fc fragments by passing through a protein A column ( Monoclonal Antibodies: Principles and Practice, ( 1995)). When the original antibody is an antibody of the IgG subclass that has no protein A-binding activity, the Fab can be recovered by ion-exchange chromatography in a fraction eluted at a low salt concentration (Monoclonal Antibodies: Principles and Practice, third edition (1995)). In addition, Fab can also be produced by genetic engineering techniques using Escherichia coli.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En Fab ekspresjonsvektor kan f.eks. fremstilles ved kloning av DNA-et som koder for antistoff V regionen beskrevet i punktene 1(2) og 1(3) inn i en vektor for Fab ekspresjon. Som vektoren for Fab ekspresjon kan en hvilken som helst vektor anvendes, så lenge som et DNA for Fab kan innskytes og uttrykkes. Eksempler inkluderer pIT106 ( Science, 240, 1041 </span>A Fab expression vector can e.g. is produced by cloning the DNA that codes for the antibody V region described in points 1(2) and 1(3) into a vector for Fab expression. As the vector for Fab expression, any vector can be used, as long as a DNA for Fab can be inserted and expressed. Examples include pIT106 (Science, 240, 1041</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1988)) og lignende. Fab kan dannes og akkumuleres i et inklusjonslegeme eller periplasmisk rom ved å innføre Fab ekspresjonvektoren i en passende Escherichia coli. Aktiv Fab kan oppnås fra inklusjonslegemet ved hjelp av en refoldings metode generelt anvendt for protein, og når den er uttrykt i det periplasmiske rom lekkes aktiv Fab i kultursupernatanten. </span>(1988)) and the like. Fab can be formed and accumulate in an inclusion body or periplasmic space by introducing the Fab expression vector into an appropriate Escherichia coli. Active Fab can be obtained from the inclusion body using a refolding method generally used for protein, and when it is expressed in the periplasmic space, active Fab is leaked into the culture supernatant.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensartet Fab kan renses etter refoldingen eller fra kultur-supernatanten ved anvendelse av en antistoff-forbundet kolonne ( Antibody Engineering, A Practical Guide, W.H. Freeman and Company (1992)). </span>The uniform Fab can be purified after the refolding or from the culture supernatant using an antibody coupled column ( Antibody Engineering, A Practical Guide, W.H. Freeman and Company (1992)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) Fremstilling av F(ab')2</span>(2) Preparation of F(ab')2</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">F(ab')2 kan fremstilles ved å behandle IgG med et proteolytisk enzym papain. Etter papainbehandlingen kan den gjen-vinnes som ensartet F(ab')2 ved hjelp av en renseprosedyre som ligner på tilfellet med Fab ( Monoclonal Antibodies: Principles and Practice, tredje utgave, Academic Press </span>F(ab')2 can be produced by treating IgG with a proteolytic enzyme papain. After the papain treatment, it can be recovered as uniform F(ab')2 by a purification procedure similar to the case of Fab (Monoclonal Antibodies: Principles and Practice, Third Edition, Academic Press</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1995)). I tillegg kan den også fremstilles ved hjelp av metoden beskrevet i punkt 2(3) hvori Fab&lt;1&gt;behandles med maleimid slik som o-PDM, bismaleimidheksan eller lignende til å danne en tioeterbinding, eller en metode hvori den behandles med DTNB til å danne en S-S binding ( Antibody Engineering, A Practical Approach, IRL PRESS (1966)). </span>(1995)). In addition, it can also be prepared using the method described in point 2(3) in which Fab&lt;1&gt; is treated with maleimide such as o-PDM, bismaleimide hexane or the like to form a thioether bond, or a method in which it is treated with DTNB to form an S-S bond ( Antibody Engineering, A Practical Approach, IRL PRESS (1966)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3) Fremstilling av Fab&lt;1&gt;</span>(3) Preparation of Fab&lt;1&gt;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fab&lt;1&gt;kan fremstilles ved genmanipuleringsteknikker ved anvendelse av Escherichia coli. En Fab&lt;1&gt;ekspresjonsvektor kan f.eks. konstrueres ved å klone DNA-et som koder for antistoff V regionen beskrevet i punktene 1(2) og (3) inn i en vektor for Fab&lt;1&gt;ekspresjon. Som vektoren for Fab&lt;1&gt;ekspresjon kan en hvilken som helst vektor anvendes, så lenge som et DNA for Fab&lt;1&gt;kan innskytes og uttrykkes. Eksempler inkluderer pAK19 ( Bio/ Techonolgy, 10., 163 (1992)) og lignende. Fab&lt;1&gt;kan dannes og akkumuleres i et inklusjonslegeme eller periplasmisk rom ved innføring av Fab&lt;1&gt;ekspresjonsvektoren i en passende Escherichia coli. Aktiv Fab&lt;1&gt;kan oppnås fra inklusjonslegemet ved hjelp av en refoldingsmetode som generelt anvendes for protein, og når den er uttrykt i det periplasmiske rom kan de utvinnes i ekstracellulær enhet ved å oppbryte cellene med en behandling slik som partiell lysozymnedbryt ning, osmotisk trykksjokk, lydbehandling eller lignende. Ensartet Fab' kan renses etter refoldingen eller fra den oppbrutte cellesuspensjon ved anvendelse av en protein G kolonne eller lignende ( Antibody Engineering, A Practical Approach, IRL PRESS (1966)), </span>Fab&lt;1&gt; can be produced by genetic engineering techniques using Escherichia coli. A Fab&lt;1&gt; expression vector can e.g. is constructed by cloning the DNA encoding the antibody V region described in points 1(2) and (3) into a vector for Fab&lt;1&gt; expression. As the vector for Fab&lt;1&gt; expression, any vector can be used, as long as a DNA for Fab&lt;1&gt; can be inserted and expressed. Examples include pAK19 (Bio/Techonolgy, 10., 163 (1992)) and the like. Fab&lt;1&gt; can be formed and accumulated in an inclusion body or periplasmic space by introducing the Fab&lt;1&gt; expression vector into an appropriate Escherichia coli. Active Fab&lt;1&gt; can be obtained from the inclusion body using a refolding method generally used for protein, and when expressed in the periplasmic space they can be recovered in the extracellular unit by breaking up the cells with a treatment such as partial lysozyme degradation, osmotic pressure shock , sound processing or the like. The uniform Fab' can be purified after the refolding or from the disrupted cell suspension using a protein G column or the like ( Antibody Engineering, A Practical Approach, IRL PRESS (1966)),</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(4) Fremstilling av scFv </span>(4) Preparation of scFv</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">scFv kan fremstilles ved anvendelse av en fag eller Escherichia coli ved hjelp genmanipuleringsteknikker. Et DNA som koder for scFv produseres f.eks. ved å ligere DNA-er som koder for antistoff VH og VL beskrevet i punktene 1(2) og (3) via et DNA som koder for en polypeptid-linker omfattende en aminosyresekvens av 12 rester eller mer. En scFv ekspresjonsvektor kan konstrueres ved å klone det resulterende DNA inn i en vektor for scFv ekspresjon. Som vektoren for scFv ekspresjon kan en hvilken som helst vektor anvendes, så lenge som et DNA for scFv kan innskytes og uttrykkes. Eksempler inkluderer pCANTAB5E (produsert av Pharmacia), Phfa (Hum. Antibody Hybridoma, 5, 48 (1994)) og lignende. scFv ekspresjonsvektoren ble innført i en passende Escherichia coli og infisert med en hjelper-fag for derved å oppnå en fag som uttrykker scFv på fag-overflaten i en fusjonert form med fag-overflateproteinet. scFv kan også dannes og akkumuleres i inklusjonslegemet eller det periplasmiske rom av Escherichia coli som scFv ekspresjonsvektor innføres i. Aktiv scFv kan oppnås fra inklusjonslegemet ved hjelp av en refoldingsmetode som generelt anvendes for protein, og når den er uttrykt i det periplasmiske rom kan den utvinnes ekstracellulært ved oppbryting av cellene med en behandling slik som delvis lysozymnedbrytning, osmotisk trykksjokk, lydbehandling eller lignende. Ensartet scFv kan renses etter refoldingen eller fra den oppbrutte cellesuspensjon ved kationbytterkromato-grafi eller lignende ( Antibody Engineering, A Practical Approach, IRL PRESS (1996)). </span>The scFv can be produced using a phage or Escherichia coli using genetic engineering techniques. A DNA that codes for the scFv is produced, e.g. by ligating DNAs encoding antibody VH and VL described in items 1(2) and (3) via a DNA encoding a polypeptide linker comprising an amino acid sequence of 12 residues or more. An scFv expression vector can be constructed by cloning the resulting DNA into a vector for scFv expression. As the vector for scFv expression, any vector can be used, as long as a DNA for scFv can be inserted and expressed. Examples include pCANTAB5E (manufactured by Pharmacia), Phfa (Hum. Antibody Hybridoma, 5, 48 (1994)) and the like. The scFv expression vector was introduced into a suitable Escherichia coli and infected with a helper phage to thereby obtain a phage which expresses the scFv on the phage surface in a fused form with the phage surface protein. scFv can also form and accumulate in the inclusion body or periplasmic space of Escherichia coli into which the scFv expression vector is introduced. Active scFv can be obtained from the inclusion body using a refolding method generally used for protein, and when expressed in the periplasmic space it can be recovered extracellularly by breaking up the cells with a treatment such as partial lysozyme degradation, osmotic pressure shock, sound treatment or the like. Uniform scFv can be purified after refolding or from the disrupted cell suspension by cation exchange chromatography or the like (Antibody Engineering, A Practical Approach, IRL PRESS (1996)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(5) Fremstilling av diabody </span>(5) Preparation of diabody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Diabody kan fremstilles ved å forandre størrelsen av polypeptid-linkeren for fremstilling av scFv til omtrent 3 til 10 rester. Et divalent diabody kan fremstilles når VH og VL av en antistoff-species anvendes, og et diabody som har to forskjellige spesifisiteter når VH og VL av to antistoff-species anvendes ( FEBS Letters, 453, 164 (1999), Int. J. Cancer, 77., 763 (1998)). </span>Diabodies can be made by varying the size of the polypeptide linker to make the scFv to about 3 to 10 residues. A divalent diabody can be produced when VH and VL of one antibody species are used, and a diabody having two different specificities when VH and VL of two antibody species are used (FEBS Letters, 453, 164 (1999), Int. J. Cancer , 77, 763 (1998)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(6) Fremstilling av dsFv </span>(6) Preparation of dsFv</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">dsFv kan fremstilles ved anvendelse av Escherichia coli ved hjelp av genmanipuleringsteknikker. Først produseres DNA-er hvori en kodet aminosyrerest er erstattet med en cysteinrest ved innføring av mutering i passende posisjoner av DNA-ene som koder for antistoff VH og VL beskrevet i punktene 1(2) og 1(3). VH og VL ekspresjonsvektorer kan produseres ved å klone hvert av de resulterende DNA-er inn i en vektor for dsFv ekspresjon. Som vektoren for dsFv ekspresjon kan en hvilken som helst vektor anvendes, så lenge som et DNA for dsFv kan innskytes og uttrykkes. Eksempler inkluderer pULI9 ( Protein Engineering, 6 97 (1994) og lignende. VH og VL ekspresjonsvektorene innføres i en passende Escherichia coli for derved å danne og akkumulere VH og VL i inklusjonslegemet eller det periplasmiske rom. VH og VL oppnås fra inklusjonslegemet eller det periplasmiske rom og blandes, og aktiv dsFv kan oppnås ved hjelp av en refoldingsmetode som generelt anvendes for protein. Etter refoldingen kan den ytterligere renses ved ionebytterkromatografi og gelfiltrering eller lignende ( Protein Engineering, !_&gt;6 97 (1994) ) . </span>dsFv can be produced using Escherichia coli using genetic engineering techniques. First, DNAs are produced in which a coded amino acid residue is replaced by a cysteine residue by introducing mutations in appropriate positions of the DNAs that code for antibodies VH and VL described in points 1(2) and 1(3). VH and VL expression vectors can be produced by cloning each of the resulting DNAs into a vector for dsFv expression. As the vector for dsFv expression, any vector can be used, as long as a DNA for dsFv can be inserted and expressed. Examples include pULI9 ( Protein Engineering, 6 97 (1994) and the like. The VH and VL expression vectors are introduced into an appropriate Escherichia coli to thereby form and accumulate VH and VL in the inclusion body or periplasmic space. VH and VL are obtained from the inclusion body or periplasmic room and mixed, and active dsFv can be obtained by means of a refolding method that is generally used for protein. After the refolding, it can be further purified by ion exchange chromatography and gel filtration or the like (Protein Engineering, !_&gt;6 97 (1994) ).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(7) Fremstilling av peptid omfattende CDR </span>(7) Preparation of peptide comprising CDR</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et peptid omfattende CDR kan fremstilles ved en kjemisk syntesemetode slik som Fmoc, tBoc eller lignende. Et DNA som koder for et peptid omfattende CDR fremstilles også, og det resulterende DNA klones inn i en passende vektor for ekspresjon for derved å fremstille peptidet omfattende CDR. Som vektoren for ekspresjon kan en hvilken som helst vektor an vendes, så lenge som et DNA som koder for et peptid omfattende et CDR innskytes og uttrykkes. Eksempler inkluderer pLEX (produsert av Invitrogen), pAX4a+ (produsert av Invitrogen) og lignende. Ekspresjonsvektoren innføres i en passende Escherichia coli slik at peptidet omfattende CDR kan dannes og akkumuleres i inklusjonslegemet eller det periplasmiske rom. Peptidet omfattende CDR kan oppnås fra inklusjonslegemet eller det periplasmiske rom, og det kan renses ved ionebytterkromtografi og gelfiltrering eller lignende { Protein Engineering, 7, 697 (1994)). 3.Evaluering av aktivitet og egenskap til antistoffet i
henhold til den foreliggende oppfinnelse. </span>A peptide comprising CDRs can be prepared by a chemical synthesis method such as Fmoc, tBoc or the like. A DNA encoding a CDR-comprising peptide is also prepared, and the resulting DNA is cloned into an appropriate vector for expression to thereby produce the CDR-comprising peptide. As the vector for expression, any vector can be used, as long as a DNA encoding a peptide comprising a CDR is inserted and expressed. Examples include pLEX (manufactured by Invitrogen), pAX4a+ (manufactured by Invitrogen) and the like. The expression vector is introduced into a suitable Escherichia coli so that the CDR-comprising peptide can be formed and accumulate in the inclusion body or periplasmic space. The peptide comprising the CDR can be obtained from the inclusion body or the periplasmic space, and it can be purified by ion exchange chromatography and gel filtration or the like {Protein Engineering, 7, 697 (1994)). 3.Evaluation of activity and properties of the antibody i
according to the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) Evaluering av bindende aktivitet for antigen </span>(1) Evaluation of binding activity for antigen</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En bindende aktivitet av antistoffet i henhold til den foreliggende oppfinnelse for et antigen kan måles ved ELISA (enzyme-linked immunosorbent assay), fluorescerende antistof f -teknikk { Cancer Immunol. Immunother., 36., 373 (1993)), overflateplasmon-resonans ved anvendelse av slikt som BIAcore og lignende. Spesifikt produseres et syntetisk peptid omfattende en CCR4 partiell sekvens og et konjugat fremstilles ved å kjemisk forbinde dette til et bærerprotein slik som bovint serumalbumin eller lignende. En CCR4 bindende aktivitet av antistoffet i henhold til den foreliggende oppfinnelse kan måles ved immobilisering av konjugatet på en ELISA-plate, å la det reagere med antistoffet i henhold til den foreliggende oppfinnelse, videre å la det reagere med et merket antistoff eller bindende fragment slik som et peroksydase- eller biotin-merket antistoff eller bindende fragment, og deretter å måle et fargestoff ved anvendelse av et absorpsjonsfotometer. </span>A binding activity of the antibody according to the present invention for an antigen can be measured by ELISA (enzyme-linked immunosorbent assay), fluorescent antibody technique {Cancer Immunol. Immunother., 36., 373 (1993)), surface plasmon resonance using the likes of BIAcore and the like. Specifically, a synthetic peptide comprising a CCR4 partial sequence is produced and a conjugate is prepared by chemically linking this to a carrier protein such as bovine serum albumin or the like. A CCR4 binding activity of the antibody according to the present invention can be measured by immobilizing the conjugate on an ELISA plate, allowing it to react with the antibody according to the present invention, further allowing it to react with a labeled antibody or binding fragment as as a peroxidase- or biotin-labeled antibody or binding fragment, and then measuring a dye using an absorption photometer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) Reaktivitet for CCR4-uttrykkende celler </span>(2) Reactivity for CCR4-expressing cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For å undersøke reaktiviteten for CCR4-uttrykkende celler, er det foretrukket å anvende en metode for effektivt å påvise CCR4 uttrykt på celleoverflaten. Metoden inkluderer flow- cytometri ved anvendelse av fluorescerende antistoff-teknikk og lignende. Når reaktivitet med levende kroppsceller slik som blodplate og lignende undersøkes, er det i tillegg foretrukket å utføre undersøkelsen under betingelser som ligger så nær den levende kroppen som mulig. På grunn av disse år-saker, når reaktivitet av anti-CCR4 antistoffet i henhold til den foreliggende oppfinnelse undersøkes, er det mest ønskelig å utføre undersøkelsen ved flow-cytometri ved anvendelse av fluorescerende antistoff-teknikk. </span>To examine the reactivity for CCR4-expressing cells, it is preferred to use a method to efficiently detect CCR4 expressed on the cell surface. The method includes flow cytometry using the fluorescent antibody technique and the like. When reactivity with living body cells such as platelets and the like is examined, it is also preferred to carry out the examination under conditions that are as close to the living body as possible. Because of these issues, when reactivity of the anti-CCR4 antibody according to the present invention is examined, it is most desirable to perform the examination by flow cytometry using the fluorescent antibody technique.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffet anvendt i fluorescerende antistoff-teknikken kan være enten et antistoff merket med et fluorescerende materiale slik som FITC, biotin eller lignende, eller et umerket antistoff. Avhengig av tilstedeværelsen eller fraværet av en merking av det anvendte antistoff og dens type, anvendes fluorescens-merket avidin, et fluorescens-merket anti-humant immunglobulin-antistoff og lignende. Reaktiviteten kan evalueres ved å utføre reaksjonen ved tilsetning av en tilstrekkelig mengde av et anti-CCR4 antistoff (generelt fra 0,1 til 10 ug/ml som den endelige konsentrasjon) til en testet prøve og ved sammenligning av dets reaktivitet med dem for et nega-tivt kontroll-antistoff og en positiv kontroll-antistoff. </span>The antibody used in the fluorescent antibody technique can be either an antibody labeled with a fluorescent material such as FITC, biotin or the like, or an unlabeled antibody. Depending on the presence or absence of a label of the antibody used and its type, fluorescently labeled avidin, a fluorescently labeled anti-human immunoglobulin antibody and the like are used. The reactivity can be evaluated by performing the reaction by adding a sufficient amount of an anti-CCR4 antibody (generally from 0.1 to 10 µg/ml as the final concentration) to a tested sample and by comparing its reactivity with that of a nega -tive control antibody and a positive control antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3) Cytotoksisk aktivitet </span>(3) Cytotoxic activity</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den cytotoksiske aktivitet for CCR4-uttrykkende celler kan evalueres ved å måle CDC aktivitet, ADCC aktivitet og lignende ( Cancer Immunol. Immunother. , 36., 373 (1993)). Forandringer i mengden produsert cytokin kan måles ved hjelp av ELISA-metoden, fluorescerende antistoff-teknikk og lignende ved anvendelse av et antistoff for cytokin. </span>The cytotoxic activity for CCR4-expressing cells can be evaluated by measuring CDC activity, ADCC activity and the like ( Cancer Immunol. Immunother. , 36., 373 (1993)). Changes in the amount of cytokine produced can be measured using the ELISA method, fluorescent antibody technique and the like using an antibody for cytokine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(4) Aktivitet med inhibering av ligandbinding </span>(4) Activity with inhibition of ligand binding</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aktivitet med inhibering av ligandbinding av anti-CCR4 antistoffet i henhold til den foreliggende oppfinnelse kan undersøkes ved å anvende en merking av TARC eller MDC som en ligand som har en bindende aktivitet til CCR4 og en CCR4-ut- trykkende celle eller en cellemembran fraksjon derav. TARC eller MDC kan merkes ved hjelp av en hvilken som helst teknikk som kan påvises, og eksempler inkluderer fluorescens-merking, enzymmerking, strålingsmerking og lignende. Spesifikke eksempler inkluderer metoden ved å måle den bindings-inhiberende aktivitet ved anvendelse av en strålingsmerking beskrevet i WO 00/42074. </span>An activity with inhibition of ligand binding of the anti-CCR4 antibody according to the present invention can be investigated by using a labeling of TARC or MDC as a ligand that has a binding activity to CCR4 and a CCR4-expressing cell or a cell membrane fraction hence. TARC or MDC can be labeled using any detectable technique, and examples include fluorescence labeling, enzyme labeling, radiolabeling, and the like. Specific examples include the method of measuring the binding inhibitory activity using a radiolabel described in WO 00/42074.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aktivitet med inhibering av ligandbinding av det anti-CCR4 antistoff i henhold til den foreliggende oppfinnelse kan også undersøkes ved å anvende en cellerespons indusert ved binding av et ligand til CCR4 som en pekepinn. Celleresponsen kan </span>An activity of inhibiting ligand binding of the anti-CCR4 antibody according to the present invention can also be investigated by using a cell response induced by binding of a ligand to CCR4 as a cue. The cell response can</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">være en hvilken som helst type så lenge som den induseres ved å bringe et ligand i kontakt med en CCR4-uttrykkende celle, og eksempler inkluderer forandringer i intracellulær kalsium-konsentrasjon, cellemigrasjon og lignende. Spesifikke eksempler inkluderer metoden som måler migrasjonsinhibering av en CCR4-uttrykkende celle indusert ved en CCR4 ligand beskrevet i WO 00/42074. </span>can be any type as long as it is induced by contacting a ligand with a CCR4-expressing cell, and examples include changes in intracellular calcium concentration, cell migration, and the like. Specific examples include the method measuring migration inhibition of a CCR4-expressing cell induced by a CCR4 ligand described in WO 00/42074.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(5)Undersøkelse av gjenkjennelsessekvens </span>(5) Examination of recognition sequence</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aminosyresekvens som kan gjenkjennes av antistoffet i henhold til den foreliggende oppfinnelse kan bestemmes ved anvendelse av et syntetisk peptid som er designet basert på den primære sekvens av dets korresponderende antigenprotein. </span>An amino acid sequence that can be recognized by the antibody of the present invention can be determined using a synthetic peptide designed based on the primary sequence of its corresponding antigen protein.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En primær sekvens av det syntetiske peptid designes basert på den primære sekvens av antigenproteinet. For å fremstille et protein hvori det syntetiske peptid er kryssbundet med et </span>A primary sequence of the synthetic peptide is designed based on the primary sequence of the antigen protein. To prepare a protein in which the synthetic peptide is cross-linked with a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">bærerprotein, kan en cysteinrest tilsettes til karboksy-enden eller amino-enden av det syntetiske peptid. Det resulterende protein kan anvendes i ELISA som vil beskrives i det etter-følgende. Om nødvendig, kan N-enden og C-enden av det syntetiske peptid også henholdsvis være acetylert og amidert. </span>carrier protein, a cysteine residue can be added to the carboxy-terminus or the amino-terminus of the synthetic peptide. The resulting protein can be used in ELISA, which will be described in the following. If necessary, the N-terminus and C-terminus of the synthetic peptide can also be respectively acetylated and amidated.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et peptid kan syntetiseres ved hjelp av en generell væske-fase- eller fastfase-peptid syntetiseringsmetode, en hvilken som helst kombinert metode derav eller en modifisert metode derav ( International Journal of Peptide Protein Research, 35., 161-214 (1990), "Solid-Phase Peptide Synthesis", Methods in Enzymology, vol 289, forfattet av Gregg B. Fields, Academic Press (1997), "Peptide Synthesis Protocols", Methods in Molecular Biology, vol. 35, forfattet av Michael W. Pennington og Ben M. Dunn, Humana Press (1994)). </span>A peptide may be synthesized by a general liquid-phase or solid-phase peptide synthesis method, any combined method thereof or a modified method thereof (International Journal of Peptide Protein Research, 35., 161-214 (1990), " Solid-Phase Peptide Synthesis", Methods in Enzymology, vol 289, authored by Gregg B. Fields, Academic Press (1997), "Peptide Synthesis Protocols", Methods in Molecular Biology, vol. 35, authored by Michael W. Pennington and Ben M. Dunn, Humana Press (1994)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I tillegg kan det også anvendes en automatisk peptidsyntetiseringsinnretning. Syntese av et peptid ved hjelp av en peptidsyntetiseringsinnretning kan utføres ved hjelp av en kommersielt tilgjengelig peptidsyntetiseringsinnretning slik som peptidsyntetiseringsinnretningen produsert av Shimadzu Corp., peptidsyntetiseringsinnretningen produsert av Advanced ChemTech Inc, USA (i det etterfølgende referert til som "ACT") eller lignende, ved anvendelse av f^-Fmoc-aminosyrer, N&lt;01-&gt;Boe-aminosyrer eller lignende hvis sidekjeder er passende beskyttet og i overensstemmelse med respektive synteseprogrammer. De beskyttede aminosyrer anvendt som materialet og bærerharpikser kan anskaffes fra ABI Inc., Shimadzu Corp., Kokusan Kagaku K.K.. NovaBiochem, Watanabe Kagaku K.K., ACT, AnaSpec Inc., Peptide Research Institute og lignende. </span>In addition, an automatic peptide synthesizing device can also be used. Synthesis of a peptide using a peptide synthesizing device can be performed using a commercially available peptide synthesizing device such as the peptide synthesizing device manufactured by Shimadzu Corp., the peptide synthesizing device manufactured by Advanced ChemTech Inc, USA (hereinafter referred to as "ACT") or the like, by use of f^-Fmoc amino acids, N&lt;01-&gt;Boe amino acids or the like whose side chains are suitably protected and in accordance with respective synthesis programs. The protected amino acids used as the material and carrier resins can be obtained from ABI Inc., Shimadzu Corp., Kokusan Kagaku K.K., NovaBiochem, Watanabe Kagaku K.K., ACT, AnaSpec Inc., Peptide Research Institute and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som metoden for bestemmelse av en aminosyresekvens som er gjenkjennelig ved hjelp av antistoffet i henhold til den foreliggende oppfinnelse ved anvendelse av det syntetiske peptid, kan det anvendes en hvilken som helst teknikk så lenge som den er en metode som kan påvise binding av det syntetiske peptid til antistoffet. Aminosyresekvensen som er </span>As the method for determining an amino acid sequence recognizable by the antibody of the present invention using the synthetic peptide, any technique can be used as long as it is a method that can detect binding of the synthetic peptide to the antibody. The amino acid sequence that is</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">gjenkjennelig ved antistoffet kan f.eks. bestemmes ved å merke det syntetiske peptid med et fluorescerende materiale, et radioaktivt materiale eller lignende og å undersøke bindingsaktiviteten av det resulterende merkede peptid til antistoffet. Den kan også utføres ved kryssbinding av det syntetiske peptid med et protein slik som bovint serumalbumin (BSA) eller lignende og evaluering av reaktiviteten av det </span>recognizable by the antibody can e.g. is determined by labeling the synthetic peptide with a fluorescent material, a radioactive material or the like and examining the binding activity of the resulting labeled peptide to the antibody. It can also be carried out by cross-linking the synthetic peptide with a protein such as bovine serum albumin (BSA) or the like and evaluating the reactivity of the</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">resulterende protein med antistoffet ved hjelp av ELISA eller lignende. I tillegg kan en aminosyresekvens som er gjenkjennelig ved antistoffet i henhold til den foreliggende oppfinnelse også bestemmes ved å anvende en substans som det allerede er bekreftet at antistoffet binder til, slik som et antistoffprotein, og å undersøke et syntetisk peptid som inhiberer binding av antistoffet til substansen. </span>resulting protein with the antibody using ELISA or the like. In addition, an amino acid sequence recognizable by the antibody according to the present invention can also be determined by using a substance to which the antibody has already been confirmed to bind, such as an antibody protein, and examining a synthetic peptide that inhibits binding of the antibody to the substance.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(4)Metode for påvisning og kvantifisering av CCR4 ved anvendelse av anti-CCR-antistoff </span>(4) Method for detection and quantification of CCR4 using anti-CCR antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den foreliggende oppfinnelse tilhører en metode for immunologisk påvisning og bestemmelse av CCR4 eller en celle som uttrykker CCR4 på overflaten derav ved anvendelse av antistoffet i henhold til den foreliggende oppfinnelse. </span>The present invention belongs to a method for immunological detection and determination of CCR4 or a cell that expresses CCR4 on its surface using the antibody according to the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metodene for immunologisk påvisning og bestemmelse av CCR4 eller en celle som uttrykker CCR4 på overflaten derav ved anvendelse av antistoffet i henhold til den foreliggende oppfinnelse inkluderer en immunfluorescerende metode, ELISA (enzyme-linked immunosorbent assay), en radioaktivt materiale-merket immunanalyse (RIA), en immunhitsokjemisk fargemetode slik som en immunocytt-fargemetode, en immunvev-fargemetode eller lignende (ABC metode, CSA metode etc.), den ovennevnte enzym immunanalyse, en sandwich ELISA ( Monoclonal Antibody Experiment Manual (publisert av Kodansha Scientific, 1987), Second Series Biochemical Experiment Course, Vol. 5, Immunobiochemistry Research Method, publisert av Tokyo Kagaku Dojin (1986)). </span>The methods for immunological detection and determination of CCR4 or a cell expressing CCR4 on its surface using the antibody according to the present invention include an immunofluorescent method, ELISA (enzyme-linked immunosorbent assay), a radioactive material-labelled immunoassay (RIA) , an immunohistochemical staining method such as an immunocyte staining method, an immune tissue staining method or the like (ABC method, CSA method, etc.), the above-mentioned enzyme immunoassay, a sandwich ELISA ( Monoclonal Antibody Experiment Manual (published by Kodansha Scientific, 1987), Second Series Biochemical Experiment Course, Vol. 5, Immunobiochemistry Research Method, published by Tokyo Kagaku Dojin (1986)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den immunfluorescerende metoden omfatter å reagere en separert celle, vev eller lignende med antistoffet i henhold til den foreliggende oppfinnelse, å reagerer reaktanten med et anti-immunglobulin antistoff eller bindingsfragment merket med en fluorescens substans slik som fluoresceinisotiocyanat (FITC) eller lignende, og deretter å måle fluorescenssub-stansen med et flow-cytometer. </span>The immunofluorescent method comprises reacting a separated cell, tissue or the like with the antibody according to the present invention, reacting the reactant with an anti-immunoglobulin antibody or binding fragment labeled with a fluorescent substance such as fluorescein isothiocyanate (FITC) or the like, and then measure the fluorescence substance with a flow cytometer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ELISA (enzyme-linked immunosorbent assay) omfatter å reagere en separert celle elle cellelysat derav, vev eller vevs-lysatet derav, cellekultur-supernatant, serum, preuralvæske, ascitesvæske, okulærvæske eller lignende med antistoffet i henhold til den foreliggende oppfinnelse, å reagere reaktanten med et anti-immunglobulin antistoff eller bindingsfragment merket med et enzym slik som peroksydase, biotin eller lignende, og deretter å måle den resulterende utviklede farge med et absorpsjonsfotometer. </span>ELISA (enzyme-linked immunosorbent assay) comprises reacting a separated cell or cell lysate thereof, tissue or tissue lysate thereof, cell culture supernatant, serum, preural fluid, ascites fluid, ocular fluid or the like with the antibody according to the present invention, reacting the reactant with an anti-immunoglobulin antibody or binding fragment labeled with an enzyme such as peroxidase, biotin or the like, and then measuring the resulting developed color with an absorption photometer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den radioaktivt material-merkede immunanalyse (RIA) omfatter å reagere en separert celle eller cellelysat, vev eller vevslysat, cellekultur-supernatant, serum, preuralvæske, ascitesvæske, okulærvæske eller lignende med antistoffet i henhold til den foreliggende oppfinnelse videre å reagere reaktanten med anti-immunoglobulin antistoff eller bindingsfragment merket med radioisotop, og deretter å måle radioaktiviteten med en scintillasjonsteller eller lignende. </span>The radioactive material-labeled immunoassay (RIA) comprises reacting a separated cell or cell lysate, tissue or tissue lysate, cell culture supernatant, serum, preural fluid, ascites fluid, ocular fluid or the like with the antibody according to the present invention, further reacting the reactant with anti- immunoglobulin antibody or binding fragment labeled with a radioisotope, and then measuring the radioactivity with a scintillation counter or the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Immunocytt- fargemetoden og immunvev-fargemetoden omfatter å reagere en separert celle, vev eller lignende med antistoffet i henhold til den foreliggende oppfinnelse, å reagere reaktanten med et anti-immunglobulin antistoff eller bindingsfragment merket med en fluorescenssubstans slik som fluoresceinisotiocyanat (FITC) eller lignende, eller et enzym slik som peroksydase, biotin eller lignende, og deretter å obser-vere cellen, vevet eller lignende med et mikroskop. </span>The immunocyte staining method and the immune tissue staining method comprise reacting a separated cell, tissue or the like with the antibody according to the present invention, reacting the reactant with an anti-immunoglobulin antibody or binding fragment labeled with a fluorescent substance such as fluorescein isothiocyanate (FITC) or the like, or an enzyme such as peroxidase, biotin or the like, and then observing the cell, tissue or the like with a microscope.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sandwich-ELISA er en metode som omfatter å adsorbere, på en plate, ett av to antistoffer som har en forskjellig epitop blant antistoffene i henhold til den foreliggende oppfinnelse; å merke et annet antistoff med en fluorescenssubstans slik som FITC eller lignende, eller et enzym slik som peroksydase, biotin eller lignende; og reagere en separert celle eller cellelysat, vev eller vevslysat, cellekultur-supernatant, serum, preuralvæske, ascitesvæske, okulærvæske eller lignende med den antistoff-adsorberende plate; og der etter å reagere dette med det merkede antistoff for å utføre en reaksjon i samsvar med den merkede substans. </span>Sandwich ELISA is a method which comprises adsorbing, on a plate, one of two antibodies which have a different epitope among the antibodies according to the present invention; labeling another antibody with a fluorescent substance such as FITC or the like, or an enzyme such as peroxidase, biotin or the like; and reacting a separated cell or cell lysate, tissue or tissue lysate, cell culture supernatant, serum, preural fluid, ascites fluid, ocular fluid or the like with the antibody-adsorbing plate; and there after reacting this with the labeled antibody to effect a reaction consistent with the labeled substance.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(5)Metode for anvendelse av humant CDR-podet antistoff eller antistoffragment derav </span>(5) Method for using human CDR-grafted antibody or antibody fragment thereof</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Siden antistoffet i henhold til den foreliggende oppfinnelse spesifikt binder til CCR4 som er uttrykt på en dyrket cellelinje og utviser cytotoksisk aktivitet slik som CDC aktivitet, ADCC aktivitet og lignende, vil det være anvendelig ved diagnostisering og behandling av sykdommer som relaterer til CCR4 slik som Th2-medierte sykdommer og lignende. Siden forholdet av aminosyresekvenser avledet fra humant antistoff er høyere enn det i antistoffer av et ikke-humant dyr, er det også forventet at det utviser sterk cytotoksisk aktivitet i menneskekroppen, det ikke utviser immunogenisitet, og dets effekter fortsetter i lang tid. </span>Since the antibody according to the present invention specifically binds to CCR4 which is expressed on a cultured cell line and exhibits cytotoxic activity such as CDC activity, ADCC activity and the like, it will be applicable in the diagnosis and treatment of diseases related to CCR4 such as Th2 -mediated diseases and the like. Since the ratio of amino acid sequences derived from human antibody is higher than that of antibodies of a non-human animal, it is also expected that it exhibits strong cytotoxic activity in the human body, it does not exhibit immunogenicity, and its effects continue for a long time.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I tillegg kan produksjonen av Th2 cytokiner som produseres av celler slik som IL-4, IL-5, IL-13 og lignende, inhiberes ved å administrere antistoffet i henhold til foreliggende oppfinnelse til celler eller vev til et forsøksindivid. </span>In addition, the production of Th2 cytokines produced by cells such as IL-4, IL-5, IL-13 and the like can be inhibited by administering the antibody according to the present invention to cells or tissues of a test subject.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som cellen som uttrykker CCR4 som relaterer til den foreliggende oppfinnelse, eksemplifiseres Th2-celle og lignende. Th2-cellen anvendt i den foreliggende oppfinnelse er foretrukket aktivert Th2-celle eller hukommelses-Th2-celle. Eksempler inkluderer celler som har CD45RA- eller CD45R0+ og CD4+ egenskaper. </span>As the cell expressing CCR4 that relates to the present invention, Th2 cell and the like are exemplified. The Th2 cell used in the present invention is preferably activated Th2 cell or memory Th2 cell. Examples include cells that have CD45RA- or CD45R0+ and CD4+ properties.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De cytotoksiske aktiviteter til antistoffet i henhold til den foreliggende oppfinnelse frembringes f.eks. når antistoffet i henhold til den foreliggende oppfinnelse binder til CCR4-ut-trykkende celler slik som en Th2-celle for derved å indusere apoptose i cellen. Cellen kan også obstrueres og utarmes ved indusering av apoptose. </span>The cytotoxic activities of the antibody according to the present invention are produced, e.g. when the antibody according to the present invention binds to CCR4-expressing cells such as a Th2 cell to thereby induce apoptosis in the cell. The cell can also be obstructed and depleted by inducing apoptosis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metoden for diagnostisering av Th2-medierte immunsykdommer eller cancertyper inkluderer også en metode hvori en human CCR4 positiv celle som eksisterer i celler eller vev til et forsøksindivid påvises immunologisk som beskrevet ovenfor. </span>The method for diagnosing Th2-mediated immune diseases or cancers also includes a method in which a human CCR4 positive cell existing in cells or tissues of a test subject is detected immunologically as described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffet i henhold til den foreliggende oppfinnelse kan videre anvendes som et diagnostisk middel for CCR4-relaterte sykdommer slik som Th2-medierte immunsykdommer eller cancertyper, eller sykdommer hvori de morbide tilstander skrider frem på grunn av abnorm økning eller reduksjon av Th2-celler. </span>The antibody according to the present invention can further be used as a diagnostic agent for CCR4-related diseases such as Th2-mediated immune diseases or types of cancer, or diseases in which the morbid conditions progress due to abnormal increase or decrease of Th2 cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Siden antistoffet i henhold til den foreliggende oppfinnelse kan redusere eller utarme CCR4-uttrykkende celler ved dets cytotoksiske aktivitet, kan det videre tilveiebringe en diagnostisk metode eller terapeutisk metode for CCR4-relaterte sykdommer slik som Th2-medierte immunsykdommer eller cancertyper, som anvender antistoffet i henhold til den foreliggende oppfinnelse, og terapeutiske og forebyggende midler for CCR4-relaterte sykdommer slik som Th2-medierte immunsykdommer eller cancertyper som omfatter antistoffet i henhold den foreliggende oppfinnelse som en aktiv bestanddel. </span>Since the antibody according to the present invention can reduce or deplete CCR4-expressing cells by its cytotoxic activity, it can further provide a diagnostic method or therapeutic method for CCR4-related diseases such as Th2-mediated immune diseases or cancer types, which uses the antibody according to to the present invention, and therapeutic and preventive agents for CCR4-related diseases such as Th2-mediated immune diseases or cancer types that comprise the antibody according to the present invention as an active ingredient.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De Th2-medierte immunsykdommer inkluderer, uten hensyn til om de er milde eller alvorlige, inflammatoriske sykdommer slik som akutt eller kronisk luftveis-hypersensitivitet eller bronkialastma, atopiske hudsykdommer inkluderende atopisk dermatitt, allergisk rhinitt, pollinosis og lignende; sykdommer forårsaket av inflammasjonskompetente celler slik som eosinofil, mastcelle og lignende som kan propageres eller aktiveres ved cytokin og kjemokin frigjort fra Th2-celler, biologisk funksjonelle molekyler slik som IgE og lignende som produseres ved cytokin og kjemokin frigjort fra Th2-celler, og lignende; og immunsykdommer hvori de morbide tilstander skrider frem på grunn av abnorme forandringer i Th2-celler. </span>The Th2-mediated immune diseases include, regardless of whether they are mild or severe, inflammatory diseases such as acute or chronic airway hypersensitivity or bronchial asthma, atopic skin diseases including atopic dermatitis, allergic rhinitis, pollinosis and the like; diseases caused by inflammation-competent cells such as eosinophils, mast cells and the like that can be propagated or activated by cytokines and chemokines released from Th2 cells, biologically functional molecules such as IgE and the like that are produced by cytokines and chemokines released from Th2 cells, and the like; and immune diseases in which the morbid conditions progress due to abnormal changes in Th2 cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistoffet i henhold til den foreliggende oppfinnelse kan administreres alene, men det er generelt foretrukket å tilveiebringe det i form av en farmasøytisk formulering produ sert ved å blande det med minst en farmasøytisk akseptabel bærer i samsvar med en metode som er velkjent på det tekniske området farmasøytika. </span>The antibody according to the present invention can be administered alone, but it is generally preferred to provide it in the form of a pharmaceutical formulation produced by mixing it with at least one pharmaceutically acceptable carrier in accordance with a method well known in the technical field of pharmaceuticals .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er foretrukket å velge en administreringsrute som er den mest effektive med hensyn til å utføre den tiltenkte behandling slik som oral administrering eller parenteral administrering, f.eks. intraoral administrering, trakeal administrering, rektal administrering, subkutan injeksjon, intra-muskulær injeksjon, intravenøs injeksjon og lignende. Intra-venøs injeksjon er foretrukket ved en antistoff- eller pep-tidformulering. </span>It is preferred to select a route of administration that is most effective in effecting the intended treatment such as oral administration or parenteral administration, e.g. intraoral administration, tracheal administration, rectal administration, subcutaneous injection, intra-muscular injection, intravenous injection and the like. Intravenous injection is preferred with an antibody or peptide formulation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Doseringsformen inkluderer sprayer, kapsler, tabletter, granuler, siruper, emulsjoner, stikkpiller, injeksjoner, salver, plastere og lignende. </span>The dosage form includes sprays, capsules, tablets, granules, syrups, emulsions, suppositories, injections, ointments, plasters and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formuleringer som er egnet for oral administrering inkluderer emulsjoner, siruper, kapsler, tabletter, pulvere, granuler og lignende. </span>Formulations suitable for oral administration include emulsions, syrups, capsules, tablets, powders, granules and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Flytende fremstillinger slik som emulsjoner og siruper kan fremstilles ved å anvende additiver slik som vann; sakka-rider, f.eks. sukrose, sorbitol, fruktose; glykoler, f.eks. polyetylenglykol, propylenglykol; oljer, f.eks. sesamolje, olivenolje, soyaolje; antiseptika, f.eks. p-hydroksybenzoat; og smaksstoffer, f.eks. jordbærsmak, peppermynte. </span>Liquid preparations such as emulsions and syrups can be prepared by using additives such as water; sakka rider, e.g. sucrose, sorbitol, fructose; glycols, e.g. polyethylene glycol, propylene glycol; oils, e.g. sesame oil, olive oil, soybean oil; antiseptics, e.g. p-hydroxybenzoate; and flavourings, e.g. strawberry flavor, peppermint.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kapsler, tabletter, pulvere, granuler og lignende kan fremstilles ved anvendelse av additiver slik som fyllstoffer, f.eks. laktose, glukose, sukrose, mannitol; desintegrasjons-midler, f.eks. stivelse, natriumalginat; smøremidler, f.eks. magnesiumstearat, talkum; bindemidler, f.eks. polyvinyl-alkohol, hydroksypropylcellulose, gelatin; surfaktanter, f.eks. fettsyreestere; og plastifiseringsmidler, f.eks. glyserin. </span>Capsules, tablets, powders, granules and the like can be produced using additives such as fillers, e.g. lactose, glucose, sucrose, mannitol; disintegration agents, e.g. starch, sodium alginate; lubricants, e.g. magnesium stearate, talc; binders, e.g. polyvinyl alcohol, hydroxypropyl cellulose, gelatin; surfactants, e.g. fatty acid esters; and plasticizers, e.g. glycerin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formuleringer som er egnet for parenteral administrering inkluderer injeksjoner, stikkpiller, sprayer og lignende. </span>Formulations suitable for parenteral administration include injections, suppositories, sprays and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Injeksjoner kan fremstilles ved anvendelse av en bærer slik som en saltoppløsning, glukoseoppløsning eller en blanding derav, eller lignende. </span>Injections can be prepared using a carrier such as a saline solution, glucose solution or a mixture thereof, or the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Stikkpiller kan fremstilles ved anvendelse av en bærer slik som kakaosmør, hydrogenert fett, en karboksylsyre eller lignende. </span>Suppositories can be prepared using a carrier such as cocoa butter, hydrogenated fat, a carboxylic acid or the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre kan sprayer fremstilles fra selve antistoffet eller ved anvendelse av en bærer eller lignende som ikke stimulerer slimhinnene i munnen og luftveiene hos pasienter og kan lette absorpsjon av antistoffet eller antistoffragmentet derav ved å dispergere det som svært små partikler. </span>Furthermore, sprays can be prepared from the antibody itself or by using a carrier or the like that does not stimulate the mucous membranes in the mouth and respiratory tract of patients and can facilitate absorption of the antibody or antibody fragment thereof by dispersing it as very small particles.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bæreren inkluderer laktose, glyserin og lignende. Avhengig av egenskapene til antistoffet eller peptidet og bæreren som skal anvendes, kan det produseres aerosoler, tørre pulvere og lignende. Additivene eksemplifisert i de orale fremstilling-ene kan også tilsettes til de parenterale fremstillinger. </span>The carrier includes lactose, glycerin and the like. Depending on the properties of the antibody or peptide and the carrier to be used, aerosols, dry powders and the like can be produced. The additives exemplified in the oral preparations can also be added to the parenteral preparations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dosen og hyppigheten ved administrering varierer avhengig av den tiltenkte terapeutiske effekt, administeringsmetode, be-handlingsperiode, alder, kroppsvekt og lignende, men dosen er generelt fra 0,01 mg/kg til 20 mg/kg pr. døgn pr. voksen. </span>The dose and frequency of administration vary depending on the intended therapeutic effect, method of administration, treatment period, age, body weight and the like, but the dose is generally from 0.01 mg/kg to 20 mg/kg per day per adult.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den foreliggende oppfinnelse beskrives i det etterfølgende basert på eksempler, men den foreliggende oppfinnelse er ikke begrenset til disse. </span>The present invention is described below based on examples, but the present invention is not limited to these.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kort beskrivelse av tegningene </span>Brief description of the drawings</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 1 viser trinn for konstruksjon av et plasmid pKM2160GalO. Figur 2 viser trinn for konstruksjon av et plasmid pKM2160Gall. Symbolet&lt;*&gt;viser posisjonen av genetisk muta-sjonskodon som modifiserer en aminosyrerest. Figur 3 viser trinn for konstruksjon av et plasmid pKM2160Gal3. Symbolet&lt;*&gt;viser posisjonen for genetisk muta-sjonskodon som modifiserer en aminosyrerest. Figur 4 viser trinn for konstruksjon av et plasmid pKM2160LV0. Figur 5 viser trinn for konstruksjon av et plasmid pKM2160LVl. Symbolet&lt;*&gt;viser posisjonen for genetisk muta-sjonskodon som modifiserer en aminosyrerest. Figur 6 viser trinn for konstruksjon av et plasmid pKANTEX216 0LV0 og plasmid pKANTEX216 0Gal0LV0. Figur 7 viser reaktivitet av en kultursupernatant oppnådd ved transient uttrykking av en ekspresjonsvektor av hvert anti-CCR4 CDR-podet antistoff i COS-7 celle, med et CCR4 partielt peptid i samsvar med ELISA. Figur 8 viser reaktivitet av en kultursupernatant oppnådd ved transient uttrykking av en ekspresjonsvektor av hvert anti-CCR4 CDR-podet antistoff fremstilt ved anvendelse av andre FR-er i COS-7 celle, med CCR4 partielt peptid i samsvar med </span>Figure 1 shows steps for construction of a plasmid pKM2160GalO. Figure 2 shows steps for construction of a plasmid pKM2160Gall. The symbol&lt;*&gt; shows the position of the genetic mutation codon that modifies an amino acid residue. Figure 3 shows steps for construction of a plasmid pKM2160Gal3. The symbol&lt;*&gt; shows the position of genetic mutation codon that modifies an amino acid residue. Figure 4 shows steps for construction of a plasmid pKM2160LV0. Figure 5 shows steps for construction of a plasmid pKM2160LV1. The symbol&lt;*&gt; shows the position of genetic mutation codon that modifies an amino acid residue. Figure 6 shows steps for construction of a plasmid pKANTEX216 0LV0 and plasmid pKANTEX216 0Gal0LV0. Figure 7 shows reactivity of a culture supernatant obtained by transient expression of an expression vector of each anti-CCR4 CDR-grafted antibody in COS-7 cell, with a CCR4 partial peptide in accordance with ELISA. Figure 8 shows reactivity of a culture supernatant obtained by transient expression of an expression vector of each anti-CCR4 CDR-grafted antibody prepared using other FRs in COS-7 cell, with CCR4 partial peptide according to</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ELISA. </span>ELISA.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 9 viser reaktivitet av et renset anti-CCR4 CDR-podet antistoff med et CCR4 partielt peptid. Figur 10 viser reaktivitet av et renset anti-CCR4 CDR-podet antistoff med en CCR4 høy-ekspresjonscelle (CCR4/EL-4). Fig 11 viser affinitet av et renset anti-CCR4 CDR-podet antistoff med et CCR4 partielt peptid målt ved anvendelse av en overflateplasmon-resonansføler. Figur 12 viser cytotoksisitet i samsvar med ADCC aktivitet mot CCR4/EL-4 celle. Figur 13 viser effekt på inhibering av produksjon av IL-4, IL-13 og IFN-Y fra humant PBMC. Figur 14 viser bindingsaktivitet av hvert antistoff til en human blodplate. Figur 15 viser trinn for konstruksjon av plasmider pKM2160VH41 og pKM2160VL61. Figur 16 viser trinn for konstruksjon av et plasmid pKANTEX216 0H. Figur 17 viser trinn for konstruksjon av et plasmid pKANTEX216 0. </span>Figure 9 shows reactivity of a purified anti-CCR4 CDR-grafted antibody with a CCR4 partial peptide. Figure 10 shows reactivity of a purified anti-CCR4 CDR-grafted antibody with a CCR4 high-expressing cell (CCR4/EL-4). Figure 11 shows affinity of a purified anti-CCR4 CDR-grafted antibody with a CCR4 partial peptide measured using a surface plasmon resonance sensor. Figure 12 shows cytotoxicity in accordance with ADCC activity against CCR4/EL-4 cells. Figure 13 shows the effect on inhibiting the production of IL-4, IL-13 and IFN-Y from human PBMC. Figure 14 shows the binding activity of each antibody to a human platelet. Figure 15 shows steps for construction of plasmids pKM2160VH41 and pKM2160VL61. Figure 16 shows steps for construction of a plasmid pKANTEX216 0H. Figure 17 shows steps for construction of a plasmid pKANTEX216 0.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Beste måte for utførelse av oppfinnelsen </span>Best method for carrying out the invention</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 1 </span>Example 1</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Produksjon av humant CDR-podet antistoff for CCR4: </span>Production of human CDR-grafted antibody for CCR4:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Designing av cDNA som koder for VH og VL av humant CDR-podet antistoff for CCR4 (1)Designing av aminosyresekvens av VH av humant CDR-podet
antistoff for CCR4 Først ble en aminosyresekvens av VH av et humant CDR-podet antistoff for CCR4 (anti-CCR4 CDR-podet antistoff) designet som følger. En aminosyresekvens av FR av VH av et humant antistoff ble valgt for poding av aminosyresekvenser av CDR1, 2 og 3 av VH representert ved SEQ ID N0:1, 2 og 3 ved anvendelse av anti-CCR4 muse-antistoffet KM2160 ( Int. Immunol., 11, 81 (199)) etablert i referanseeksempel 1. Humane antistoffer som har høy homologi med KM216 0 ble hentet fra aminosyresekvens -databaser for eksisterende proteiner ved BLASTP-metoden ( Nucleic Acid Res. , 2_5, 3389 (1997) ) ved anvendelse av GCG Package (produsert av Genetics Computer Group) som et sekvensanalyseringssystem. Når homologien av den aktuelle aminosyresekvens ble sammenlignet med homologi-bedømmelsene, var SWISSPROT database-aksesjonsnummer P01781, lg Heavy chain V-III region Gal ( Hoppe. Seylers. Z. Physiol. Chem., 354, 1505-1509 (1973); i det etterfølgende referert til som "Gal") et humant antistoff som utviser den høyeste homologi på 82,5%, slik at FR aminosyresekvensen av antistoffet ble valgt. Posisjoner hvor aminosyrerestene ikke kan bestemmes unikt (posisjoner 28 og 30 fra N-enden av et sekretorisk antistoff) og en aminosyrerest som har lav frembringelses-frekvens i sekvenser av humane antistoffer (Thr som den endelige rest av V region) ble imidlertid funnet i FR aminosyresekvensen av Gal på databasen. Ile og Ser som rester funnet i muse-KM2160 ble følgelig valgt som posisjoner 28 og 30, og Thr som den endelige rest av V region ble erstattet med Ser. Siden aminosyrerestene finnes i høy forekomst i sekvenser av hvilke som helst humane antistoffer ( Sequences of Proteins of Immunologi cal Interest, US Dep. Health and Human Services, 1991), avviker de ikke fra humane antistoffsekvenser. </span>1. Designing cDNA encoding VH and VL of human CDR-grafted antibody for CCR4 (1) Designing amino acid sequence of VH of human CDR-grafted
antibody for CCR4 First, an amino acid sequence of the VH of a human CDR-grafted antibody for CCR4 (anti-CCR4 CDR-grafted antibody) was designed as follows. An amino acid sequence of FR of VH of a human antibody was selected for grafting amino acid sequences of CDR1, 2 and 3 of VH represented by SEQ ID NO:1, 2 and 3 using the anti-CCR4 mouse antibody KM2160 ( Int. Immunol. , 11, 81 (199)) established in Reference Example 1. Human antibodies having high homology to KM216 0 were obtained from amino acid sequence databases for existing proteins by the BLASTP method ( Nucleic Acid Res. , 2_5, 3389 (1997) ) using of the GCG Package (manufactured by Genetics Computer Group) as a sequence analysis system. When the homology of the amino acid sequence in question was compared to the homology judgments, SWISSPROT database accession number P01781, lg Heavy chain V-III region Gal ( Hoppe. Seylers. Z. Physiol. Chem., 354, 1505-1509 (1973); i hereinafter referred to as "Gal") a human antibody exhibiting the highest homology of 82.5%, so the FR amino acid sequence of the antibody was selected. However, positions where the amino acid residues cannot be uniquely determined (positions 28 and 30 from the N-terminus of a secretory antibody) and an amino acid residue that has a low occurrence frequency in sequences of human antibodies (Thr as the final residue of the V region) were found in FR the amino acid sequence of Gal on the database. Accordingly, Ile and Ser as residues found in mouse KM2160 were chosen as positions 28 and 30, and Thr as the final residue of the V region was replaced with Ser. Since the amino acid residues are found in high abundance in sequences of any human antibodies (Sequences of Proteins of Immunologic Interest, US Dep. Health and Human Services, 1991), they do not differ from human antibody sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">VH aminosyresekvensen GalO av anti-CCR4 CDR-podet antistoff representert ved SEQ ID NO:4 ble designet ved å pode aminosyresekvenser av CDR1, 2 og 3 av VH av anti-CCR4 muse-antistof fet KM216 0 representert ved henholdsvis SEQ ID N0:1, 2 og 3, til passende posisjoner i den bestemte human antistoff FR aminosyresekvens. En nukleotidsekvens som koder for aminosyresekvensen av SEQ ID NO:4 er representert ved SEQ ID NO: 49. </span>The VH amino acid sequence GalO of anti-CCR4 CDR-grafted antibody represented by SEQ ID NO:4 was designed by grafting amino acid sequences of CDR1, 2 and 3 of VH of anti-CCR4 mouse antibody fat KM216 0 represented by SEQ ID NO:1 respectively , 2 and 3, to appropriate positions in the determined human antibody FR amino acid sequence. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO:4 is represented by SEQ ID NO:49.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aminosyresekvens av VH av det anti-CCR4 CDR-podede antistoff ble også designet basert på de felles sekvenser som er klassifisert av Kabat et al. </span>An amino acid sequence of the VH of the anti-CCR4 CDR-grafted antibody was also designed based on the common sequences classified by Kabat et al.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kabat et al. har klassifisert VH av forskjellige allerede kjente humane antistoffer i tre undergrupper (HSG I til III) basert på homologien av deres aminosyresekvenser og rapportert felles sekvenser i hver undergruppe (Seguences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). Der er en mulighet at immunogenisitet av de felles sekvenser vil reduseres hos mennesker. For å fremstille et anti-CCR4 CDR-podet antistoff som har høy aktivitet, blant FR aminosyresekvenser av de felles sekvenser av tre undergrupper av det humane antistoff VH, ble følgelig en FR aminosyresekvens som har den høyeste homologi med FR aminosyresekvensen av VH av KM2160 valgt i designingen. Tabell 1 viser et resultat av gjenopprettingen av homologi mellom FR aminosyresekvensene av de felles sekvenser av hver undergruppe av det humane antistoff VH og FR aminosyresekvensen av VH av KM2160. Som vist i tabell 1, utviste FR aminosyresekvensen av VH regionen av KM216 0 den høyeste homologi med undergruppen III. </span>Kabat et al. have classified the VH of various already known human antibodies into three subgroups (HSG I to III) based on the homology of their amino acid sequences and reported common sequences in each subgroup (Sequences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). There is a possibility that immunogenicity of the common sequences will be reduced in humans. Accordingly, in order to prepare an anti-CCR4 CDR-grafted antibody having high activity, among the FR amino acid sequences of the common sequences of three subgroups of the human antibody VH, an FR amino acid sequence having the highest homology with the FR amino acid sequence of the VH of KM2160 was selected in the design. Table 1 shows a result of the restoration of homology between the FR amino acid sequences of the common sequences of each subgroup of the human antibody VH and the FR amino acid sequence of the VH of KM2160. As shown in Table 1, the FR amino acid sequence of the VH region of KM216 0 exhibited the highest homology with subgroup III.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Basert på de ovennevnte resultater, ble VH aminosyresekvensen </span>
Based on the above results, VH was the amino acid sequence</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HVO av anti-CCR4 CDR-podet antistoff representert ved SEQ ID NO:38 designet ved poding av aminosyresekvens av CDR av VH av anti-CCR4 muse-antistoffet KM2160 til en passende posisjon av aminosyresekvensen av FR av den felles sekvensen av undergruppe III av det humane antistoff VH. En nukleotidsekvens som koder for aminosyresekvensen av SEQ ID NO:38 er representert ved SEQ ID NO:57. </span>HVO of the anti-CCR4 CDR-grafted antibody represented by SEQ ID NO:38 designed by grafting the amino acid sequence of the CDR of the VH of the anti-CCR4 mouse antibody KM2160 to an appropriate position of the amino acid sequence of the FR of the common sequence of subgroup III of the human antibody VH. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO:38 is represented by SEQ ID NO:57.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2)Designing av aminosyresekvens av VL av humant CDR-podet antistoff for CCR4 </span>(2) Designing amino acid sequence of VL of human CDR-grafted antibody for CCR4</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble en aminosyresekvens av VL av et anti-CCR4 CDR-podet antistoff designet som følger. En aminosyresekvens av FR av VL av et humant antistoff ble valgt for poding av aminosyresekvenser av CDR1, 2 og 3 av VL av anti-CCR4 muse-antistof f KM2160 representert ved henholdsvis SEQ ID NO:5, 6 og 7. Kabat et al. har klassifisert VL av forskjellige allerede kjente humane antistoffer i fire undergrupper (HSG I til IV) basert på homologien av deres aminosyresekvenser og rapportert felles sekvenser i hver undergruppe (Seguences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). Blant FR aminosyresekvenser av de felles sekvensene av fire undergrupper av det humane antistoff VL, ble følgelig en FR aminosyresekvens som har den høyeste homologi med FR aminosyresekvensen av VL av KM2160 valgt. Tabell 2 viser et resultat av gjenopprettelsen av homologi mellom FR aminosyresekvensene av den felles sekvensen av hver undergruppe av det humane antistoff VL og FR aminosyresekvensen av VL av KM2160. Som vist i tabell 2, utviste FR aminosyresekvensen av VL av KM2160 den høyeste homologi med undergruppen </span>Then, an amino acid sequence of the VL of an anti-CCR4 CDR-grafted antibody was designed as follows. An amino acid sequence of FR of VL of a human antibody was chosen for grafting amino acid sequences of CDR1, 2 and 3 of VL of anti-CCR4 mouse antibody f KM2160 represented by SEQ ID NO:5, 6 and 7, respectively. Kabat et al. have classified the VL of various already known human antibodies into four subgroups (HSG I to IV) based on the homology of their amino acid sequences and reported common sequences in each subgroup (Sequences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). Accordingly, among the FR amino acid sequences of the common sequences of four subgroups of the human antibody VL, an FR amino acid sequence having the highest homology with the FR amino acid sequence of the VL of KM2160 was selected. Table 2 shows a result of the restoration of homology between the FR amino acid sequences of the common sequence of each subgroup of the human antibody VL and the FR amino acid sequence of the VL of KM2160. As shown in Table 2, the FR amino acid sequence of the VL of KM2160 exhibited the highest homology with the subgroup</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">II. </span>II.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Basert på de ovennevnte resultater, ble VL aminosyresekvensen </span>
Based on the above results, VL was the amino acid sequence</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">LVO av anti-CCR4 CDR-podet antistoff representert ved SEQ ID NO:8 designet ved poding av aminosyresekvensene av CDR1, 2 og 3 av VL av anti-CCR4 muse-antistoff KM2160 representert ved henholdsvis SEQ ID NO:5, 6 og 7, til passende posisjoner i aminosyresekvensen av FR av den felles sekvensen av undergruppe II av det humane antistoffet VL. En nukleotidsekvens som koder for aminosyresekvensen av SEQ ID NO:8 er representert ved SEQ ID NO:53. </span>LVO of anti-CCR4 CDR-grafted antibody represented by SEQ ID NO:8 designed by grafting the amino acid sequences of CDR1, 2 and 3 of VL of anti-CCR4 mouse antibody KM2160 represented by SEQ ID NO:5, 6 and 7 respectively, to appropriate positions in the amino acid sequence of the FR of the common sequence of subgroup II of the human antibody VL. A nucleotide sequence encoding the amino acid sequence of SEQ ID NO:8 is represented by SEQ ID NO:53.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3)Modifisering av VH og VL av humant CDR-podet antistoff for CCR4 </span>(3) Modification of VH and VL of human CDR-grafted antibody for CCR4</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">VH aminosyresekvensene GalO og HVO, og VL aminosyresekvensen LVO av anti-CCR4 CDR-podet antistoff designet i det ovennevnte er antistoffer hvori CDR aminosyresekvensen av anti-CCR4 muse-antistoffet KM2160 alene er podet til de valgte FR aminosyresekvenser av humant antistoff. Når poding med kun CDR aminosyresekvens av et muse-antistoff utføres, blir imidlertid aktiviteten av et humant CDR-podet antistoff ofte redusert slik at, for å unngå reduksjonen, visse aminosyrerester blant FR aminosyrerestene som er forskjellige mellom et humant antistoff og et muse-antistoff, som anses å ha innvirkninger på aktiviteten, generelt podes sammen med CDR aminosyresekvensen. Følgelig ble det i dette eksempelet ut-ført en undersøkelse for å identifisere FR aminosyrerestene som anses å ha innvirkninger på aktiviteten. </span>The VH amino acid sequences GalO and HVO, and the VL amino acid sequence LVO of the anti-CCR4 CDR-grafted antibody designed in the above are antibodies in which the CDR amino acid sequence of the anti-CCR4 mouse antibody KM2160 alone is grafted to the selected FR amino acid sequences of human antibody. However, when CDR-only amino acid sequence grafting of a mouse antibody is performed, the activity of a human CDR-grafted antibody is often reduced so that, to avoid the reduction, certain amino acid residues among the FR amino acid residues that are different between a human antibody and a mouse antibody , which are considered to have effects on activity, are generally grafted together with the CDR amino acid sequence. Accordingly, in this example, an investigation was carried out to identify the FR amino acid residues which are considered to have an impact on the activity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Først ble tredimensjonale strukturer av antistoff V regioner (GalOLVO og HVOLVO) omfattende aminosyresekvenser GalO og HVO av VH og aminosyresekvens LVO av VL i det anti-CCR4 CDR-podede antistoff designet i det ovennevnte konstruert ved anvendelse av en datamaskin-modelleringsteknikk. Koordinatene for den tredimensjonale struktur ble frembrakt ved anvendelse av en AbM programvare (produsert av Oxford Molecular), og fremvisning av de tredimensjonale strukturer ved anvendelse av en Pro-Explore programvare (produsert av Oxford Molecular) eller RasMol (produsert av Glaxo) i samsvar med de respektive vedlagte instruksjoner fra produsenten. Videre ble data-maskinmodeller av de tredimensjonale strukturer av V regioner av anti-CCR4 muse-antistoff KM2160 konstruert på den samme måten. I tillegg ble modeller av tredimensjonale strukturer omfattende modifiserte aminosyresekvenser konstruert på den samme måten, hvori visse rester av FR aminosyresekvensene av VH og VL av GalOLVO eller HVOLVO, som er forskjellige fra det anti-CCR4 muse-antistoffet KM2160, ble erstattet med andre rester funnet i korresponderende posisjoner i det anti-CCR4 muse-antistoffet KM2160, og de tredimensjonale strukturene av V regioner av det anti-CCR4 muse-antistoffet KM2160, GalOLVO eller HVOLVO og de modifiserte produkt ble sammenlignet. </span>First, three-dimensional structures of antibody V regions (GalOLVO and HVOLVO) comprising amino acid sequences GalO and HVO of VH and amino acid sequence LVO of VL in the anti-CCR4 CDR-grafted antibody designed above were constructed using a computer modeling technique. The coordinates of the three-dimensional structure were generated using an AbM software (manufactured by Oxford Molecular), and display of the three-dimensional structures using a Pro-Explore software (manufactured by Oxford Molecular) or RasMol (manufactured by Glaxo) in accordance with the respective attached instructions from the manufacturer. Furthermore, computer models of the three-dimensional structures of V regions of anti-CCR4 mouse antibody KM2160 were constructed in the same way. In addition, models of three-dimensional structures comprising modified amino acid sequences were constructed in the same way, in which certain residues of the FR amino acid sequences of VH and VL of GalOLVO or HVOLVO, which are different from the anti-CCR4 mouse antibody KM2160, were replaced with other residues found at corresponding positions in the anti-CCR4 mouse antibody KM2160, and the three-dimensional structures of V regions of the anti-CCR4 mouse antibody KM2160, GalOLVO or HVOLVO and the modified product were compared.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som et resultat ble den tredimensjonale strukturen av den antigenbindende region endret slik at Ala i posisjon 40, Gly i posisjon 42, Lys i posisjon 43, Gly i posisjon 44 og Lys i posisjon 76 og Ala i posisjon 97 i GalO, Thr i posisjon 28 og Ala i posisjon 97 for HVO og Ile i posisjon 2, Val i posisjon 3, Gin i posisjon 50 og Val i posisjon 88 i LVO ble valgt som rester ansett til å ha innvirkning på aktiviteten av antistoff blant FR aminosyrerestene av GalOLVO eller HVOLVO. Blant disse valgte aminosyrerester, er minst en aminosyre modifisert til en eller flere aminosyrerester funnet i muse-antistoffet KM2160 slik at VH og VL av det humane CDR-podede antistoff som har forskjellige modifikasjoner ble designet. </span>As a result, the three-dimensional structure of the antigen-binding region was changed so that Ala at position 40, Gly at position 42, Lys at position 43, Gly at position 44 and Lys at position 76 and Ala at position 97 in GalO, Thr at position 28 and Ala at position 97 for HVO and Ile at position 2, Val at position 3, Gin at position 50 and Val at position 88 in LVO were selected as residues considered to have an effect on the activity of antibody among the FR amino acid residues of GalOLVO or HVOLVO. Among these selected amino acid residues, at least one amino acid is modified to one or more amino acid residues found in the mouse antibody KM2160 so that the VH and VL of the human CDR-grafted antibody having different modifications were designed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Først, hva angår VH, ble det designet f.eks. Gall representert ved SEQ ID NO:9 hvori Ala i posisjon 97 av GalO var modifisert, Gal2 representert ved SEQ ID NO:10 hvori Gly i posisjon 42 og Gly i posisjon 44 av GalO var modifisert, Gal3 representert ved SEQ ID NO:11 hvori Ala i posisjon 97, Gly i posisjon 42 og Gly i posisjon 44 av GalO var modifisert, HVI representert ved SEQ ID NO:39 hvori Thr i posisjon 28 av HVO var modifisert, HV2 representert ved SEQ ID NO:40 hvori Ala i posisjon 97 av HVO var modifisert, og HV3 representert ved SEQ ID NO:41 hvori Thr i posisjon 28 og Ala i posisjon 97 av HVO var modifisert. Videre, hva angår VL, ble det designet f.eks. LV1 representert ved SEQ ID NO:12 hvori Ile i posisjon 2 var modifisert, LV2 representert ved SEQ ID NO:13 hvori Val i posisjon 3 var modifisert, og LV3 representert ved SEQ ID NO:14 hvori Ile i posisjon 2 og Val i posisjon 3 var modifisert. Nukleotidsekvenser som koder for aminosyresekvensene representert ved SEQ ID NO:9 til 11, 39 til 41 og 12 til 14 er representert ved henholdsvis SEQ ID NO:50 til 52, 58 til 60 og 54 til 56. 2.Konstruksjon av cDNA som koder for anti-CCR4 CDR-podet
antistoff. (1)konstruksjon av cDNA som koder for VH av anti-CCR4 CDR-
podet antistoff </span>First, regarding VH, it was designed e.g. Gall represented by SEQ ID NO:9 in which Ala in position 97 of GalO was modified, Gal2 represented by SEQ ID NO:10 in which Gly in position 42 and Gly in position 44 of GalO were modified, Gal3 represented by SEQ ID NO:11 in which Ala in position 97, Gly in position 42 and Gly in position 44 of GalO were modified, HVI represented by SEQ ID NO:39 in which Thr in position 28 of HVO was modified, HV2 represented by SEQ ID NO:40 in which Ala in position 97 of HVO was modified, and HV3 represented by SEQ ID NO:41 in which Thr in position 28 and Ala in position 97 of HVO were modified. Furthermore, as regards VL, it was designed e.g. LV1 represented by SEQ ID NO:12 in which Ile in position 2 was modified, LV2 represented by SEQ ID NO:13 in which Val in position 3 was modified, and LV3 represented by SEQ ID NO:14 in which Ile in position 2 and Val in position 3 was modified. Nucleotide sequences that code for the amino acid sequences represented by SEQ ID NO:9 to 11, 39 to 41 and 12 to 14 are represented by SEQ ID NO:50 to 52, 58 to 60 and 54 to 56, respectively. 2. Construction of cDNA that codes for the anti-CCR4 CDR graft
antibody. (1) construction of cDNA encoding the VH of the anti-CCR4 CDR-
grafted antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cDNA som koder for aminosyresekvensen GalO av VH av det anti-CCR4 CDR-podede antistoff designet i 1(1) i eksempel 1 ble konstruert ved anvendelse av PCR som følger. </span>cDNA encoding the amino acid sequence GalO of VH of the anti-CCR4 CDR-grafted antibody designed in 1(1) of Example 1 was constructed using PCR as follows.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Først, en komplett antistoff-aminosyresekvens ved ligering av den designede aminosyresekvens med den H kjede sekretoriske signalsekvens av anti-CCR4 muse-antistoff KM2160 representert ved SEQ ID NO:15. Deretter ble aminosyresekvensen omdannet til genetiske kodoner. Når to eller flere genetiske kodoner er tilstede for en aminosyrerest, ble et korresponderende genetisk kodon bestemt ved å ta i betraktning bruken av kodon funnet i nukleotidsekvenser av antistoffgener (Seguences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). En nukleotidsekvens av cDNA som koder for aminosyresekvensen av komplett antistoff V region ble designet ved ligering av de bestemte genetiske kodoner, og bindende nukleotidsekvenser av primere for PCR amplifikasjon (inkluderende restriksjonsenzym-gjenkjennelsessekvenser for kloning inn i en vektor for ekspresjon av humanisert antistoff) ble tilsatt til dens 5'-ende og 3'-ende. Den designede nukleotidsekvens ble inndelt i totalt 6 nukleotidsekvenser som hver har omtrent 100 nukleotider idet det telles fra 5'-enden (tilgrensende nukleotidsekvenser er designet slik at de har en komplementær sekvens av omtrent 2 0 nukleotider på deres ende), og 6 syntetiske oligonukleotider av SEQ ID NO:16, 17, 18, 19, 20 og 21 ble syntetisert i reciproke rekkefølger av en sense kjede og en antisense kjede (produsert av GENSET). </span>First, a complete antibody amino acid sequence by ligation of the designed amino acid sequence with the H chain secretory signal sequence of anti-CCR4 mouse antibody KM2160 represented by SEQ ID NO:15. Then the amino acid sequence was converted into genetic codons. When two or more genetic codons are present for an amino acid residue, a corresponding genetic codon was determined by considering codon usage found in nucleotide sequences of antibody genes (Sequences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). A nucleotide sequence of cDNA encoding the amino acid sequence of complete antibody V region was designed by ligation of the specific genetic codons, and binding nucleotide sequences of primers for PCR amplification (including restriction enzyme recognition sequences for cloning into a vector for expression of humanized antibody) were added to its 5' end and 3' end. The designed nucleotide sequence was divided into a total of 6 nucleotide sequences each having approximately 100 nucleotides counting from the 5' end (adjacent nucleotide sequences are designed to have a complementary sequence of approximately 20 nucleotides at their end), and 6 synthetic oligonucleotides of SEQ ID NO:16, 17, 18, 19, 20 and 21 were synthesized in reciprocal orders of a sense chain and an antisense chain (manufactured by GENSET).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PCR ble utført ved å tilsette hvert oligonukleotid til en reaksjonsoppløsning inneholdende 0,2 mM dNTP-er og 1 mM magnesiumklorid til å gi en sluttkonsentrasjon på 0,1 uM, og å innstille sluttvolumet til 50 yl ved anvendelse av 0,4 uM M13 primer RV (produsert av Takara Shuzo), 0,4 uM M13 primer M3 (produsert av GENSET) og 2,5 enheter KOD polymerase (produsert av T0Y0B0). Reaksjonen ble utført ved 3 0 cykluser, idet hver cyklus består av 94°C i 3 0 sekunder, 55°C i 3 0 sekunder og 74°C i 6 0 sekunder, og deretter 1 cyklus ved 74°C i 10 minutter. Reaksjonsoppløsningen ble renset ved anvendelse av et QIA hurtig PCR rense-kit (produsert av QIAGEN) og til sist oppløst i sterilt vann. Reaksjonsoppløsningen fikk reagere ved 37°C i 1 time ved anvendelse av 10 enheter av et restriksjonsenzym Apal (produsert av Takara Shuzo) og 10 enheter av et restriksjonsenzym Noti (produsert av Takara Shuzo). Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et Apal-Noti fragment på omtrent 0,47 kb ble utvunnet. </span>PCR was performed by adding each oligonucleotide to a reaction solution containing 0.2 mM dNTPs and 1 mM magnesium chloride to give a final concentration of 0.1 µM, and setting the final volume to 50 µl using 0.4 µM M13 primer RV (manufactured by Takara Shuzo), 0.4 µM M13 primer M3 (manufactured by GENSET) and 2.5 units of KOD polymerase (manufactured by T0Y0B0). The reaction was carried out at 30 cycles, each cycle consisting of 94°C for 30 seconds, 55°C for 30 seconds and 74°C for 60 seconds, and then 1 cycle at 74°C for 10 minutes. The reaction solution was purified using a QIA rapid PCR purification kit (manufactured by QIAGEN) and finally dissolved in sterile water. The reaction solution was allowed to react at 37°C for 1 hour using 10 units of a restriction enzyme Apal (produced by Takara Shuzo) and 10 units of a restriction enzyme Noti (produced by Takara Shuzo). The reaction solution was fractionated by agarose gel electrophoresis, and an Apal-Noti fragment of approximately 0.47 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter fikk 3 ug plasmid pBluescript II SK(-) (produsert av Stratagene) reagere med fragmentet ved anvendelse av 10 enheter av et restriksjonsenzym Apal (produsert av Takara Shuzo) og 10 enheter av et restriksjonsenzym Noti (produsert av Takara Shuzo) ved 37°C i 1 time. Den nevnte reaksjons- oppløsningen ble fraksjonert ved agarose gel elektroforese, og et Apal- Notl fragment på omtrent 2,95 kb ble utvunnet. </span>Then, 3 µg of plasmid pBluescript II SK(-) (manufactured by Stratagene) was allowed to react with the fragment using 10 units of a restriction enzyme ApaI (manufactured by Takara Shuzo) and 10 units of a restriction enzyme Noti (manufactured by Takara Shuzo) at 37° C for 1 hour. The aforementioned reaction solution was fractionated by agarose gel electrophoresis, and an Apal-Notl fragment of approximately 2.95 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det resulterende Apal-Noti fragment av PCR produktet av VH av det anti-CCR4 CDR-podede antistoff og Apal-Notl fragmentet av plasmid pBluescript II SK(-) ble så ligert ved anvendelse av Solution I i DNA Ligation Kit Ver. 2 (produsert av Takara Shuzo) i samsvar med produsentens instruksjoner. Escherichia coli DH5a (produsert av TOYOBO) ble transformert ved anvendelse av rekombinant plasmid DNA oppløsningen oppnådd på denne måten, hvert plasmid DNA ble fremstilt fra transformantklonene og nukleotidsekvensene ble analysert ved anvendelse av Big Dye Terminator Kit ver. 2 (produsert av Applied Biosystems). Som et resultat av nukleotidsekvensanalysen, ble det oppnådd et plasmid pKM2160GalO vist i fig. 1 som har mål-nukleotidsekvensen. Escherichia coli transformert med pKM2160GalO, Escherichia coli DH5a/pKM2160GalO, er blitt deponert 22. august 2001 som FERM BP-7709 i International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>The resulting ApaI-NotI fragment of the PCR product of the VH of the anti-CCR4 CDR-grafted antibody and the ApaI-NotI fragment of plasmid pBluescript II SK(-) were then ligated using Solution I in the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo) in accordance with the manufacturer's instructions. Escherichia coli DH5a (manufactured by TOYOBO) was transformed using recombinant plasmid DNA solution thus obtained, each plasmid DNA was prepared from the transformant clones and the nucleotide sequences were analyzed using Big Dye Terminator Kit ver. 2 (manufactured by Applied Biosystems). As a result of the nucleotide sequence analysis, a plasmid pKM2160GalO shown in fig. 1 which has the target nucleotide sequence. Escherichia coli transformed with pKM2160GalO, Escherichia coli DH5a/pKM2160GalO, has been deposited on August 22, 2001 as FERM BP-7709 in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1 -Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble FR aminosyrerestene designet i 1(3) i eksempel 1 modifisert som følger. De genetiske kodoner for aminosyrerester etter modifiseringen ble modifisert til å ha genetiske kodoner funnet i muse-antistoffet KM2160. </span>Then, the FR amino acid residues designed in 1(3) in Example 1 were modified as follows. The genetic codons for amino acid residues after the modification were modified to have genetic codons found in the mouse antibody KM2160.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I modifisering av Ala i posisjon 97 til Gly, ble PCR utført ved anvendelse av 25 ng av plasmidet pKM2160GalO fremstilt i dette punkt som templatet, først ved oppvarming ved 94°C i 2 minutter og deretter utføring av 35 cykluser av reaksjonen, idet hver cyklus består av 94°C i 15 sekunder, 55° i 3 0 sekunder og 6 8°C i 4 0 sekunder, i 50 yl av et reaksjonssystem fremstilt ved å tilsette hvert av de syntetiske DNA-er for genoverføring omfattende nukleotidsekvensene representert ved SEQ ID 22 og 23 (produsert av GENSET) som primere til å gi en sluttkonsentrasjon på 0,4 yM og ved anvendelse av 2,5 enheter KOD pluss polymerase (produsert av TOYOBO) i overensstemmelse med produsentens instruksjoner. Reaksjonsoppløsningen ble renset ved anvendelse av et QIA hurtig PCR rense-kit (produsert av QIAGEN) og til slutt oppløst i sterilt vann. Det totale volum fikk reagere i 1 time ved 3 7°C ved anvendelse av 10 enheter av et restriksjonsenzym Pstl (produsert av Takara Shuzo) og fikk deretter reagere i 1 time ved 3 7°C ved anvendelse av 10 enheter av et restriksjonsenzym Dralll (produsert av New England Biolabs). Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et Pstl-Dralll fragment på omtrent 0,58 kb ble utvunnet. </span>In modifying Ala at position 97 to Gly, PCR was performed using 25 ng of the plasmid pKM2160GalO prepared at this point as the template, first by heating at 94°C for 2 minutes and then performing 35 cycles of the reaction, each cycle consists of 94°C for 15 seconds, 55° for 30 seconds and 68°C for 40 seconds, in 50 µl of a reaction system prepared by adding each of the synthetic DNAs for gene transfer comprising the nucleotide sequences represented by SEQ ID 22 and 23 (manufactured by GENSET) as primers to give a final concentration of 0.4 µM and using 2.5 units of KOD plus polymerase (manufactured by TOYOBO) in accordance with the manufacturer's instructions. The reaction solution was purified using a QIA rapid PCR purification kit (manufactured by QIAGEN) and finally dissolved in sterile water. The total volume was reacted for 1 hour at 37°C using 10 units of a restriction enzyme Pstl (manufactured by Takara Shuzo) and then reacted for 1 hour at 37°C using 10 units of a restriction enzyme Dralll ( produced by New England Biolabs). The reaction solution was fractionated by agarose gel electrophoresis, and a Pstl-DralII fragment of approximately 0.58 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter fikk 3 ug av plasmidet pKM2160GalO reagere ved 37°C </span>Then 3 µg of the plasmid pKM2160GalO was allowed to react at 37°C</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">i 1 time ved anvendelse av 10 enheter av et restriksjonsenzym Pstl (produsert av Takara Shuzo) og deretter undergå reaksjonen ved 37°C i 1 time ved anvendelse av 10 enheter av et </span>for 1 hour using 10 units of a restriction enzyme Pstl (manufactured by Takara Shuzo) and then undergo the reaction at 37°C for 1 hour using 10 units of a</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">restriksjonsenzym Dralll (produsert av New England Biolabs). </span>restriction enzyme Dralll (manufactured by New England Biolabs).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et Pstl-Dralll fragment på omtrent 2,7 kb ble utvunnet. </span>The reaction solution was fractionated by agarose gel electrophoresis, and a Pstl-DralII fragment of approximately 2.7 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det således oppnådde Pstl-Dralll fragment avledet fra PCR produktet og Pstl-Dralll fragmentet avledet fra plasmidet pKM216 0GalO ble så ligert ved anvendelse av Solution I i DNA Ligation Kit Ver. 2 (produsert av Takara Shuzo) i overensstemmelse med produsentens instruksjoner. Escherichia coli DH5a (produsert av TOYOBO) ble transformert ved anvendelse av rekombinant plasmid DNA oppløsningen oppnådd på denne måten, hvert plasmid DNA ble fremstilt fra transformantklonene og nukleotidsekvensene ble analysert ved anvendelse av Big Dye Terminator Kit Ver. 2 (produsert av Applied Biosystems). Som et resultat av nukleotidsekvensanalysen, ble det oppnådd et plasmid pKM2160Gall vist i fig. 2 som har den mål-nukleotidsekvensen. Escherichia coli transformert med plasmidet pKM2160Gall, Escherichia coli DH5a/pKM2160Gall, er blitt deponert 22. august 2001 som FERM BP-7710 i International </span>The thus obtained Pstl-Dralll fragment derived from the PCR product and the Pstl-Dralll fragment derived from the plasmid pKM216 0GalO were then ligated using Solution I in the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo) in accordance with the manufacturer's instructions. Escherichia coli DH5a (manufactured by TOYOBO) was transformed using recombinant plasmid DNA solution thus obtained, each plasmid DNA was prepared from the transformant clones and the nucleotide sequences were analyzed using Big Dye Terminator Kit Ver. 2 (manufactured by Applied Biosystems). As a result of the nucleotide sequence analysis, a plasmid pKM2160Gall shown in fig. 2 which has the target nucleotide sequence. Escherichia coli transformed with the plasmid pKM2160Gall, Escherichia coli DH5a/pKM2160Gall, has been deposited on 22 August 2001 as FERM BP-7710 in the International</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Patent Organism Depositary, National Institute of Advanced </span>Patent Organism Depository, National Institute of Advanced</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I modifikasjoner av Gly i posisjon 42 til Asp og Gly i posisjon 44 til Arg, ble det oppnådd et plasmid pKM2160Gal2 ved å utføre metoden stort sett lik den ovennevnte, med unntak av at det syntetiske DNAs for genoverføring omfattende nukleotidsekvensen representert ved SEQ ID NO:24 (produsert av GENSET) og M13 primer RV (produsert av Takara Shuzo) ble anvendt som PCR primere. Escherichia coli transformert med plasmidet pKM2160Gal2, Escherichia coli DH5a/pKM216 0Gal2, er blitt deponert 22. august 2001 som FERM BP-7711 i International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>In modifications of Gly at position 42 to Asp and Gly at position 44 to Arg, a plasmid pKM2160Gal2 was obtained by performing the method substantially similar to the above, except that the synthetic DNAs for gene transfer comprising the nucleotide sequence represented by SEQ ID NO: 24 (produced by GENSET) and M13 primer RV (produced by Takara Shuzo) were used as PCR primers. Escherichia coli transformed with the plasmid pKM2160Gal2, Escherichia coli DH5a/pKM216 0Gal2, has been deposited on August 22, 2001 as FERM BP-7711 in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Modifisering av alle de ovennevnte tre rester ble videre konstruert som følger. Omtrent 0,5 ug av hver av pKM2160Gall og pKM2160Gal2 oppnådd i det ovennevnte fikk reagere ved 37°C i 1 time ved anvendelse av 10 enheter av Nhel (produsert av Takara Shuzo) og fikk deretter reagere ved 3 7°C i 1 time ved anvendelse av Seal (produert av Takara Shuzo). Reaksjonsopp-løsningen ble fraksjonert ved agarose gel elektroforese, og et Miel-Scal fragment på omtrent 1,3 kb avledet fra pKM2160Gall og et fragment på omtrent 2,0 kb avledet fra pKM2160Gal2 ble utvunnet. De resulterende to fragmenter ble ligert ved anvendelse av Solution I i DNA Ligation Kit Ver. 2 (produsert av Takara Shuzo) i overensstemmelse med produsentens instruksjoner. Escherichia coli DH5a (produsert av TOYOBO) ble transformert ved anvendelse av rekombinant plasmid DNA oppløsningen oppnådd på denne måten, hvert plasmid DNA ble fremstilt fra transformantklonene og nukleotidsekvenser ble analysert ved anvendelse av Big Dye Terminator Kit ver. 2 (produsert av Applied Biosystems). Som et resultat av nukleotidsekvensanalysen, ble det oppnådd et plasmid pKM2160Gal3 vist i fig. 3 som har mål-nukleotidsekvensen. Escherichia coli transformert med plasmidet pKM2160Gal3, Escherichia coli DH5a/pKM216 0Gal3, er blitt deponert 22. august 2001 som FERM BP-7712 i International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>Modification of all the above three residues was further constructed as follows. About 0.5 µg of each of pKM2160Gal and pKM2160Gal2 obtained in the above was reacted at 37°C for 1 hour using 10 units of NheI (manufactured by Takara Shuzo) and then reacted at 37°C for 1 hour at application of Seal (manufactured by Takara Shuzo). The reaction solution was fractionated by agarose gel electrophoresis, and a Miel-Scal fragment of approximately 1.3 kb derived from pKM2160Gal and a fragment of approximately 2.0 kb derived from pKM2160Gal2 were recovered. The resulting two fragments were ligated using Solution I in the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo) in accordance with the manufacturer's instructions. Escherichia coli DH5a (manufactured by TOYOBO) was transformed using recombinant plasmid DNA solution obtained in this way, each plasmid DNA was prepared from the transformant clones and nucleotide sequences were analyzed using Big Dye Terminator Kit ver. 2 (manufactured by Applied Biosystems). As a result of the nucleotide sequence analysis, a plasmid pKM2160Gal3 shown in fig. 3 which has the target nucleotide sequence. Escherichia coli transformed with the plasmid pKM2160Gal3, Escherichia coli DH5a/pKM216 0Gal3, has been deposited on August 22, 2001 as FERM BP-7712 in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble et cDNA som koder for aminosyresekvensen HVO av VH av det anti-CCR4 CDR-podede antistoff designet i 1(1) i eksempel 1 konstruert ved anvendelse av PCR som følger. </span>Then, a cDNA encoding the amino acid sequence HVO of VH of the anti-CCR4 CDR-grafted antibody designed in 1(1) of Example 1 was constructed using PCR as follows.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Først, en komplett antistoff-aminosyresekvens ved ligering av den designede aminosyresekvens med den H kjede sekretoriske signalsekvens av anti-CCR4 muse-antistoff KM2160 representert ved SEQ ID NO:15. Deretter ble aminosyresekvensen omdannet til genetiske kodoner. Når to eller flere genetiske kodoner er tilstede fore en aminosyrerest, ble et korresponderende genetisk kodon bestemt ved å ta i betraktning bruken av kodon funnet i nukleotidsekvenser av antistoffgener (Seguences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). De bestemte genetiske kodoner ble ligert slik at en nukleotidsekvens av cDNA som koder for aminosyresekvensen av komplett antistoff V region ble designet, og å tilsette nukleotidsekvenser av primere for PCR amplifikasjon (inkluderende restriksjonsenzym-gjenkjennelsessekvenser for kloning inn i en vektor for anvendelse for ekspresjon av humanisert antistoff) ble addert til dens 5&lt;1-&gt;ende og 3'-ende. </span>First, a complete antibody amino acid sequence by ligation of the designed amino acid sequence with the H chain secretory signal sequence of anti-CCR4 mouse antibody KM2160 represented by SEQ ID NO:15. Then the amino acid sequence was converted into genetic codons. When two or more genetic codons are present for an amino acid residue, a corresponding genetic codon was determined by considering codon usage found in nucleotide sequences of antibody genes (Sequences of Proteins of Immunological Interest, US Dep. Health and Human Services, 1991). The determined genetic codons were ligated so that a nucleotide sequence of cDNA encoding the amino acid sequence of complete antibody V region was designed, and adding nucleotide sequences of primers for PCR amplification (including restriction enzyme recognition sequences for cloning into a vector for use in expression of humanized antibody) was added to its 5&lt;1&gt; end and 3' end.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den designede nukleotidsekvens ble inndelt i totalt 6 nukleotidsekvenser som hver har omtrent 100 nukleotider idet det telles fra 5'-enden (tilgrensende nukleotidsekvenser er designet slik at de har en dupliseringssekvens av omtrent 20 nukleotider på deres ender) og 6 syntetiske oligonukleotider av SEQ ID NO:16, 42, 43, 44, 45 og 21 ble syntetisert i reciproke rekkefølger av en sense kjede og en antisense kjede (produsert av GENSET), og deretter ble pKM2160HV0 oppnådd ved hjelp av en lignende metode som for pKM2160GalO beskrevet i dette punkt. Escherichia coli transformert med plasmidet pKM2160HV0, Escherichia coli DH5a/pKM216 0HV0, er blitt deponert 27. august 2001 som FERM BP-7718 i International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>The designed nucleotide sequence was divided into a total of 6 nucleotide sequences each having approximately 100 nucleotides counting from the 5' end (adjacent nucleotide sequences are designed to have a duplication sequence of approximately 20 nucleotides at their ends) and 6 synthetic oligonucleotides of SEQ ID NO :16, 42, 43, 44, 45, and 21 were synthesized in reciprocal orders of a sense chain and an antisense chain (produced by GENSET), and then pKM2160HV0 was obtained by a similar method to that of pKM2160GalO described in this section. Escherichia coli transformed with the plasmid pKM2160HV0, Escherichia coli DH5a/pKM216 0HV0, has been deposited on August 27, 2001 as FERM BP-7718 in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I modifikasjon av Thr i posisjon 28 til Ile, ble pKM2160HVl som har mål-nukletidsekvensen oppnådd ved å utføre reaksjonen som ligner på konstruksjonen av det ovennevnte plasmid pKM216 0HV0, ved anvendelse av et oligonukleotid som har nukleotidsekvensen representert ved SEQ ID NO:69 i stedet for oligonukleotidet som har nukleotidsekvensen representert ved SEQ ID NO:42, og ved anvendelse av et oligonukleotid som har nukletoidsekvensen representert ved SEQ ID NO:46 i stedet for oligonukleotidet som har nukletidsekvensen representert ved SEQ ID NO:43. Escherichia coli transformert med plasmidet pKM2160HVl, Escherichia coli DH5a/pKM216 0HVl, er blitt deponert 27. august 2001 som FERM BP-7719 i International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukua-shi, Ibaraki-ken 305-8566 Japan). </span>In modification of Thr at position 28 to Ile, pKM2160HV1 having the target nucleotide sequence was obtained by performing the reaction similar to the construction of the above plasmid pKM216 0HV0, using an oligonucleotide having the nucleotide sequence represented by SEQ ID NO:69 instead for the oligonucleotide having the nucleotide sequence represented by SEQ ID NO:42, and using an oligonucleotide having the nucleotide sequence represented by SEQ ID NO:46 instead of the oligonucleotide having the nucleotide sequence represented by SEQ ID NO:43. Escherichia coli transformed with the plasmid pKM2160HVl, Escherichia coli DH5a/pKM216 0HVl, has been deposited on August 27, 2001 as FERM BP-7719 in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukua-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I modifikasjon av Thr i posisjon 28 til Ile og Ala i posisjon 97 til Gly, ble pKM2160HV3 som har mål-nukleotidsekvensen oppnådd ved reaksjonen som ligner på konstruksjonen av det ovennevnte plasmid pKM2160HV0, ved anvendelse av et oligonukleotid som har nukleotidsekvensen representert ved SEQ ID NO:69 i stedet for oligonukleotidet som har nukleotidsekvensen representert ved SEQ ID NO:42, ved anvendelse av et oligonukleotid som har nukletidsekvensen representert ved SEQ ID NO:46 i stedet for oligonukleotidet som har nukleotidsekvensen representert ved SEQ ID NO:43 og ved anvendelse av et oligonukleotid som har nukleotidsekvensen representert ved SEQ ID NO:47 i stedet for oligonukleotidet som har nukleotidsekvensen representert ved SEQ ID NO:45. Escherichia coli transformert med plasmidet pKM2160HV3, Escherichia coli DH5a/pKM216 0HV3, er blitt deponert 27. august 2001 som FERM BP-7721 i international Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>In modification of Thr at position 28 to Ile and Ala at position 97 to Gly, pKM2160HV3 having the target nucleotide sequence was obtained by the reaction similar to the construction of the above-mentioned plasmid pKM2160HV0, using an oligonucleotide having the nucleotide sequence represented by SEQ ID NO :69 instead of the oligonucleotide having the nucleotide sequence represented by SEQ ID NO:42, using an oligonucleotide having the nucleotide sequence represented by SEQ ID NO:46 instead of the oligonucleotide having the nucleotide sequence represented by SEQ ID NO:43 and using an oligonucleotide having the nucleotide sequence represented by SEQ ID NO:47 instead of the oligonucleotide having the nucleotide sequence represented by SEQ ID NO:45. Escherichia coli transformed with the plasmid pKM2160HV3, Escherichia coli DH5a/pKM216 0HV3, has been deposited on August 27, 2001 as FERM BP-7721 in the international Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I modifikasjon av Ala i posisjon 97 til Gly, ble plasmidet konstruert som følger. Omtrent 0,5 ug av hvert av de oppnådde pKM2160HV0 og pKM2160HV3 fikk reagere ved 37°C i 1 time ved anvendelse av 10 enheter av et restriksjonsenzym Nhel (produsert av Takara Shuzo) og fikk deretter reagere ved 37°C i 1 time ved anvendelse av Seal (produsert av Takara Shuzo). </span>Modifying Ala at position 97 to Gly, the plasmid was constructed as follows. About 0.5 µg of each of the obtained pKM2160HV0 and pKM2160HV3 was reacted at 37°C for 1 hour using 10 units of a restriction enzyme NheI (manufactured by Takara Shuzo) and then reacted at 37°C for 1 hour using by Seal (produced by Takara Shuzo).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et Miel-Scal fragment på omtrent 1,3 kb avledet fra pKM2160HV3 og et fragment fra omtrent 2,0 kb avledet pKM2160HV0 ble utvunnet. De resulterende to fragmenter ble ligert ved anvendelse av Solution I i DNA Ligation Kit Ver. 2 (produsert av Takara Shuzo) i overensstemmelse med produsentens instruksjoner. Escherichia coli DH5a (produsert av TOYOBO) ble transformert ved anvendelse av rekombinant plasmid DNA oppløsningen oppnådd på denne måten, hvert plasmid DNA ble fremstilt fra transformantklonene og nukleotidsekvenser ble analysert ved anvendelse av Big Dye Terminator Kit ver. 2 (produsert av Applied Biosystems). Som et resultat av en nukleotidsekvensanalysen, ble det oppnådd et plasmid pKM2160HV2 som har mål-nukleotidsekvensen. Escherichia coli transformert med plasmidet pKM2160HV2, Escherichia coli DH5a/pKM216 0HV2, er blitt deponert 27. august 2001 som FERM BP-7720 i International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>The reaction solution was fractionated by agarose gel electrophoresis, and an approximately 1.3 kb Miel-Scal fragment derived from pKM2160HV3 and an approximately 2.0 kb fragment derived from pKM2160HV0 were recovered. The resulting two fragments were ligated using Solution I in the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo) in accordance with the manufacturer's instructions. Escherichia coli DH5a (produced by TOYOBO) was transformed using recombinant plasmid DNA solution obtained in this way, each plasmid DNA was prepared from the transformant clones and nucleotide sequences were analyzed using Big Dye Terminator Kit ver. 2 (manufactured by Applied Biosystems). As a result of a nucleotide sequence analysis, a plasmid pKM2160HV2 having the target nucleotide sequence was obtained. Escherichia coli transformed with the plasmid pKM2160HV2, Escherichia coli DH5a/pKM216 0HV2, has been deposited on August 27, 2001 as FERM BP-7720 in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2)Konstruksjon av cDNA som koder for VL av anti-CCR4 CDR-podet antistoff </span>(2) Construction of cDNA encoding VL of anti-CCR4 CDR-grafted antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et cDNA som koder for aminosyresekvensen LVO av VL av det anti-CCR4 CDR-podede antistoff designet i 1(2) i eksempel 1 ble konstruert ved anvendelse av PCR på lignende måte som tilfellet med VH som følger. I dette tilfellet ble L kjede sekvensen av anti-CCR4 muse-antistoff KM2160 som har amino syresekvensen representert ved SEQ ID NO:25 anvendt som den sekretoriske signalsekvens. </span>A cDNA encoding the amino acid sequence LVO of VL of the anti-CCR4 CDR-grafted antibody designed in 1(2) of Example 1 was constructed using PCR in a similar manner to the case of VH as follows. In this case, the L chain sequence of anti-CCR4 mouse antibody KM2160 having the amino acid sequence represented by SEQ ID NO:25 was used as the secretory signal sequence.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Først ble 6 syntetiske oligonukleotider som har nukleotidsekvensene beskrevet i SEQ IDNO:26, 27, 28, 29, 30 og 31 syntetisert (produsert av GENSET). PCR ble utført ved å tilsette hvert oligonukleotid til 50 yl av en reaksjons-oppløsning til å gi en sluttkonsentrasjon på 0,1 yM, og ved anvendelse av 0,4 yM av M13 primer RV (produsert av Takara Shuzo) og 0,4 yM av M13 primer M4 (produsert av Takara Shuzo) eller M13 primer M3 (produsert av GENSET) representert ved SEQ ID NO:32 og 2,5 enheter av KOD polymerase (produsert av TOYOBO). Reaksjonen ble utført ved 3 0 cykluser, idet hver cyklus består av 94°C i 3 0 sekunder, 55°C i 3 0 sekunder og 74°C i 6 0 sekunder, og deretter 1 cyklus ved 72°C i 10 minutter. Reaksjonsoppløsningen ble renset ved anvendelse av et QIA hurtig PCR rense-kit (produsert av QIAGEN) og til sist oppløst i sterilt vann. Reaksjonsoppløsningen fikk reagere ved anvendelse av 10 enheter av et restriksjonsenzym ScoRI (produsert av Takara Shuzo) og 10 enheter av et restriksjonsenzym Xhol (produsert av Takara Shuzo) ved 3 7°C i 1 time. Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et EcoRI-Xhol fragment på omtrent 0,44 kb ble utvunnet. </span>First, 6 synthetic oligonucleotides having the nucleotide sequences described in SEQ IDNO:26, 27, 28, 29, 30 and 31 were synthesized (produced by GENSET). PCR was performed by adding each oligonucleotide to 50 µl of a reaction solution to give a final concentration of 0.1 µM, and using 0.4 µM of M13 primer RV (manufactured by Takara Shuzo) and 0.4 µM of M13 primer M4 (produced by Takara Shuzo) or M13 primer M3 (produced by GENSET) represented by SEQ ID NO:32 and 2.5 units of KOD polymerase (produced by TOYOBO). The reaction was carried out at 30 cycles, each cycle consisting of 94°C for 30 seconds, 55°C for 30 seconds and 74°C for 60 seconds, and then 1 cycle at 72°C for 10 minutes. The reaction solution was purified using a QIA rapid PCR purification kit (manufactured by QIAGEN) and finally dissolved in sterile water. The reaction solution was allowed to react using 10 units of a restriction enzyme ScoRI (produced by Takara Shuzo) and 10 units of a restriction enzyme XhoI (produced by Takara Shuzo) at 37°C for 1 hour. The reaction solution was fractionated by agarose gel electrophoresis, and an EcoRI-XhoI fragment of approximately 0.44 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter fikk 3 yg av plasmidet pBluescript II SK(-) (produsert av Stratagene) reagere ved anvendelse av 15 enheter av et restriksjonsenzym EcoRI (produsert av Takara Shuzo) og 15 enheter av et restriksjonsenzym Xhol (produsert av Takara Shuzo) ved 37°C i 1 time. Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et EcoRI-XhoI fragment på omtrent 2,95 kb ble utvunnet. </span>Then, 3 µg of the plasmid pBluescript II SK(-) (manufactured by Stratagene) was reacted using 15 units of a restriction enzyme EcoRI (manufactured by Takara Shuzo) and 15 units of a restriction enzyme XhoI (manufactured by Takara Shuzo) at 37°C for 1 hour. The reaction solution was fractionated by agarose gel electrophoresis, and an EcoRI-XhoI fragment of approximately 2.95 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det resulterende EcoRI-XhoI fragment av PCR produktet av VL av det anti-CCR4 CDR-podede antistoff og EcoRI- XhoI fragmentet av plasmid pBluescript II SK(-) ble således ligert ved anvendelse av Solution I i DNA Ligation Kit Ver. 2 (produsert av Takara Shuzo) i overensstemmelse med produsentens instruk sjoner. Escherichia coli DH5a (produsert av TOYOBO) ble transformert ved anvendelse av rekombinant plasmid DNA opp-løsningen oppnådd på denne måten, hvert plasmid DNA ble fremstilt fra transformantklonene og nukleotidsekvenser ble analysert ved anvendelse av Big Dye Terminator Kit ver. 2 (produsert av Applied Biosystems). Som et resultat av nukleotidsekvensanalysen, ble det oppnådd et plasmid pKM216 0LV4 vist i fig. 4 som har mål-nukleotidsekvensen. Escherichia coli transformert med pKM216 0LV0, Escherichia coli DH5a/ pKM2160LV0, er blitt deponert 22. august 2001 som FERM BP-7713 i International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1-, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>The resulting EcoRI-XhoI fragment of the PCR product of the VL of the anti-CCR4 CDR-grafted antibody and the EcoRI-XhoI fragment of plasmid pBluescript II SK(-) were thus ligated using Solution I in the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo) in accordance with the manufacturer's instructions. Escherichia coli DH5a (produced by TOYOBO) was transformed using the recombinant plasmid DNA solution thus obtained, each plasmid DNA was prepared from the transformant clones and nucleotide sequences were analyzed using the Big Dye Terminator Kit ver. 2 (manufactured by Applied Biosystems). As a result of the nucleotide sequence analysis, a plasmid pKM216 0LV4 shown in fig. 4 which has the target nucleotide sequence. Escherichia coli transformed with pKM216 0LV0, Escherichia coli DH5a/ pKM2160LV0, has been deposited on August 22, 2001 as FERM BP-7713 in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1-, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble FR aminosyrerester designet i 1(3) i eksempel 1 modifisert som følger. De genetiske kodoner for aminosyrerester etter modifiseringen ble modifisert til å ha genetiske kodoner funnet i muse-antistoffet KM2160. </span>Then, FR amino acid residues designed in 1(3) in Example 1 were modified as follows. The genetic codons for amino acid residues after the modification were modified to have genetic codons found in the mouse antibody KM2160.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I modifikasjon av Ile i posisjon 2 til Val, ble et plasmid pKM216 0LVl vist i fig. 5 som har mål-nukleotidsekvensen oppnådd ved å utføre reaksjonen som ligner på konstruksjonen av det ovennevnte plasmid pKM2160LV0, ved anvendelse av et oligonukleotid som har nukleotidsekvensen representert ved SEQ ID NO:33 i stedet for oligonukleotidet som har nukleotidsekvensen representert ved SEQ ID NO:27. Escherichia coli transformert med plasmidet pKM2160LVl, Escherichia coli DH5a/ pKM2160LVl, er blitt deponert 22. august 2001 som FERM BP-7714 i International Patent Organism Depositary, National Institute of Advanced Industraial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>In modification of Ile in position 2 to Val, a plasmid pKM216 0LV1 was shown in fig. 5 having the target nucleotide sequence obtained by performing the reaction similar to the construction of the above-mentioned plasmid pKM2160LV0, using an oligonucleotide having the nucleotide sequence represented by SEQ ID NO:33 instead of the oligonucleotide having the nucleotide sequence represented by SEQ ID NO:27 . Escherichia coli transformed with the plasmid pKM2160LVl, Escherichia coli DH5a/ pKM2160LVl, has been deposited on August 22, 2001 as FERM BP-7714 in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">På samme måte, ble hvert at mål-plasmidene pKM216 0LV2 og pKM216 0LV3 oppnådd ved anvendelse av et oligonukleotid som har nukleotidsekvensen representert ved SEQ ID NO:34 i stedet for oligonukleotidet som har nukleotidsekvensen representert ved SEQ ID NO:27 når Val i posisjon 3 var modifisert til Leu, og ved anvendelse av et oligonukleotid som har nukleotidsekvensen representert ved SEQ ID NO:35 i stedet for oligonukleotidet som har nukleotidsekvensen representert ved SEQ ID NO:27 når begge av de ovennevnte to rester var modifisert. </span>Similarly, the target plasmids pKM216 0LV2 and pKM216 0LV3 were each obtained by using an oligonucleotide having the nucleotide sequence represented by SEQ ID NO:34 instead of the oligonucleotide having the nucleotide sequence represented by SEQ ID NO:27 when Val in position 3 was modified to Leu, and using an oligonucleotide having the nucleotide sequence represented by SEQ ID NO:35 instead of the oligonucleotide having the nucleotide sequence represented by SEQ ID NO:27 when both of the above two residues were modified.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Escherichia coli transformert med plasmidet pKM2160LV2, Escherichia coli DH5a/pKM216 0LV2, og Escherichia coli transformert med plasmidet pKM2160LV3, Escherichia coli DH5a/pKM216 0LV3, er blitt deponert 22. august 2001 som henholdsvis FERM BP-7715 og FERM BP-7716 i International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). (3)Konstruksjon av anti-CCR4 CDR-podet antistoff-ekspresjonsvektor </span>Escherichia coli transformed with the plasmid pKM2160LV2, Escherichia coli DH5a/pKM216 0LV2, and Escherichia coli transformed with the plasmid pKM2160LV3, Escherichia coli DH5a/pKM216 0LV3, have been deposited on August 22, 2001 as FERM BP-7715 and FERM BP-7716 respectively in International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). (3) Construction of anti-CCR4 CDR-grafted antibody expression vector</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En anti-CCR4 CDR-podet antistoff-ekspresjonsvektor </span>An anti-CCR4 CDR-grafted antibody expression vector</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">pKANTEX216 0Gal0LV0 ble konstruert ved anvendelse av en vektor for humanisert antistoff-ekspresjon pKANTEX93 ( Mol. Immunol., 37, 1035 (2000)) og plasmidene pKM2160GalO og pKM2160LV0 oppnådd i 2(1) og (2) i eksempel 1 som følger. </span>pKANTEX2160Gal0LV0 was constructed using a vector for humanized antibody expression pKANTEX93 ( Mol. Immunol., 37, 1035 (2000)) and the plasmids pKM2160Gal0 and pKM2160LV0 obtained in 2(1) and (2) of Example 1 as follows.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Plasmidet pKM2160LV0 (3 ug) oppnådd i 2(2) i eksempel 1 fikk reagere med 10 enheter av et restriksjonsenzym BsiWI (produsert av New England Biolabs) ved 55°C i 1 time og deretter med 10 enheter av et restriksjonsenzym ScoRI (produsert av Takara Shuzo) ved 37°C i 1 time. Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et BsiWI-ScoRI fragment på omtrent 0,44 kb ble utvunnet. </span>The plasmid pKM2160LV0 (3 µg) obtained in 2(2) of Example 1 was allowed to react with 10 units of a restriction enzyme BsiWI (produced by New England Biolabs) at 55°C for 1 hour and then with 10 units of a restriction enzyme ScoRI (produced by Takara Shuzo) at 37°C for 1 hour. The reaction solution was fractionated by agarose gel electrophoresis, and a BsiWI-ScoRI fragment of approximately 0.44 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3 ug av vektoren for humanisert antistoff-ekspresjon pKANTEX93 fikk deretter reagere med 10 enheter av et restriksjonsenzym BsiWI (produsert av New England Biolabs) ved 55°C </span>3 µg of the humanized antibody expression vector pKANTEX93 was then reacted with 10 units of a restriction enzyme BsiWI (manufactured by New England Biolabs) at 55°C</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">i 1 time og deretter med 10 enheter av et restriksjonsenzym EcoRI (produsert av Takara Shuzo) ved 37°C i 1 time. Reak-sjonsoppløsningen ble fraksjonert ved agarose gel elektro- </span>for 1 hour and then with 10 units of a restriction enzyme EcoRI (manufactured by Takara Shuzo) at 37°C for 1 hour. The reaction solution was fractionated by agarose gel electrophoresis</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">forese, og et BsiWI- EcoRI fragment på omtrent 12,75 kb ble utvunnet. </span>forese, and a BsiWI-EcoRI fragment of approximately 12.75 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det resulterende BsiWI-EcoRI fragment avledet fra pKM216 0LV0 og BsiWI-EcoRI fragmentet avledet fra pKANTEX93 ble så legert ved anvendelse av Solution I i DNA Ligation Kit Ver. 2 (produsert av Takara Shuzo) i overensstemmelse med produsentens instruksjoner. Escherichia coli DH5a (produsert av TOYOBO) ble transformert ved anvendelse av rekombinant plasmid DNA oppløsningen oppnådd på denne måten for derved å oppnå et plasmid pKANTEX216 0LV0 vist i fig. 6. 3 ug av plasmidet pKM2160GalO oppnådd i 2(1) i eksempel 1 fikk deretter reagere med 10 enheter av et restriksjonsenzym Apal (produsert av Takara Shuzo) ved 37°C i 1 time og deretter med 10 enheter av et restriksjonsenzym Noti (produsert av Takara Shuzo) ved 37°C i 1 time. Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et Apal-Notl fragment på omtrent 0,47 kb ble utvunnet. 3 ug av plasmidet pKANTEX216 0LV0 oppnådd i den ovennevnte fikk så reagere med 10 enheter av et restriksjonsenzym Apal (produsert av Takara Shuzo) ved 3 7°C i 1 time og deretter med 10 enheter av et restriksjonsenzym Noti (produsert av Takara Shuzo) ved 37°C i 1 time. Reaksjonsoppløsningen ble fraksjonert ved agarose gel elektroforese, og et Apal-Noti fragment på omtrent 0,45 kb ble utvunnet. </span>The resulting BsiWI-EcoRI fragment derived from pKM216 0LV0 and the BsiWI-EcoRI fragment derived from pKANTEX93 were then ligated using Solution I in the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo) in accordance with the manufacturer's instructions. Escherichia coli DH5a (produced by TOYOBO) was transformed using the recombinant plasmid DNA solution thus obtained to thereby obtain a plasmid pKANTEX216 0LV0 shown in Fig. 6. 3 µg of the plasmid pKM2160GalO obtained in 2(1) in Example 1 was then allowed to react with 10 units of a restriction enzyme Apal (produced by Takara Shuzo) at 37°C for 1 hour and then with 10 units of a restriction enzyme Noti (produced by Takara Shuzo) at 37°C for 1 hour. The reaction solution was fractionated by agarose gel electrophoresis, and an ApaI-NotI fragment of approximately 0.47 kb was recovered. 3 µg of the plasmid pKANTEX216 0LV0 obtained in the above was then allowed to react with 10 units of a restriction enzyme ApaI (produced by Takara Shuzo) at 37°C for 1 hour and then with 10 units of a restriction enzyme Noti (produced by Takara Shuzo) at 37°C for 1 hour. The reaction solution was fractionated by agarose gel electrophoresis, and an Apal-Noti fragment of approximately 0.45 kb was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det resulterende Apal-Notl fragment avledet fra pKM2160GalO og Apal-Noti fragmentet avledet fra plasmidet pKANTEX216 0LV0 ble deretter ligert ved anvendelse av Solution I i DNA Ligation Kit Ver. 2 (produsert av Takara Shuzo) i overensstemmelse med produsentens instruksjoner. Escherichia coli DH5a (produsert av TOYOBO) ble transformert ved anvendelse av rekombinant plasmid DNA oppløsningen oppnådd på denne måten, og hvert plasmid DNA ble fremstilt fra transformantklonene. Som et resultat av at nukleotidsekvensene av de således oppnådde plasmider ble analysert ved anvendelse av Big Dye Terminator Kit ver. 2 (produsert av Applied Biosystems), ble det bekreftet av det var oppnådd en ekspresjonsvektor pKANTEX216 0Gal0LV0 vist i fig. 6 som mål-DNA-et var blitt klonet inn i. </span>The resulting ApaI-NotI fragment derived from pKM2160GalO and the ApaI-NotI fragment derived from the plasmid pKANTEX216 0LV0 were then ligated using Solution I in the DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo) in accordance with the manufacturer's instructions. Escherichia coli DH5a (produced by TOYOBO) was transformed using the recombinant plasmid DNA solution thus obtained, and each plasmid DNA was prepared from the transformant clones. As a result, the nucleotide sequences of the thus obtained plasmids were analyzed using the Big Dye Terminator Kit ver. 2 (manufactured by Applied Biosystems), it was confirmed that an expression vector pKANTEX216 0Gal0LV0 shown in fig. 6 into which the target DNA had been cloned.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I tillegg ble ekspresjonsvektorer fremstilt ved anvendelse av den samme metoden på VH og VL hvori aminosyrerester av annen FR ble modifisert, inkluderende HVO. </span>In addition, expression vectors were prepared using the same method on VH and VL in which amino acid residues of other FR were modified, including HVO.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Spesifikt ble 22 ekspresjonsvektorer pKM2160Gal0LV0, pKM216 0GalOLVl, pKM2160GalOLV2, pKM216 0GalOLV3, pKM216 0GallLVl, pKM2160GallLV3, pKM216 0Gal2LVl, pKM216 0Gal2LV3, pKM2160Gal3LVl, pKM216 0Gal3LV3, pKM216 0HV0LV0, pKM216 0HV0LVl, pKM2160HV0LV2, pKM2160HV0LV3, pKM216 0HV1LVO, pKM216 0HVlLVl, pKM2160HV1LV2, pKM2160HV1LV3, pKM216 0HV2 LVO, pKM216 0HV2LV3, pKM2160HV3LV0 og pKM2160HV3LV3, konstruert ved henholdsvis å kombinere pKM2160GalO, pKM2160Gall, pKM2160Gal2, pKM2160Gal3, pKM2160HV0, pKM2160HVl, pKM2160HV2 og pKM2160HV3 konstruert i 2(1) i eksempel 1 med pKM2160LV0, pKM2160LVl, pKM2160LV2 og pKM216 0LV3 konstruert i 2(2) i eksempel 1. </span>Spesifikt ble 22 ekspresjonsvektorer pKM2160Gal0LV0, pKM216 0GalOLVl, pKM2160GalOLV2, pKM216 0GalOLV3, pKM216 0GallLVl, pKM2160GallLV3, pKM216 0Gal2LVl, pKM216 0Gal2LV3, pKM2160Gal3LVl, pKM216 0Gal3LV3, pKM216 0HV0LV0, pKM216 0HV0LVl, pKM2160HV0LV2, pKM2160HV0LV3, pKM216 0HV1LVO, pKM216 0HVlLVl, pKM2160HV1LV2, pKM2160HV1LV3, pKM216 0HV2 LVO, pKM216 0HV2LV3, pKM2160HV3LV0 og pKM2160HV3LV3, konstruert ved henholdsvis å kombinere pKM2160GalO, pKM2160Gall, pKM2160Gal2, pKM2160Gal3, pKM2160HV0, pKM2160HVl, pKM2160HV2 og pKM2160HV3 konstruert i 2(1) i eksempel 1 med pKM2160LV0, pKM2160LVl, pKM2160LV2 og pKM216 0LV3 konstruert in 2(2) in example 1.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 2 </span>Example 2</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ekspresjon av anti-CCR4 CDR-podet antistoff i dyreceller: 1.Transient ekspresjon av anti-CCR4 CDR-podet antistoff ved
anvendelse av COS-7 celle (ATCC CRL 1651) </span>Expression of anti-CCR4 CDR-grafted antibody in animal cells: 1.Transient expression of anti-CCR4 CDR-grafted antibody by
use of COS-7 cell (ATCC CRL 1651)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1)Transient ekspresjon i COS-7 celle </span>(1) Transient expression in COS-7 cell</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I en 6 brønn plate (produsert av Iwaki Glass) ble lxl0&lt;5&gt;celler/ml COS-7 celle dispensert ved 2 ml/brønn ved anvendelse av DMEM nedium (produsert av Bibco) inneholdende 10% FCS og dyrket over natten ved 37°C. Pr. 100 yl OPTI-MEM medium (produsert av Bibco) ble 3 yl Fu-GENETM 6 Transfer Reagent (produsert av Roche) tilsatt og 1 yg av hver av de 22 anti- CCR4 CDR-podet antistoff-ekspresjonsvektorer oppnådd i punkt 2(3) i eksempel 1 ble videre tilsatt dertil, og blandingen ble hensatt ved romtemperatur i 15 minutter for å danne et DNA-liposom kompleks. Hver av reaksjonsoppløsningene ble tilsatt dråpevis til den ovennevnte COS-7 celle og grundig blandet, etterfulgt av dyrking ved 3 7°C. Etter dyrking i 72 timer ved kultur-supernatantene ble utvunnet og aktiviteten av det anti-CCR4 CDR-podede antistoff i kultur-supernatantene ble evaluert. </span>In a 6-well plate (manufactured by Iwaki Glass), lx10&lt;5&gt; cells/ml COS-7 cells were dispensed at 2 ml/well using DMEM medium (manufactured by Bibco) containing 10% FCS and cultured overnight at 37° C. Per 100 µl of OPTI-MEM medium (manufactured by Bibco) 3 µl of Fu-GENETM 6 Transfer Reagent (manufactured by Roche) was added and 1 µg of each of the 22 anti-CCR4 CDR-grafted antibody expression vectors obtained in point 2( 3) in Example 1 was further added thereto, and the mixture was left at room temperature for 15 minutes to form a DNA-liposome complex. Each of the reaction solutions was added dropwise to the above COS-7 cell and thoroughly mixed, followed by cultivation at 37°C. After cultivation for 72 hours the culture supernatants were recovered and the activity of the anti-CCR4 CDR grafted antibody in the culture supernatants was evaluated.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2)Evaluering av reaktivitet av anti-CCR4 CDR-podet antistoff for human CCR4 </span>(2) Evaluation of reactivity of anti-CCR4 CDR-grafted antibody for human CCR4</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aktiviteten av de resulterende kultur-supernatanter av 22 antistoffer ble evaluert som følger. </span>The activity of the resulting culture supernatants of 22 antibodies was evaluated as follows.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Forbindelse 1 (SEQ ID NO:37) ble valgt som et humant CCR4 ekstracellulær region peptid som kan reagere med det anti-CCR4 kimære antistoff KM27 6 0 produsert ved transformanten KM2760 (FERM BP-7054) fremstilt i referanseeksempel 2. For å anvende forbindelse 1 i aktivitetsmålingen ved hjelp av ELISA, ble dens konjugat med BSA (bovint serumalbumin) (produsert av Nakalai Tesque) fremstilt og anvendt som antigenet. </span>Compound 1 (SEQ ID NO:37) was selected as a human CCR4 extracellular region peptide that can react with the anti-CCR4 chimeric antibody KM27 60 produced by the transformant KM2760 (FERM BP-7054) prepared in Reference Example 2. To use compound 1 in the activity measurement by ELISA, its conjugate with BSA (bovine serum albumin) (produced by Nakalai Tesque) was prepared and used as the antigen.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dvs., 100 ml av 25 mg/ml SMCC (4-(N-maleimidometyl)cyklo-heksan-1-karboksylsyre-N-hydroksysuccinimidester) (produsert av Sigma)-DMSO-oppløsning ble tilsatt dråpevis til 900 ml PBS-oppløsning inneholdende 10 mg BSA under vortexblanding og omrørt forsiktig i 30 minutter. Til en gelfiltreringskolon-ne, slik som NAP-10 kolonne eller lignende, ekvilibrert med 25 ml PBS, ble det tilsatt 1 ml av reaksjonsoppløsningen og eluatet eluert med 1,5 ml PBS ble anvendt som en BSA-SMCC-oppløsning (BSA-konsentrasjon ble beregnet ved A2eomåling) . Deretter ble 250 ml PBS tilsatt til 0,5 mg av forbindelse 1 som deretter ble fullstendig oppløst ved tilsetning av 250 ml DMF, og deretter ble den ovennevnte BSA-SMCC-oppløsning (BSA-innhold: 1,25 mg) tilsatt under vortexblanding og forsiktig omrørt i 3 timer. Reaksjonsoppløsningen ble dialysert over natten ved 4°C mot PBS, natriumazid ble tilsatt dertil til å gi en sluttkonsentrasjon på 0,05% og deretter ble den resulterende blandingen filtrert ved anvendelse av et 0,22 mm filter til å gi en BSA-forbindelse 1-oppløsning. </span>That is, 100 ml of 25 mg/ml SMCC (4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid-N-hydroxysuccinimide ester) (manufactured by Sigma) DMSO solution was added dropwise to 900 ml of PBS solution containing 10 mg BSA under vortex mixing and stirred gently for 30 minutes. To a gel filtration column, such as a NAP-10 column or the like, equilibrated with 25 ml of PBS, 1 ml of the reaction solution was added and the eluate eluted with 1.5 ml of PBS was used as a BSA-SMCC solution (BSA concentration was calculated by A2eo measurement) . Then, 250 mL of PBS was added to 0.5 mg of compound 1 which was then completely dissolved by adding 250 mL of DMF, and then the above BSA-SMCC solution (BSA content: 1.25 mg) was added under vortex mixing and gently stirred for 3 hours. The reaction solution was dialyzed overnight at 4°C against PBS, sodium azide was added thereto to give a final concentration of 0.05% and then the resulting mixture was filtered using a 0.22 mm filter to give a BSA compound 1 -resolution.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I en 96-brønns ELISA-plate (produsert av Greiner) ble 0,05 ug/ml av det fremstilte konjugat dispensert inn ved 50 yl/ brønn og ble hensatt ved 4°C over natten for adsorpsjon. Etter vasking med PBS, ble PBS inneholdende 1% BSA (i det etterfølgende referert til som "1% BSA-PBS") tilsatt dertil ved 100 yl/brønn og fikk reagere ved romtemperatur i 1 time for å blokkere de gjenværende aktive grupper. Etter vasking av hver brønn med PBS inneholdende 0,05% Tween 20 (i det etterfølgende referert til "Tween-PBS"), ble en kultur-supernatant av transformanten tilsatt ved 50 yl/brønn og fikk reagere ved romtemperatur i 1 time. Etter reaksjonen og etter-følgende vasking av hver brønn med Tween-PBS, ble en peroksydase -merket geit anti-humant IgG(y) antistoff-oppløsning (produsert av American Qualex) fortynnet 6.000 ganger med 1% BSA-PBS tilsatt som en sekundær antistoffoppløsning i 50 yl/ brønn porsjoner og fikk reagere ved romtemperatur i 1 time. Etter reaksjonen og etterfølgende vasking med Tween-PBS, ble en ABTS-substratoppløsning (en oppløsning fremstilt ved å oppløse 0,55 g 2,2&lt;1-&gt;azino-bis(3-etylbenzotiazolin-6-sulfon-syre) ammonium i 1 liter 0,1 M citratbuffer (pH 4,2) og å tilsette 1 yl/ml hydrogenperoksyd rett før bruk) tilsatt ved 50 yl/brønn for å utvikle farge, og reaksjonen ble stanset 20 minutter deretter ved tilsetning av 5% SDS-oppløsning ved 50 yl/brønn. Deretter ble absorbans ved 415 nm målt. </span>In a 96-well ELISA plate (manufactured by Greiner), 0.05 µg/ml of the prepared conjugate was dispensed at 50 µl/well and was left at 4°C overnight for adsorption. After washing with PBS, PBS containing 1% BSA (hereinafter referred to as "1% BSA-PBS") was added thereto at 100 µl/well and allowed to react at room temperature for 1 hour to block the remaining active groups. After washing each well with PBS containing 0.05% Tween 20 (hereafter referred to as "Tween-PBS"), a culture supernatant of the transformant was added at 50 µl/well and allowed to react at room temperature for 1 hour. After the reaction and subsequent washing of each well with Tween-PBS, a peroxidase-labeled goat anti-human IgG(γ) antibody solution (manufactured by American Qualex) diluted 6,000-fold with 1% BSA-PBS was added as a secondary antibody solution in 50 μl/well portions and allowed to react at room temperature for 1 hour. After the reaction and subsequent washing with Tween-PBS, an ABTS substrate solution (a solution prepared by dissolving 0.55 g of 2,2&lt;1-&gt;azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) ammonium in 1 liter of 0.1 M citrate buffer (pH 4.2 and to add 1 μl/ml hydrogen peroxide immediately before use) added at 50 μl/well to develop color, and the reaction was stopped 20 min thereafter by addition of 5% SDS solution at 50 yl/well. Then absorbance at 415 nm was measured.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre, for å sammenligne konsentrasjoner av et produsert humant IgG antistoff i kultur-supernatantene, ble et geit anti-humant IgG(y) antistoff (produsert av American Qualex) fortynnet 2.000 ganger med PBS anvendt som antigenet. </span>Furthermore, to compare concentrations of a produced human IgG antibody in the culture supernatants, a goat anti-human IgG(y) antibody (manufactured by American Qualex) diluted 2,000 times with PBS was used as the antigen.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i fig. 7 og fig. 8. Hvert humant CCR4 CDR-podet antistoff utviste nesten den samme aktivitet av det humane kimære antistoff KM2760. </span>The results are shown in fig. 7 and fig. 8. Each human CCR4 CDR-grafted antibody exhibited almost the same activity of the human chimeric antibody KM2760.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2.Stabil ekspresjon av anti-CCR4 CDR-podet antistoff ved anvendelse av dyreceller </span>2.Stable expression of anti-CCR4 CDR-grafted antibody using animal cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et anti-CCR CDR-podet antistoff ble uttrykt i dyreceller ved anvendelse av anti-CCR4 CDR-podet antistoff-ekspresjonsvektoren oppnådd i 2(3) i eksempel 1 som følger. </span>An anti-CCR CDR-grafted antibody was expressed in animal cells using the anti-CCR4 CDR-grafted antibody expression vector obtained in 2(3) of Example 1 as follows.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1)Stabil ekspresjon i rotte-myelomcellelinje YB2/0 celle </span>(1)Stable expression in rat myeloma cell line YB2/0 cell</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(ATCC CRL 1581) </span>(ATCC CRL 1581)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hvert humant CDR-podet antistoff ekspresjonsplasmid ble brakt til en lineær tilstand ved å digerere det med et restriksjonsenzym Aatll (produsert av TOYOBO), 10 ug av det dige-rerte produkt ble innført i 4xl0&lt;6&gt;celler av rotte-myelom-cellelinjen YB2/0 celle (ATCC CRL 1581) ved elektroporering ( Cytotechnology, 3_, 133 (1990) ) , og deretter ble cellene suspendert i 40 ml H-SFM (produsert av GIBCO-BRL) medium (supplert med 5% fetalt bovint serum (FBS)) og dispensert ved 200 ul/brønn inn i en 96-brønns mikrotiterplate (produsert av Sumitomo Bakelite) . Etter dyrking av 37°C i 1 til 3 døgn i en 5% C02inkubator, ble G418 (produsert av Nakalai Tesque) tilsatt dertil til å gi en konsentrasjon på 1 mg/ml og dyrkingen ble fortsatt i 1 til 2 uker for å oppnå G418-resistente transformanter. </span>Each human CDR-grafted antibody expression plasmid was brought to a linear state by digesting it with a restriction enzyme AatII (manufactured by TOYOBO), 10 µg of the digested product was introduced into 4x10&lt;6&gt; cells of the rat myeloma cell line YB2 /0 cell (ATCC CRL 1581) by electroporation ( Cytotechnology, 3_, 133 (1990) ), and then the cells were suspended in 40 ml of H-SFM (manufactured by GIBCO-BRL) medium (supplemented with 5% fetal bovine serum (FBS )) and dispensed at 200 µl/well into a 96-well microtiter plate (manufactured by Sumitomo Bakelite). After culturing at 37°C for 1 to 3 days in a 5% CO2 incubator, G418 (manufactured by Nakalai Tesque) was added thereto to give a concentration of 1 mg/ml and cultivation was continued for 1 to 2 weeks to obtain G418 -resistant transformants.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kultur-supernatanter ble utvunnet fra brønner hvori kolonier av transformantene som utviser G418-resistens ble konfluente, og antigen-bindende aktiviteter av anti-CCR4 humane CDR-podede antistoffer i kultur-supernatantene ble målt ved hjelp av ELISA vist i 1(2) i eksempel 2. </span>Culture supernatants were recovered from wells in which colonies of the transformants exhibiting G418 resistance became confluent, and antigen-binding activities of anti-CCR4 human CDR-grafted antibodies in the culture supernatants were measured by ELISA shown in 1(2) of example 2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For å øke antistoff-ekspresjonsmengden ved anvendelse av et dhfr genamplifikasjonssystem, ble transformantene i brønner hvori ekspresjon av et anti-CCR4 kimært antistoff ble funnet i kultur-supernatantene suspendert til å gi en densitet på 1 til 2xl0&lt;5&gt;celler/ml i H-SFM medium inneholdende 1 mg/ml G418 og 50 nM metotreksat (i det etterfølgende referert som "MTX") som er en inhibitor av et dhfr genprodukt dihydrofolatreduk tase og dispensert i 1 ml porsjoner inn i en 24-brønns plate (produsert av Greiner). Transformanter som utviser 5 0 nM MTX-resistens ble indusert ved dyrking ved 37°C i 1 til 2 uker i en 5% C02inkubator. Når transf ormantene ble konfluente i brønnene, ble antigen-bindende aktiviteter av anti-CCR4 humane CDR-podede antistoffer i kultur-supernatantene målt ved hjelp av ELISA vist i 1(2) i eksempel 2. Med hensyn til transformanter i brønner hvor ekspresjon av anti-CCR4 humane CDR-podede antistoffer ble funnet i kultur-supernatantene, ble MTX-konsentrasjonen økt til 100 nM og deretter til 200 nM ved hjelp av den ovennevnte metoden, og en transformant som er i stand til å vokse i H-SFM medium inneholdende 1 mg/ml G418 og 200 nM MTX og som også er i stand til å i høy grad å uttrykke det anti-CCR4 humane CDR-podede antistoff ble til sist oppnådd. For den således oppnådde transformant ble enkeltcelle-isolering (kloning) utført ved begrensende fortynningsanalyse for å oppnå en transformant-celleklon som utviser den høyeste ekspresjon av det anti-CCR4 humane CDR-podede antistoff. En antistoff-produserende celle KM8760 oppnådd ved genoverføringen av en ekspresjonsvektor pKANTEX216 0GallLV3 og en antistoff-produserende celle KM8759 oppnådd ved genoverføringen av en ekspresjonsvektor pKANTEX2160Gal2LV3 er blitt deponert 30. juli 2002 som henholdsvis FERM BP-8130 og FERM BP8129 i International Depositary Authority hos International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan). </span>To increase the amount of antibody expression using a dhfr gene amplification system, the transformants in wells in which expression of an anti-CCR4 chimeric antibody was found in the culture supernatants were suspended to give a density of 1 to 2x10&lt;5&gt;cells/ml in H -SFM medium containing 1 mg/ml G418 and 50 nM methotrexate (hereinafter referred to as "MTX") which is an inhibitor of a dhfr gene product dihydrofolate reductase and dispensed in 1 ml portions into a 24-well plate (manufactured by Greiner ). Transformants exhibiting 50 nM MTX resistance were induced by cultivation at 37°C for 1 to 2 weeks in a 5% CO 2 incubator. When the transformants became confluent in the wells, antigen-binding activities of anti-CCR4 human CDR-grafted antibodies in the culture supernatants were measured by ELISA shown in 1(2) of Example 2. With respect to transformants in wells where expression of anti-CCR4 human CDR-grafted antibodies were found in the culture supernatants, the MTX concentration was increased to 100 nM and then to 200 nM using the above method, and a transformant capable of growing in H-SFM medium containing 1 mg/ml G418 and 200 nM MTX and also capable of highly expressing the anti-CCR4 human CDR-grafted antibody was finally obtained. For the transformant thus obtained, single cell isolation (cloning) was performed by limiting dilution analysis to obtain a transformant cell clone exhibiting the highest expression of the anti-CCR4 human CDR-grafted antibody. An antibody-producing cell KM8760 obtained by the gene transfer of an expression vector pKANTEX216 0GallLV3 and an antibody-producing cell KM8759 obtained by the gene transfer of an expression vector pKANTEX2160Gal2LV3 have been deposited on July 30, 2002 as FERM BP-8130 and FERM BP8129, respectively, in the International Depository Authority at the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2)Rensing av anti-CCR4 CDR-podet antistoff fra kultur-supernatant en </span>(2) Purification of anti-CCR4 CDR-grafted antibody from culture supernatant one</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Når en transformant som utviser G418 resistens kom tilsyne og ble konfluent, ble mediet byttet til 300 til 1.100 ml H-SFM medium inneholdende Daigo's GF21 (produsert av Wako Pure Chemical Industries) ved en konsentrasjon på 5%, etterfulgt av dyrking i 3 til 5 døgn. Når den ble konfluent, ble kultur-supernatanten utvunnet. Et renseprotein ble oppnådd ved å rense det anti-CCR4 CDR-podede antistoff fra omtrent 300 til 1.100 ml av kultur-supernatanten ved anvendelse av en Prosep-A kolonne (produsert av Millipore) i overensstemmelse med de vedlagte instruksjoner. </span>When a transformant exhibiting G418 resistance appeared and became confluent, the medium was changed to 300 to 1,100 ml of H-SFM medium containing Daigo's GF21 (manufactured by Wako Pure Chemical Industries) at a concentration of 5%, followed by cultivation for 3 to 5 day and night. Once confluent, the culture supernatant was recovered. A purified protein was obtained by purifying the anti-CCR4 CDR-grafted antibody from approximately 300 to 1,100 ml of the culture supernatant using a Prosep-A column (manufactured by Millipore) in accordance with the attached instructions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3.Evaluering av aktivitet av renset anti-CCR4 CDR-podet antistoff </span>3.Evaluation of activity of purified anti-CCR4 CDR-grafted antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aktiviteten ble evaluert ved anvendelse av anti-CCR4 CDR-podede antistoffer avledet fra antistoff-produserende celler oppnådd ved å innføre ekspresjonsvektorer av GalOLVO, GalOLVl, GalOLV3, GallLVl, GallLV3, Gal2LVl, Gal2LV3, Gal3LVl og Gal3LV3 i YB2/0 (i det etterfølgende ganske enkelt referert til som henholdsvis "GalOLVO", "GalOLVl", "GalOLV3", "GallLVl", "GallLV3", "Gal2LVl", "Gal2LV3", "Gal3LVl" og "Gal3LV3"). </span>The activity was evaluated using anti-CCR4 CDR-grafted antibodies derived from antibody-producing cells obtained by introducing expression vectors of GalOLVO, GalOLVl, GalOLV3, GallLVl, GallLV3, Gal2LVl, Gal2LV3, Gal3LVl and Gal3LV3 into YB2/0 (in the following simply referred to as "GalOLVO", "GalOLVl", "GalOLV3", "GallLVl", "GallLV3", "Gal2LVl", "Gal2LV3", "Gal3LVl" and "Gal3LV3"), respectively.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) Måling av bindingsaktivitet av et anti-CCR4 CDR-podet antistoff for humant CCR4 (ELISA-metode) </span>(1) Measurement of binding activity of an anti-CCR4 CDR-grafted antibody for human CCR4 (ELISA method)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Målingen ble utført på samme måte som metoden beskrevet i punkt 1(2) i eksempel 2. Resultatene er vist i fig. 9. Hvert anti-CCR4 CDR-podet antistoff utviste nesten den samme aktivitet som den for det humane kimære antistoff KM2760. </span>The measurement was carried out in the same way as the method described in point 1(2) in example 2. The results are shown in fig. 9. Each anti-CCR4 CDR-grafted antibody exhibited almost the same activity as that of the human chimeric antibody KM2760.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) Reaktivitet av et anti-CCE4 CDR-podet antistoff med human CCR4-høyt-uttrykkende celle (fluorescerende antistoff-teknikk </span>(2) Reactivity of an anti-CCE4 CDR-grafted antibody with human CCR4-high-expressing cell (fluorescent antibody technique</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inn i en 96-brønns plate ble det dispensert 2xl0&lt;5&gt;eller mer av CCR4/EL-4 celler, CCR4-høyt-uttrykkende celler oppnådd i referanseeksempel 3. En antistoffoppløsning ble fremstilt ved å fortynne hvert av de rensede antistoffer og et humant immunglobulin (produsert av Welfide) for å forebygge ikke-spesifikk farging til å gi konsentrasjoner på henholdsvis 10 ug/ml og 3,75 mg/ml, med en buffer for FACS, og antistoff-oppløsningen ble tilsatt ved 100 ul/brønn og fikk reagere i 30 minutter i is. Som en negativ kontroll ble det anvendt 10 ug/ml av et anti-humant IL-5 reseptor a kjede antistoff (WO 97/10354) . Etter vasking to ganger med 200 ul/brønn av bufferen for FACS, ble et PE-merket anti-humant IgG antistoff (produsert av Coulter) fortynnet 100 ganger tilsatt ved 50 ul/brønn. Etter reaksjonen i is under avskjerming og etter-følgende vasking tre ganger med 200 ul/brønn av bufferen for FACS, ble reaksjonsproduktet suspendert i 500 yl av bufferen for FACS og fluorescensintensiteten ble målt ved anvendelse av et flow-cytometer. Resultatene er vist i fig. 10. Alle de anti-CCR4 CDR-podede antistoffer utviste nesten den samme aktivitet som det humane kimære antistoff KM2760. </span>Into a 96-well plate was dispensed 2x10&lt;5&gt; or more of CCR4/EL-4 cells, CCR4-high-expressing cells obtained in Reference Example 3. An antibody solution was prepared by diluting each of the purified antibodies and a human immunoglobulin (manufactured by Welfide) to prevent non-specific staining to give concentrations of 10 µg/ml and 3.75 mg/ml, respectively, with a buffer for FACS, and the antibody solution was added at 100 µl/well and given react for 30 minutes in ice. As a negative control, 10 µg/ml of an anti-human IL-5 receptor α chain antibody (WO 97/10354) was used. After washing twice with 200 µl/well of the buffer for FACS, a PE-labeled anti-human IgG antibody (manufactured by Coulter) diluted 100-fold was added at 50 µl/well. After the reaction in ice under shielding and subsequent washing three times with 200 µl/well of the buffer for FACS, the reaction product was suspended in 500 µl of the buffer for FACS and the fluorescence intensity was measured using a flow cytometer. The results are shown in fig. 10. All of the anti-CCR4 CDR-grafted antibodies exhibited almost the same activity as the human chimeric antibody KM2760.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3)Måling av aktivitet av anti-CCR4 CDR-podet antistoff til å binde en human CCR4 (BIAcore-metode) </span>(3)Measurement of activity of anti-CCR4 CDR-grafted antibody to bind a human CCR4 (BIAcore method)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For å måle bindingsaktiviteten mer detaljert, ble bindingsaktiviteten av forskjellige rensede antistoffer målt ved anvendelse av BIAcore 2000 (produsert av BIACORE) som følger. I dette tilfellet ble HBS-EP (produsert av BIACORE) anvendt som bufferen for fortynning av prøver og for målingen. Først ble 5 yl 0,05 yg/ml oppløsning av forbindelse 1 som et biotinylert CCR4 partielt peptid tilsatt til en følerspiss SA (produsert av BIACORE) ved en strømningshastighet på 5 yl/ minutt og immobilisert på følerspissen. </span>To measure the binding activity in more detail, the binding activity of various purified antibodies was measured using BIAcore 2000 (manufactured by BIACORE) as follows. In this case, HBS-EP (manufactured by BIACORE) was used as the buffer for dilution of samples and for the measurement. First, 5 µl 0.05 µg/ml solution of compound 1 as a biotinylated CCR4 partial peptide was added to a probe tip SA (manufactured by BIACORE) at a flow rate of 5 µl/minute and immobilized on the probe tip.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Til den preparerte følerspiss immobilisert med biotinylert forbindelse 1 ble 20 yl 4 yg/ml oppløsning av hvert av de rensede antistoffer tilsatt ved en strømningshastighet på 5 yl/minutt, og etter fullførelse av tilsetningen ble dissosiasjonsreaksjonen overvåkes i 4 minutter og deretter ble føler-spissoverflaten regenerert ved tilsetning av 5 yl 10 mM HC1 to ganger. På denne måten ble det oppnådd en bindingsreak-sjonskurve (sensorgram) for forbindelse 1. </span>To the prepared sensor tip immobilized with biotinylated compound 1, 20 µl of 4 µg/ml solution of each of the purified antibodies was added at a flow rate of 5 µl/minute, and after completion of the addition, the dissociation reaction was monitored for 4 minutes and then the sensor tip surface was regenerated by adding 5 µl 10 mM HCl twice. In this way, a binding reaction curve (sensorgram) was obtained for compound 1.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i fig. 11. Ordinaten representerer en resonansenhet (RE) som betyr en masseforandring på følerspis-sen. 1.000 RE tilsvarer f.eks. en masseforandring på omtrent 1 ng/mm&lt;2&gt;protein. Det ble vist at KM2760 hadde en markert stabil og høy bindingsaktivitet, fordi den utviste en tidsav-hengig bindingsaktivitet for forbindelse 1 og dissosiasjon av dens binding ble knapt funnet ved dissosiasjonsreaksjonen. </span>The results are shown in fig. 11. The ordinate represents a resonance unit (RE) which means a mass change at the sensor tip. 1,000 RE corresponds to e.g. a mass change of approximately 1 ng/mm&lt;2&gt;protein. It was shown that KM2760 had a markedly stable and high binding activity, because it exhibited a time-dependent binding activity for compound 1 and dissociation of its binding was hardly found in the dissociation reaction.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">På den annen side, utviste hvert av de anti-CCR4 CDR-podede antistoffer nesten den samme dissosiasjonsreaksjonen som det </span>On the other hand, each of the anti-CCR4 CDR-grafted antibodies exhibited almost the same dissociation reaction as the</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane kimære antistoff KM2760, men en svak reduksjon i aktiviteten ble funnet i bindingsreaksjonen til det CCR4 partielle peptid, forbindelse 1. Det anti-CCR4 CDR-podede antistoff GalOLVO hvori CDR alene var podet utviste den laveste bindingsaktiviteten, og bindingsaktiviteten ble økt ved aminosyrerest-modifiseringen av FR. Resultatene viser at et anti-CCR4 CDR-podet antistoff som opprettholder den antigenbindende aktivitet og bindingsspesifisitet av et muse-antistoff kan fremstilles ved å pode CDR av muse-antistoffet KM2160 til et passende humant antistoff FR, og at et anti-CCR4 CDR-podet antistoff som har høyere bindingsaktivitet kan fremstilles ved å identifisere FR aminosyrerester som er viktige for bindingsaktiviteten basert på den tredimensjonale struktur og lignende av antistoff V regioner og å pode dem sammen med CDR-et. Det er forventet av de anti-CCR4 CDR-podede antistoffer fremstilt i dette eksemplet har høy bindingsaktivitet til CCR4, har redusert immunogenisitet i mennesker sammenlignet med den for muse-antistoffer og også den for humane kimære antistoffer, og har høy sikkerhet og høye terapeutiske effekter. </span>human chimeric antibody KM2760, but a slight decrease in activity was found in the binding reaction of the CCR4 partial peptide, compound 1. The anti-CCR4 CDR-grafted antibody GalOLVO in which the CDR alone was grafted showed the lowest binding activity, and the binding activity was increased by amino acid residues the modification of FR. The results show that an anti-CCR4 CDR-grafted antibody that maintains the antigen-binding activity and binding specificity of a mouse antibody can be prepared by grafting the CDRs of the mouse antibody KM2160 to a suitable human antibody FR, and that an anti-CCR4 CDR-grafted antibody having higher binding activity can be prepared by identifying FR amino acid residues important for binding activity based on the three-dimensional structure and the like of antibody V regions and grafting them together with the CDR. It is expected that the anti-CCR4 CDR-grafted antibodies prepared in this example have high binding activity to CCR4, have reduced immunogenicity in humans compared to that of mouse antibodies and also that of human chimeric antibodies, and have high safety and high therapeutic effects .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. In vitro cytotoksisk aktivitet av anti-CCR4 CDR-podet antistoff (ADCC aktivitet) </span>2. In vitro cytotoxic activity of anti-CCR4 CDR-grafted antibody (ADCC activity)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For å evaluere in vitro cytotoksisk aktivitet av det rensede anti-CCR4 CDR-podede antistoff oppnådd i 2(2) i eksempel 2, ble dets ADCC aktivitet målt som følger. </span>To evaluate in vitro cytotoxic activity of the purified anti-CCR4 CDR-grafted antibody obtained in 2(2) of Example 2, its ADCC activity was measured as follows.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1)Fremstilling av target-celle-suspensjon </span>(1)Preparation of target cell suspension</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den humane CCR4-høyt-uttrykkende celle CCR4/EL-4 oppnådd i referanseeksempel 3 ble dyrket i 10% FCS-inneholdende RPMI 1640 medium (produsert av GIBCO) inneholdende 0,5 mg/ml G418 til å gi en densitet på lxlO&lt;6&gt;celler/0,5 ml, 1,85 MBq ekviva-lent av radioaktivt natriumkromat (Na251CrOJ (produsert av Daiichi Pure Chemicals) ble tilsatt dertil og blandingen fikk reagere ved 37°C i 1,5 timer til å isotop-merke cellene. Etter reaksjonen ble cellene vasket tre ganger ved deres suspensjon i RPMI 1640 medium og sentrifugering, re-suspendert i mediet og deretter inkubert i is ved 4°C i 3 0 minutter for spontant å frigjøre den radioaktive substans. Etter sentrifugering ble 5 ml 10% FCS-inneholdende RPMI i 1640 medium tilsatt dertil til å gi en densitet på 2xl0&lt;5&gt;celler/ml som targetcelle-suspensjonen. </span>The human CCR4-high-expressing cell CCR4/EL-4 obtained in Reference Example 3 was cultured in 10% FCS-containing RPMI 1640 medium (manufactured by GIBCO) containing 0.5 mg/ml G418 to give a density of lx10&lt;6 &gt;cells/0.5 ml, 1.85 MBq equivalent of radioactive sodium chromate (Na251CrOJ (manufactured by Daiichi Pure Chemicals)) was added thereto and the mixture was allowed to react at 37°C for 1.5 hours to isotopically label the cells. After the reaction, the cells were washed three times by their suspension in RPMI 1640 medium and centrifugation, re-suspended in the medium and then incubated in ice at 4°C for 30 minutes to spontaneously release the radioactive substance. After centrifugation, 5 ml of 10% FCS-containing RPMI in 1640 medium added thereto to give a density of 2x10&lt;5&gt; cells/ml as the target cell suspension.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) Fremstilling av effektorcelle-suspensjon </span>(2) Preparation of effector cell suspension</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Friskt humant perifert blod (60 ml) ble samlet ved anvendelse av en sprøyte inneholdende 2 00 enheter (2 00 ul) av en heparin natriuminjeksjon (produsert av Takeda Pharmaceutical). Hele mengden ble fylt opp til 120 ml ved å fortynne den to ganger med det samme volum av fysiologisk saltoppløsning (produsert av Otsuka Pharmaceutical). Lymphoprep (produsert av NYCOMED) ble dispensert ved 5 ml inn i 12 rør med 15 ml kapasitets sentrifugeringsrør (produsert av Sumitomo Bakelite), det fortynnede perifere blod ble lagt over dette ved 10 ml, og blandingen ble sentrifugert ved 800 x g i 20 minutter ved romtemperatur. PBMC-fraksjoner mellom blodplasmalaget og Lymphoprep-laget ble samlet fra alle sentrifugeringsrør, suspender i 1% FCS-inneholdende RPMI 164 0 medium (i det etterfølgende referert til som "1% FCS-RPMI"), vasket to ganger ved sentrifugering ved 400 x g og 4°C i 5 minutter og deretter re-suspendert til å gi en densitet på 5xl0&lt;6&gt;celler/ ml for bruk som effektorcellene. </span>Fresh human peripheral blood (60 ml) was collected using a syringe containing 200 units (200 µl) of a heparin sodium injection (manufactured by Takeda Pharmaceutical). The entire amount was made up to 120 ml by diluting it twice with the same volume of physiological saline (manufactured by Otsuka Pharmaceutical). Lymphoprep (manufactured by NYCOMED) was dispensed at 5 mL into 12 tubes of 15 mL capacity centrifuge tubes (manufactured by Sumitomo Bakelite), the diluted peripheral blood was overlaid at 10 mL, and the mixture was centrifuged at 800 x g for 20 min at room temperature . PBMC fractions between the blood plasma layer and the Lymphoprep layer were collected from all centrifugation tubes, suspended in 1% FCS-containing RPMI 164 0 medium (hereafter referred to as "1% FCS-RPMI"), washed twice by centrifugation at 400 x g and 4°C for 5 minutes and then re-suspended to give a density of 5x10&lt;6&gt; cells/ml for use as the effector cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3) Måling av ADCC aktivitet </span>(3) Measurement of ADCC activity</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Targetcelle-suspensjonen fremstilt i (1) ble dispensert ved </span>The target cell suspension prepared in (1) was dispensed at</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50 yl (lxlO&lt;4&gt;celler/brønn) inn i brønner i en 96-brønns U-bunn-plate (produsert av Falcon). Deretter ble effektorcelle-suspensjonen fremstilt i (2) dispensert ved 100 yl </span>50 µl (lx10&lt;4&gt; cells/well) into wells of a 96-well U-bottom plate (manufactured by Falcon). Then the effector cell suspension prepared in (2) was dispensed at 100 µl</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(5xl0&lt;5&gt;celler/brønn, forholdet av effektorceller til targetceller blir 50 : 1). Hvert anti-CCR4 kimært antistoff ble så tilsatt til å gi en sluttkonsentrasjon på 0,1 ng/ml til 10 ug/ml og blandingen fikk reagere ved 37°C i 4 timer. Etter reaksjonen ble platen sentrifugert og mengden av&lt;51&gt;Cr i 100 yl av supernatanten i hver brønn ble målt ved hjelp av en Y-teller. Mengden av det spontant dissosierte&lt;51&gt;Cr ble beregnet på samme måte som ovenfor ved anvendelse av mediet alene i stedet for effektorcelle-suspensjonen og antistoff-oppløsning og måling av mengden&lt;51&gt;Cr i supernatanten. Mengden av det totale dissosierte&lt;51&gt;Cr ble beregnet på samme måte som ovenfor ved å tilsette mediet alene i stedet for antistoff-oppløsningen, og 1 N saltsyre i stedet for effektorcelle-suspensjonen, og å måle mengden&lt;51&gt;CR i supernatanten. ADCC aktiviteten ble beregnet ved hjelp av den følgende ligning: </span>(5xl0&lt;5&gt; cells/well, the ratio of effector cells to target cells is 50 : 1). Each anti-CCR4 chimeric antibody was then added to give a final concentration of 0.1 ng/ml to 10 µg/ml and the mixture allowed to react at 37°C for 4 hours. After the reaction, the plate was centrifuged and the amount of&lt;51&gt;Cr in 100 µl of the supernatant in each well was measured using a Y counter. The amount of the spontaneously dissociated&lt;51&gt;Cr was calculated in the same way as above by using the medium alone instead of the effector cell suspension and antibody solution and measuring the amount of&lt;51&gt;Cr in the supernatant. The amount of total dissociated&lt;51&gt;Cr was calculated in the same way as above by adding the medium alone instead of the antibody solution, and 1 N hydrochloric acid instead of the effector cell suspension, and measuring the amount of&lt;51&gt;CR in the supernatant. The ADCC activity was calculated using the following equation:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i fig. 12. Som vist i fig. 12, hadde det anti-CCR4 CDR-podede antistoff sterk cytotoksisk aktivitet som var antistoffkonsentrasjon-avhengig. </span>The results are shown in fig. 12. As shown in fig. 12, the anti-CCR4 CDR-grafted antibody had strong cytotoxic activity that was antibody concentration-dependent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5.Effekt av inhiberende produksjon av cytokin fra human PBMC </span>5.Effect of inhibiting production of cytokine from human PBMC</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En effekt av å inhibere cytokinproduksjon undersøkt ved anvendelse av en anti-CCR4 CDR-podet antistoff GallLV3 og et kimært antistoff KM2760. Et anti-IL-5R antistoff ble anvendt som en negativ kontroll. </span>An effect of inhibiting cytokine production investigated using an anti-CCR4 CDR-grafted antibody GallLV3 and a chimeric antibody KM2760. An anti-IL-5R antibody was used as a negative control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PBMC ble separert på samme måte som i 4(2) i eksempel 2 og dispensert ved lxlO&lt;6&gt;celler/brønn i en 96-brønns U-bunn-plate, et evaluerings-antistoff ble tilsatt dertil til å gi en sluttkonsentrasjon på 1 yg/ml, og det totale volum ble innstilt til 200 yl/brønn. ADCC aktiviteten ble indusert ved ko-dyrking ved 3 7°C i 24 timer i en strøm av 5% C02. Etter dyrkingen ble 100 yl av supernatanten fjernet, 100 yl av et medium inneholdende 10 ng/ml PMA (forbolmyristatacetat) og 2 yg/ml ionomycin (produsert av SIGMA) ble tilsatt dertil til å gi sluttkonsentrasjoner på 50 ng/ml PMA og 1 yg/ml ionomycin, og cellene ble stimulert for å indusere cytokinproduksjonen. </span>PBMC were separated in the same manner as in 4(2) of Example 2 and dispensed at lx10&lt;6&gt;cells/well in a 96-well U-bottom plate, an evaluation antibody was added thereto to give a final concentration of 1 µg/ml, and the total volume was set to 200 µl/well. The ADCC activity was induced by co-cultivation at 37°C for 24 hours in a stream of 5% CO 2 . After the cultivation, 100 µl of the supernatant was removed, 100 µl of a medium containing 10 ng/ml PMA (phorbol myristate acetate) and 2 µg/ml ionomycin (manufactured by SIGMA) was added thereto to give final concentrations of 50 ng/ml PMA and 1 µg/ml /ml of ionomycin, and the cells were stimulated to induce cytokine production.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter innføring av hvert stimulerende middel, ble dyrking utført i 24 timer, kultur-supernatanter ble utvunnet og IL-4, IL-13 og interferon (IFN)-y ble målt ved anvendelse av et cytokin-analysekit (produsert av Biosource). Produksjons-inhiberingsforholdet ble beregnet ved å definere hver cytokinproduksjon i fravær av antistoff som 0% inhiberingsfor-hold, og resultatene er vist i fig. 13. Som vist i fig. 13, på lignende måte som det kimære antistoff KM2760, inhiberte den anti-CCR4 CDR-podet antistoff GallLV3-adderte gruppe signifikant produksjon av Th2 cytokine IL-3 og IL-13 men hadde liten innvirkning på Thl cytokinet IFN-y. </span>After introduction of each stimulant, culture was performed for 24 hours, culture supernatants were recovered and IL-4, IL-13 and interferon (IFN)-γ were measured using a cytokine assay kit (manufactured by Biosource). The production-inhibition ratio was calculated by defining each cytokine production in the absence of antibody as 0% inhibition ratio, and the results are shown in Fig. 13. As shown in fig. 13, similarly to the chimeric antibody KM2760, the anti-CCR4 CDR-grafted antibody GallLV3-added group significantly inhibited the production of Th2 cytokines IL-3 and IL-13 but had little effect on the Th1 cytokine IFN-γ.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene viser at hvert anti-CCR4 CDR-podet antistoff kan utarme eller eliminere CCR4-uttrykte Th2-celler ved å akti-vere humane effektorceller effektivt og har, som et resultat, en effekt med hensyn til å inhibere produksjon av Th2 cytokin fra Th2-cellene og er derfor anvendbar i diagnostisering eller behandling av humane Th2-medierte immunsykdommer slik som bronkialastma, atopisk dermatitt og lignende. </span>The results show that each anti-CCR4 CDR-grafted antibody can deplete or eliminate CCR4-expressing Th2 cells by activating human effector cells efficiently and, as a result, has an effect in inhibiting production of Th2 cytokine from Th2- the cells and is therefore applicable in the diagnosis or treatment of human Th2-mediated immune diseases such as bronchial asthma, atopic dermatitis and the like.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6.Analyse av reaktivitet for human blodplate </span>6. Analysis of reactivity for human platelets</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1)Separasjon av human blodplate </span>(1) Separation of human platelets</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et 1/10 volum av 3,2% natriumcitrat ble tilsatt til en blod-prøve samlet fra en frisk person og grundig blandet. Blodet ble dispensert ved 5 ml inn i rør med 15 ml kapasitet (produsert av Greiner) og sentrifugert ved 90 x g i 10 minutter ved romtemperatur. Supernatantene ble samlet og ytterligere sentrifugert ved 1.950 x g i 10 minutter ved romtemperatur. Etter at man har kvittet seg med supernatanten ble pelletene suspendert i bufferen for FACS og sentrifugert ved 1.190 x g i 5 minutter ved romtemperatur for å vaske pelleten. Pellet ene ble igjen suspendert i bufferen for FACS og sentrifugert på samme måte, og deretter ble blodplater i pelletform innstilt til å gi en densitet på omtrent lxlO&lt;7&gt;pelleter/ml ved anvendelse av bufferen for FACS. </span>A 1/10 volume of 3.2% sodium citrate was added to a blood sample collected from a healthy individual and thoroughly mixed. The blood was dispensed at 5 ml into 15 ml capacity tubes (manufactured by Greiner) and centrifuged at 90 x g for 10 minutes at room temperature. The supernatants were collected and further centrifuged at 1,950 x g for 10 min at room temperature. After discarding the supernatant, the pellets were suspended in the buffer for FACS and centrifuged at 1,190 x g for 5 min at room temperature to wash the pellet. The pellet was resuspended in the buffer for FACS and centrifuged in the same manner, and then platelets in pellet form were adjusted to give a density of approximately 1x10&lt;7&gt; pellets/ml using the buffer for FACS.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2)Farging av blodplate </span>(2) Platelet staining</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hvert av de rensede anti-CCR4 humane CDR-podede antistoffer oppnådd i 3 i eksempel 2 ble tilsatt til 100 yl av blodplatesuspensjonen oppnådd i punkt 6(1) til å gi en konsentrasjon på 10 yg/100 yl og fikk reagere ved romtemperatur i 3 0 minutter i mørket. Som sammenligningskontroller, fikk hvert av et anti-CCR4 humant kimært antistoff KM2760 og et anti-muse antistoff 1G1 antistoff (produsert av Pharmingen) reagere med 100 ml av blodplatesuspensjonen ved den samme konsentrasjon. </span>Each of the purified anti-CCR4 human CDR-grafted antibodies obtained in 3 in Example 2 was added to 100 µl of the platelet suspension obtained in step 6(1) to give a concentration of 10 µg/100 µl and allowed to react at room temperature for 3 0 minutes in the dark. As comparative controls, each of an anti-CCR4 human chimeric antibody KM2760 and an anti-mouse antibody 1G1 antibody (manufactured by Pharmingen) were reacted with 100 ml of the platelet suspension at the same concentration.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter reaksjonen ble 2 ml av bufferen for FACS tilsatt til hvert av rørende med 15 ml kapasitet, og blandingen ble om-rørt og deretter vasket ved sentrifugering ved 840 x g i 5 minutter ved 4°C. Etter at man hadde kvittet seg med supernatanten ble den samme operasjonen utført igjen. Et PE-merket anti-muse IgG antistoff (produsert av Coulter) fortynnet 50 ganger med bufferen for FACS ble tilsatt ved 20 yl til røret inneholdende en prøve reagert med hvert av de humane CDR-podede antistoffer og KM2760 og fikk reagere ved romtemperatur i 3 0 minutter i mørket. Hva angår røret inneholdende prøven reagert med 1G1 antistoffet, ble 20 yl av et 50 ganger fortynnet PE-merket anti-muse IgG antistoff (produsert av DAKO) ytterligere tilsatt og fikk reagere ved romtemperatur i 3 0 minutter i mørket. </span>After the reaction, 2 ml of the buffer for FACS was added to each of the 15 ml capacity tubes, and the mixture was stirred and then washed by centrifugation at 840 x g for 5 minutes at 4°C. After discarding the supernatant, the same operation was performed again. A PE-labeled anti-mouse IgG antibody (manufactured by Coulter) diluted 50-fold with the buffer for FACS was added at 20 µl to the tube containing a sample reacted with each of the human CDR-grafted antibodies and KM2760 and allowed to react at room temperature for 3 0 minutes in the dark. As for the tube containing the sample reacted with the 1G1 antibody, 20 µl of a 50-fold diluted PE-labeled anti-mouse IgG antibody (manufactured by DAKO) was further added and allowed to react at room temperature for 30 minutes in the dark.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter reaksjonen ble 2 ml av bufferen for FACS tilsatt til hvert rør, etterfulgt av omrøring, og blandingen ble vasket ved sentrifugering ved 840 x g i 5 minutter ved 4°C. Etter at man hadde kvittet seg med supernatanten ble den samme operasjonen utført igjen. Etter suspendering av resten i 500 yl av bufferen for FACS, ble fluorescensintensiteten målt ved anvendelse av et flow-cytometer EPICS XL-MCL (produsert av Beckman Coulter). </span>After the reaction, 2 ml of the buffer for FACS was added to each tube, followed by agitation, and the mixture was washed by centrifugation at 840 x g for 5 min at 4°C. After discarding the supernatant, the same operation was performed again. After suspending the residue in 500 µl of the buffer for FACS, the fluorescence intensity was measured using a flow cytometer EPICS XL-MCL (manufactured by Beckman Coulter).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i fig. 14. 1G1 antistoffet som en sam-menligningskontroll utviste reaktivitet med blodplater, men alle de anti-CCR4 humane CDR-podede antistoffer utviste ikke spesifikk reaktivitet med humane blodplater på lignende måte som det anti-CCR4 humane kimære antistoff KM2760. </span>The results are shown in fig. 14. The 1G1 antibody as a comparison control showed reactivity with platelets, but all of the anti-CCR4 human CDR-grafted antibodies did not show specific reactivity with human platelets similarly to the anti-CCR4 human chimeric antibody KM2760.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Referanseeksempel 1 </span>Reference example 1</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fremstilling av hybridomcelle som produserer muse anti-CCR4 monoklonalt antistoff: Hybridomceller som produserer muse anti-CCR4 monoklonalt antistoff KM2160 (Int. Immunol., 11., 81 (1999)) ble produsert i samsvar med den følgende prosedyre. </span>Preparation of hybridoma cell producing mouse anti-CCR4 monoclonal antibody: Hybridoma cells producing mouse anti-CCR4 monoclonal antibody KM2160 (Int. Immunol., 11., 81 (1999)) were produced according to the following procedure.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) Fremstilling av antigen </span>(1) Preparation of antigen</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aminosyresekvensen (SEQ ID NO:48) av humant CCR4 (i det et-terfølgende referert til som "hCCR4") protein ble analysert ved anvendelse av Genetyx Mac, og forbindelse 2 (SEQ ID NO: 36) ble valgt som en partiell sekvens som anses å være passende som antigenet blant deler som har høy hydrofilisitet, N-ende og C-ende. </span>The amino acid sequence (SEQ ID NO:48) of human CCR4 (hereinafter referred to as "hCCR4") protein was analyzed using Genetyx Mac, and compound 2 (SEQ ID NO:36) was selected as a partial sequence which considered to be suitable as the antigen among parts having high hydrophilicity, N-terminus and C-terminus.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) Fremstilling av immunogen </span>(2) Preparation of immunogen</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det hCCR4 partielle peptid oppnådd i (1) i referanseeksempel </span>The hCCR4 partial peptide obtained in (1) in reference example</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1 ble anvendt som immunogenet etter fremstilling av dets konjugat med KLH (Calbiochem) ved hjelp av den følgende metode for å øke dets immunogenisitet. Spesifikt ble KLH oppløst i PBS til å gi en konsentrasjon på 10 mg/ml, 1/10 volum av 2 5 mg/ml MBS (produsert av Nakalai Tesque) ble tilsatt dråpevis dertil og blandingen fikk reagere ved omrøring i 3 0 minutter. Fritt MBS ble fjernet ved hjelp av en gel-filtreringskolonne slik som Sephadex G-25 kolonne som var blitt ekvilibrert på forhånd med PBS eller lignende, og 2,5 mg av det resulterende KLH-MB ble blandet med 1 mg av peptidet oppløst i 0,1 M natriumfosfatbuffer (pH 7,0), etter fulgt av omrøring ved romtemperatur i 3 timer. Etter reaksjonen ble blandingen dialysert mot PBS. </span>1 was used as the immunogen after preparing its conjugate with KLH (Calbiochem) using the following method to increase its immunogenicity. Specifically, KLH was dissolved in PBS to give a concentration of 10 mg/ml, 1/10 volume of 25 mg/ml MBS (manufactured by Nakalai Tesque) was added dropwise thereto and the mixture was allowed to react by stirring for 30 minutes. Free MBS was removed using a gel filtration column such as Sephadex G-25 column that had been pre-equilibrated with PBS or the like, and 2.5 mg of the resulting KLH-MB was mixed with 1 mg of the peptide dissolved in 0 .1 M sodium phosphate buffer (pH 7.0), followed by stirring at room temperature for 3 hours. After the reaction, the mixture was dialyzed against PBS.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3) Immunisering av dyr og produksjon av antistoff-produserende celler </span>(3) Immunization of animals and production of antibody-producing cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Til 5 uker gamle hunnmus (Balb/c) ble 100 ug av peptid-KLH konjugatet fremstilt i (2) i referanseeksempel 1 administrert sammen med 2 mg aluminiumgel og 1 xlO&lt;9&gt;celler av pertussis-vaksine (produsert av Chiba Serum Institute), og 2 uker etter dette ble 100 ug av konjugatet administrert en gang pr. uke for totalt 4 ganger. En blodprøve ble tatt fra hvert dyr fra den venøse pleksus i øyebunnen, dens serumtiter ble undersøkt ved hjelp av en enzym immunanalyse beskrevet i det etter-følgende, og milten ble skåret ut 3 døgn etter den endelige immunisering fra en mus som utviste en tilstrekkelig antistof f titer. Milten ble skåret ut fra en mus på den 3. dag etter den endelige administrering og skåret i biter i MEM (produsert av Nissui Pharmaceutical), og cellene ble frigjort ved anvendelse av en pinsett og sentrifugert (1.2 00 opm, 5 minutter), supernatanten ble fjernet, etterfulgt av behandling med 3 ml av en Tris-ammoniumkloridbuffer (pH 7,65) i 1 til 2 minutter for eliminere erytrocytter. De gjenværende cellene ble ytterligere vasket tre ganger med MEM og anvendt for cellefusjon. </span>To 5-week-old female mice (Balb/c), 100 µg of the peptide-KLH conjugate prepared in (2) in Reference Example 1 was administered together with 2 mg of aluminum gel and 1 x 10&lt;9&gt; cells of pertussis vaccine (manufactured by Chiba Serum Institute) , and 2 weeks after this, 100 ug of the conjugate was administered once per week for a total of 4 times. A blood sample was taken from each animal from the fundus venous plexus, its serum titer was examined by an enzyme immunoassay described below, and the spleen was excised 3 days after the final immunization from a mouse that exhibited sufficient antibody. f titer. The spleen was excised from a mouse on the 3rd day after the final administration and cut into pieces in MEM (manufactured by Nissui Pharmaceutical), and the cells were detached using tweezers and centrifuged (1,200 rpm, 5 minutes), the supernatant was removed, followed by treatment with 3 ml of a Tris-ammonium chloride buffer (pH 7.65) for 1 to 2 minutes to eliminate erythrocytes. The remaining cells were further washed three times with MEM and used for cell fusion.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(4) Fremstilling av muse-myelomcelle </span>(4) Preparation of mouse myeloma cell</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En 8-azaguanin-resistent muse-myelomcelleline, P3X63Ag8U.l (ATCC CRL-1597, i det etterfølgende referert til som "P3-Ul"), ble dyrket og anvendt som opphavslinjen i cellefusjon. </span>An 8-azaguanine-resistant mouse myeloma cell line, P3X63Ag8U.1 (ATCC CRL-1597, hereinafter referred to as "P3-Ul"), was cultured and used as the parent line in cell fusion.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(5) Fremstilling av hybridomcelle </span>(5) Preparation of hybridoma cell</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Miltcellene og myelomcellene oppnådd i (3) og (4) i referanseeksempel 1 ble blandet til et forhold på 10:1, etterfulgt av sentrifugering (1.200 opm, 5 minutter) for å fjerne supernatanten, 0,5 ml av en polyetylenglykoloppløsning (en oppløsning inneholdende 2 g polyetylenglykol-1000, 2 ml MEM og 0,7 ml DMSO) ble tilsatt til de således presipiterte celler pr. 10° miltceller ved 37°C, etterfulgt av grundig suspendering. Deretter ble 1 til 2 ml MEM tilsatt flere ganger ved 1 til 2 minutters intervaller, og sluttvolumet ble innstilt til 50 ml med MEM. Etter fjerning av supernatanten ved sentrifugering (900 opm, 5 minutter) ble presipitatet suspendert i 100 ml HAT medium, dispensert i 100 ul/brønn inn i en 96-brønns mikrotiterplate (produsert av Sumitomo Bakelite), etterfulgt av dyrking i en 5% C02inkubator ved 3 7°C i 10 til 14 døgn. Ved anvendelse av brønner hvori propagering av den fu-sjonerte celle ble observert, ble bindingsaktivitet til det hCCR4 partielle peptid (forbindelse 2) i kultur-supernatanten målt ved hjelp av ELISA (Antijbodies; A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 14 (1988), Monoclonal Antibodies: Principles and Practice, Academic Press Limited </span>The spleen cells and myeloma cells obtained in (3) and (4) in Reference Example 1 were mixed at a ratio of 10:1, followed by centrifugation (1,200 rpm, 5 minutes) to remove the supernatant, 0.5 ml of a polyethylene glycol solution (a solution containing 2 g polyethylene glycol-1000, 2 ml MEM and 0.7 ml DMSO) was added to the thus precipitated cells per 10° spleen cells at 37°C, followed by thorough suspension. Then 1 to 2 ml of MEM was added several times at 1 to 2 minute intervals, and the final volume was adjusted to 50 ml of MEM. After removing the supernatant by centrifugation (900 rpm, 5 minutes), the precipitate was suspended in 100 ml HAT medium, dispensed at 100 µl/well into a 96-well microtiter plate (manufactured by Sumitomo Bakelite), followed by cultivation in a 5% CO2 incubator at 37°C for 10 to 14 days. Using wells in which propagation of the fused cell was observed, binding activity to the hCCR4 partial peptide (compound 2) in the culture supernatant was measured by ELISA (Antibodies; A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 14 ( 1988), Monoclonal Antibodies: Principles and Practice, Academic Press Limited</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1966), etc.). Hver brønn hvori aktiviteten var bekreftet ble klonet med totalt 2 ganger med begrensende fortynning, en gang ved bytting av mediet til HT mediet og deretter bytting av mediet til det normale medium. På denne måten ble det oppnådd en hybridomcelle KM2160 som produserer muse-antistof fet KM2160. KM2160 reagerte spesifikt med det hCCR4 partielle peptid (forbindelse 2). </span>(1966), etc.). Each well in which the activity was confirmed was cloned with a total of 2 times with limiting dilution, once by changing the medium to the HT medium and then changing the medium to the normal medium. In this way, a hybridoma cell KM2160 producing mouse antibody fat KM2160 was obtained. KM2160 specifically reacted with the hCCR4 partial peptide (compound 2).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Referanseeksempel 2 </span>Reference example 2</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fremstilling av anti-CCR4 kimært antistoff: </span>Preparation of anti-CCR4 chimeric antibody:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1.Isolering og analyse av cDNA som koder for V region av
anti-CCR4 muse-antistoff: (1)Fremstilling av mRNA fra hybridomcelle som produserer
anti-CCR4 muse-antistoff </span>1.Isolation and analysis of the cDNA that codes for the V region of
anti-CCR4 mouse antibody: (1)Preparation of mRNA from hybridoma cell producing
anti-CCR4 mouse antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et mRNA ble fremstilt fra hybridomcellen KM216 0 beskrevet i referanseeksempel 1. Omtrent 48 ug mRNA ble fremstilt fra 8xl0&lt;7&gt;celler av hybridomcellen KM2160 ved anvendelse av et kit for fremstilling av mRNA, Fast Track mRNA Isolation Kit </span>An mRNA was prepared from the hybridoma cell KM2160 described in Reference Example 1. Approximately 48 µg of mRNA was prepared from 8x10&lt;7&gt; cells of the hybridoma cell KM2160 using an mRNA preparation kit, Fast Track mRNA Isolation Kit</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(produsert av Invitrogen) i overensstemmelse med produsentens instruksj oner. </span>(manufactured by Invitrogen) in accordance with the manufacturer's instructions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) Fremstilling av H kjede og L kjede cDNA bibliotek av anti-CCR4 muse-antistoff </span>(2) Preparation of H chain and L chain cDNA library of anti-CCR4 mouse antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cDNA som har EcoRI- Notl adaptere på begge termini ble syntetisert fra 5 ug av KM2160 mRNA-et oppnådd i 1(1) i referanseeksempel 2 ved anvendelse av cDNA Synthesis kit (produsert av Amersham Pharmacia Biotech) i overensstemmelse med produsentens instruksjoner. Det således fremstilte cDNA ble oppløst i 2 0 yl sterilt vann og fraksjonert ved agarose gel elektroforese, og omtrent 1,5 kb cDNA fragmenter korresponderende til H kjeden av IgG type antistoff og omtrent 1,0 kb cDNA fragmenter korresponderende til svarende til L kjeden av k type ble respektivt utvunnet ved anvendelse av QIAquick Gel Extraction Kit (produsert av QIAGEN). Ved anvendelse av AZAPII Predigested ScoRI/CIAP-Treated Vector Kit (produsert av Stratagene), ble deretter hver av 0,1 yg av de omtrent 1,5 kb cDNA fragmentene og 0,1 yg av de omtrent 1,0 kb cDNA fragmentene koblet til 1 yg av AZAPII vektoren som var blitt digerert med et restriksjonsenzym ScoRI og terminus-defos-forylert med Calf Intestine Alkaline Phosphatase i overensstemmelse med produsentens instruksjoner. Inn i A fag, ble 2,5 yl av hver reaksjonsoppløsning etter ligeringen pakket ved anvendelse av Gigapacklll Gold Packaging Extract (produsert av Stratagene) i overensstemmelse med produsentens instruksjoner, og deretter ble Escherichia coli XLl-Blue (Bioteahnigues, 5_, 376 (1987)) infisert med en passende mengde av fagen for å oppnå 9,3x10" fag-kloner som H kjede cDNA biblioteket av KM2160 og 7,4xl0&lt;4&gt;fag-kloner som L kjede cDNA biblioteket. Deretter ble hver fag fiksert på et nylon-membranfilter Hybond-N+ (produsert av Amersham Pharmacia Biotech) i overensstemmelse med produsentens instruksjoner. </span>cDNA having EcoRI-NotI adapters at both termini was synthesized from 5 µg of the KM2160 mRNA obtained in 1(1) in Reference Example 2 using the cDNA Synthesis kit (manufactured by Amersham Pharmacia Biotech) in accordance with the manufacturer's instructions. The cDNA thus prepared was dissolved in 20 ul of sterile water and fractionated by agarose gel electrophoresis, and approximately 1.5 kb cDNA fragments corresponding to the H chain of IgG type antibody and approximately 1.0 kb cDNA fragments corresponding to corresponding to the L chain of k type were respectively extracted using the QIAquick Gel Extraction Kit (manufactured by QIAGEN). Using the AZAPII Predigested ScoRI/CIAP-Treated Vector Kit (manufactured by Stratagene), 0.1 µg each of the approximately 1.5 kb cDNA fragments and 0.1 µg of the approximately 1.0 kb cDNA fragments were then ligated to 1 µg of the AZAPII vector which had been digested with a restriction enzyme ScoRI and terminus-defos-forylated with Calf Intestine Alkaline Phosphatase according to the manufacturer's instructions. Into A phage, 2.5 µl of each reaction solution after ligation was packaged using Gigapacklll Gold Packaging Extract (manufactured by Stratagene) in accordance with the manufacturer's instructions, and then Escherichia coli XLl-Blue (Bioteahnigues, 5_, 376 (1987) )) infected with an appropriate amount of the phage to obtain 9.3x10" phage clones as the H chain cDNA library of KM2160 and 7.4x10&lt;4&gt; phage clones as the L chain cDNA library. Then each phage was fixed on a nylon -membrane filter Hybond-N+ (manufactured by Amersham Pharmacia Biotech) in accordance with the manufacturer's instructions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3) Kloning av H kjede og L kjede cDNA-er av anti-CCR4 muse-antistof f </span>(3) Cloning of H chain and L chain cDNAs of anti-CCR4 mouse antibody f</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved anvendelse av ECL Direct Nucleic Acid Labeling and Detection System (produsert av Amersham Pharmacia Biotech), i overensstemmelse med produsentens instruksjoner, ble kloner på nylonmembranfiltrene av KM2160 H kjede cDNA biblioteket og L kjede cDNA biblioteket fremstilt i 1(2) i referanseeksempel 2 påvist ved anvendelse av cDNA av C regionen av et muse-antistof f (H kjede er et BamHI-EcoRI fragment av muse Cyl cDNA ( EMBO J., 3, 2047 (1984), L kjede er et Hpal- EcoRI fragment av Ck cDNA (Cell, 22., !97 (1980)) som proben, og fag-kloner sterkt bundet til proben ble oppnådd som 10 kloner for hver av H kjeden og L kjeden. Deretter ble hver fag-klon omdannet til plasmid ved in vivo eksisjonsmetoden ved anvendelse av AZAPII Cloning Kit i overensstemmelse med produsentens instruksjoner (produsert av Stratagene). Ved anvendelse av BigDye Terminator Cycle Sequencing FS Ready Reaction Kit (produsert av PE Biosystems), ble nukleotidsekvensen av cDNA inneholdt i hvert plasmid oppnådd på denne måten analysert ved hjelp av en DNA sekvenseringsinnretning ABI PRISM 3 77 fra den samme produsenten i overensstemmelse med produsentens instruksjoner. Som et resultat ble det oppnådd et plasmid pKM2160H4 inneholdende et full-lengde funk-sjonelt H kjede cDNA og et plasmid pKM2160L6 inneholdende et full-lengde L kjede cDNA, hvori en ATG sekvens ansett for å være initieringskodonet er tilstede i 5'-enden av cDNA. </span>Using the ECL Direct Nucleic Acid Labeling and Detection System (manufactured by Amersham Pharmacia Biotech), in accordance with the manufacturer's instructions, clones on the nylon membrane filters of the KM2160 H chain cDNA library and the L chain cDNA library prepared in 1(2) in Reference Example 2 were detected by using the cDNA of the C region of a mouse antibody (H chain is a BamHI-EcoRI fragment of mouse Cyl cDNA ( EMBO J., 3, 2047 (1984), L chain is an HpaI-EcoRI fragment of Ck cDNA ( Cell, 22., !97 (1980)) as the probe, and phage clones strongly bound to the probe were obtained as 10 clones for each of the H chain and the L chain. Then each phage clone was transformed into plasmid by the in vivo excision method by using the AZAPII Cloning Kit in accordance with the manufacturer's instructions (manufactured by Stratagene).Using the BigDye Terminator Cycle Sequencing FS Ready Reaction Kit (manufactured by PE Biosystems), the nucleotide sequence of the cDNA contained in each plasmid was obtained on this as analyzed using a DNA sequencing device ABI PRISM 3 77 from the same manufacturer in accordance with the manufacturer's instructions. As a result, a plasmid pKM2160H4 containing a full-length functional H chain cDNA and a plasmid pKM2160L6 containing a full-length L chain cDNA were obtained, in which an ATG sequence considered to be the initiation codon is present at the 5' end of cDNA.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(4)Analyse av aminosyresekvens av V region av anti-CCR4 muse-antistof f </span>(4) Analysis of amino acid sequence of V region of anti-CCR4 mouse antibody f</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En full nukleotidsekvens av H kjede V regionen inneholdt i plasmidet pKM216 0H4, en full aminosyresekvens av H kjede V regionen utledet derfra, en full nukleotidsekvens av L kjede V regionen inneholdt i plasmidet pKM2160L6 og en full aminosyresekvens av L kjede V regionen utledet derfra representer-es ved henholdsvis SEQ ID NO:61, 62, 63 og 64. Basert på sammenligningen med sekvensdata for kjente muse-antistoffer ( Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services (1991)) og sammenligningen med resultatene fra analyse av H kjede og L kjede N-ende amino syresekvensene av det rensede anti-CCR4 muse-antistoff KM2160 utført ved anvendelse av en protein-sekvenseringsinnretning (PPSQ-10, produsert av Shimadzu), ble det funnet at hvert således isolerte cDNA er et full-lengde cDNA som koder for anti-CCR4 muse-antistoffet KM2160 inneholdende sekretoriske signalsekvenser som er aminosyrer i posisjoner 1-19 i aminosyresekvensen representert i SEQ ID NO:15 i H kjeden og aminosyrer i posisjoner 1-19 i aminosyresekvensen representert ved SEQ ID NO:25 i L kjeden. </span>A full nucleotide sequence of the H chain V region contained in the plasmid pKM216 0H4, a full amino acid sequence of the H chain V region derived therefrom, a full nucleotide sequence of the L chain V region contained in the plasmid pKM2160L6 and a full amino acid sequence of the L chain V region derived therefrom represent- es at SEQ ID NO:61, 62, 63 and 64, respectively. Based on the comparison with sequence data for known mouse antibodies (Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services (1991)) and the comparison with the results from analysis of the H chain and L chain N-terminal amino acid sequences of the purified anti-CCR4 mouse antibody KM2160 performed using a protein sequencing device (PPSQ-10, manufactured by Shimadzu), it was found that each cDNA thus isolated is a full -length cDNA encoding the anti-CCR4 mouse antibody KM2160 containing secretory signal sequences which are amino acids in positions 1-19 of the amino acid sequence represented in SEQ ID NO:15 in the H chain the and amino acids in positions 1-19 of the amino acid sequence represented by SEQ ID NO:25 in the L chain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nyheten til aminosyresekvensene av V regionene av H kjede og L kjede av anti-CCR4 muse-antistoffet KM2160 ble deretter undersøkt. Ved anvendelse av GCG Package (versjon 9.1, produsert av Genetics Computer Group) som sekvensanalyse-ringssystemet, ble aminosyresekvens-database over kjente proteiner undersøkt ved hjelp av BLAST-metoden ( Nucleic Acids Res., 25., 3389 (1997)). Som et resultat ble det ikke funnet fullstendig sammenfallende sekvenser for både H kjeden og L kjeden, slik at det ble bekreftet at H kjede V regionen og L kjede V regionen av anti-CCR4 muse-antistoffet KM2160 er nye aminosyresekvenser. </span>The novelty of the amino acid sequences of the V regions of the H chain and L chain of the anti-CCR4 mouse antibody KM2160 was then examined. Using the GCG Package (version 9.1, produced by Genetics Computer Group) as the sequence analysis system, the amino acid sequence database of known proteins was examined by the BLAST method ( Nucleic Acids Res., 25., 3389 (1997)). As a result, completely coincident sequences were not found for both the H chain and the L chain, so it was confirmed that the H chain V region and the L chain V region of the anti-CCR4 mouse antibody KM2160 are new amino acid sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CDR-er av H kjede V regionen og L kjede V regionen av anti-CCR4 muse-antistoffet KM2160 ble også identifisert ved sammenligning med aminosyresekvenser av kjente antistoffer. Aminosyresekvenser av CDR1, CDR2 og CDR3 i H kjede V regionen av anti-CCR4 muse-antistoffet KM2160 er representert ved henholdsvis SEQ ID N0:1, 2 og 3, og aminosyresekvenser av CDR1, CDR2 og CDR3 i L kjede V regionen i henholdsvis SEQ ID NO:5, </span>CDRs of the H chain V region and the L chain V region of the anti-CCR4 mouse antibody KM2160 were also identified by comparison with amino acid sequences of known antibodies. Amino acid sequences of CDR1, CDR2 and CDR3 in the H chain V region of the anti-CCR4 mouse antibody KM2160 are represented by SEQ ID N0:1, 2 and 3, respectively, and amino acid sequences of CDR1, CDR2 and CDR3 in the L chain V region in SEQ ID NO:1, respectively ID NO:5,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6 og 7. </span>6 and 7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2.Stabil ekspresjon av anti-CCR4 kimært antistoff ved
anvendelse av dyrecelle (1)Konstruksjon av anti-CCR4 kimært antistoff ekspresjons
vektor pKANTEX216 0 </span>2.Stable expression of anti-CCR4 chimeric antibody by
use of animal cell (1) Construction of anti-CCR4 chimeric antibody expression
vector pKANTEX216 0</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En anti-CCR4 kimært antistoff ekspresjonsvektor pKANTEX2160 ble konstruert som følger, ved anvendelse av en humanisert antistoff ekspresjonsvektor pKANTEX93 som uttrykker et humant IgGl og k type antistoff og plasmidene pKM2160H4 og pKM2160L6 oppnådd i 1(3) i referanseeksempel 2. </span>An anti-CCR4 chimeric antibody expression vector pKANTEX2160 was constructed as follows, using a humanized antibody expression vector pKANTEX93 expressing a human IgGl and k type antibody and the plasmids pKM2160H4 and pKM2160L6 obtained in 1(3) of Reference Example 2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et syntetisk DNA som har nukleotidsekvensene representert ved SEQ ID NO:65 og 6 6 ble designet for å oppnå H kjede V region cDNA av KM216 0 ved PCR, og et annet syntetisk DNA som har nukleotidsekvensene representert ved SEQ ID NO:67 og 68 for oppnåelse av L kjede V region cDNA. Hvert syntetisk DNA inneholder et restriksjonsenzym som gjenkjenner sekvens i sin 5'-ende for dets kloning inn i pKANTEX93, og syntese av DNA-et ble overlatt til Genset Inc. Plasmidet pKM2160H4 (20 ng) oppnådd i 1(3) i referanseeksempel 2 ble tilsatt til en buffer inneholdende 50 yl PCR Buffer nr. 1 festet til KOD DNA Polymerase (produsert av TOYOBO), 0,2 mM dNTP-er, 1 mM magnesiumklorid og 0,5 yM av det syntetiske DNA som har nukleotidsekvensene representert ved SEQ ID NO:11 og 12, og blandingen ble oppvarmet ved 94°C i 3 minutter. Etter at 2,5 enheter av KOD DNA Polymerase (produsert av TOYOBO) var tilsatt, ble blandingen underkastet 2 5 cykluser av reaksjonen idet hver cyklus består av oppvarming ved 94°C i 3 0 sekunder, ved 58°C i 30 sekunder og ved 74°C i 1 minutt, ved anvendelse av et DNA thermal cycler GeneAmp PCR System 96 00 (produsert av PERKIN ELMER). På samme måte ble 20 ng av plasmidet pKM2160L6 oppnådd i 1(3) i referanseeksempel 6 tilsatt til en buffer inneholdende 50 yl av PCR Buffer nr. 1 festet til KOD DNA Polymerase (produsert av TOYOBO), 0,2 mM dNTP-er, 1 mM magnesiumklorid og 0,5 yM av det syntetiske DNA som har nukleotidsekvensene representert ved SEQ ID NO:67 og 68, og PCR ble utført på den samme måte som beskrevet ovenfor. Reaksjons-oppløsningen (10 yl) ble underkastet agarose gel elektroforese, og deretter ble et H kjede V region PCR produkt på omtrent 0,46 kb og et L kjede V region PCR produkt på omtrent 0,43 kb hver utvunnet ved anvendelse av QIAquick Gel Extraction Kit (produsert av QIAGEN). </span>A synthetic DNA having the nucleotide sequences represented by SEQ ID NO:65 and 66 was designed to obtain the H chain V region cDNA of KM216 0 by PCR, and another synthetic DNA having the nucleotide sequences represented by SEQ ID NO:67 and 68 for obtaining L chain V region cDNA. Each synthetic DNA contains a restriction enzyme that recognizes sequence at its 5' end for its cloning into pKANTEX93, and synthesis of the DNA was left to Genset Inc. The plasmid pKM2160H4 (20 ng) obtained in 1(3) of Reference Example 2 was added to a buffer containing 50 µl PCR Buffer No. 1 attached to KOD DNA Polymerase (manufactured by TOYOBO), 0.2 mM dNTPs, 1 mM magnesium chloride and 0.5 µM of the synthetic DNA having the nucleotide sequences represented by SEQ ID NO:11 and 12, and the mixture was heated at 94°C for 3 minutes. After 2.5 units of KOD DNA Polymerase (manufactured by TOYOBO) was added, the mixture was subjected to 25 cycles of the reaction, each cycle consisting of heating at 94°C for 30 seconds, at 58°C for 30 seconds and at 74°C for 1 minute, using a DNA thermal cycler GeneAmp PCR System 96 00 (manufactured by PERKIN ELMER). Similarly, 20 ng of the plasmid pKM2160L6 obtained in 1(3) in Reference Example 6 was added to a buffer containing 50 µl of PCR Buffer No. 1 attached to KOD DNA Polymerase (manufactured by TOYOBO), 0.2 mM dNTPs, 1 mM magnesium chloride and 0.5 µM of the synthetic DNA having the nucleotide sequences represented by SEQ ID NO:67 and 68, and PCR was performed in the same manner as described above. The reaction solution (10 µl) was subjected to agarose gel electrophoresis, and then an H chain V region PCR product of approximately 0.46 kb and an L chain V region PCR product of approximately 0.43 kb were each recovered using QIAquick Gel Extraction Kit (manufactured by QIAGEN).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">0,1 yg DNA oppnådd ved digerering av et plasmid pBluescript SK(-) (produsert av Stratagene) med et restriksjonsenzym Smal (produsert av Takara Shuzo) og omtrent 0,1 yg av hver av PCR produktene oppnådd ovenfor ble deretter tilsatt til sterilt vann til å gi et sluttvolum på 7,5 yl, og 7,5&lt;y&gt;l av oppløs-ningen I i TAKARA DNA Ligation Kit Ver. 2 (produsert av Takara Shuzo) og 0,3 yl av et restriksjonsenzym Smal ble tilsatt dertil, og blandingen fikk reagere ved 22°C over natten. Det resulterende av den rekombinante plasmid DNA oppløsning ble E. coli DH5a (produsert av TOYOBO) transformert. Hvert plasmid DNA ble fremstilt fra transformantklonene og underkastet reaksjonen ved anvendelse av BigDye Terminator Cycle </span>0.1 µg of DNA obtained by digesting a plasmid pBluescript SK(-) (manufactured by Stratagene) with a restriction enzyme Smal (manufactured by Takara Shuzo) and approximately 0.1 µg of each of the PCR products obtained above was then added to sterile water to give a final volume of 7.5 µl, and 7.5 µl of solution I in the TAKARA DNA Ligation Kit Ver. 2 (manufactured by Takara Shuzo) and 0.3 µl of a restriction enzyme Smal were added thereto, and the mixture was allowed to react at 22°C overnight. The resultant of the recombinant plasmid DNA solution was E. coli DH5a (produced by TOYOBO) transformed. Each plasmid DNA was prepared from the transformant clones and subjected to the reaction using the BigDye Terminator Cycle</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sequencing FS Ready Reaction Kit (produsert av PE Biosystems) 1 overensstemmelse med produsentens instruksjoner, og nukleotidsekvensen ble analysert ved hjelp av en DNA sekvenseringsinnretning ABI PRISM 377 fra den samme produsenten. Plasmidene pKM216 0VH41 og pKM2160VL61 vist i fig. 15 som har de </span>Sequencing FS Ready Reaction Kit (manufactured by PE Biosystems) 1 in accordance with the manufacturer's instructions, and the nucleotide sequence was analyzed using a DNA sequencing device ABI PRISM 377 from the same manufacturer. Plasmids pKM216 0VH41 and pKM2160VL61 shown in fig. 15 that they have</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ønskede nukleotidsekvenser ble således oppnådd. </span>desired nucleotide sequences were thus obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3 yg av humanisert antistoff ekspresjonsvektoren pKANTEX93 og 3 yg av pKM2160VH41 oppnådd ovenfor ble deretter tilsatt til en buffer inneholdende 30 yl 10 mM Tris-HCl (pH 7,5), 10 mM magnesiumklorid og 1 mM DTT, 10 enheter av et restriksjonsenzym Apal (produsert av Takara Shuzo) ble tilsatt dertil, og blandingen fikk reagere ved 37°C i 1 time. Reaksjonsoppløs-ningen ble underkastet etanolpresipitering, og det resulterende presipitat ble tilsatt til en buffer inneholdende 10 yl 50 mM Tris-HCl (pH 7,5), 100 mM natriumklorid, 10 mM magnesiumklorid, 1 mM DTT, 100 yg/ml BSA og 0,01% Triton X-100, 10 enheter av et restriksjonsenzym Noti (produsert av Takara Shuzo) ble tilsatt dertil, og blandingen fikk reagere ved 37°C i 1 time. Reaksjonsblandingen ble fraksjonert ved agarose gel elektroforese, og omtrent 12,75 kb og omtrent 0,44 kb Apal-Noti fragmenter av henholdsvis pKANTEX93 og pKM2160VH41 ble utvunnet. De således oppnådde to fragmenter ble forbundet ved anvendelse av TAKARA DNA Ligation Kit Ver. 2 i overensstemmelse med produsentens instruksjoner, og E. coli DH5a (produsert av TOYOBO) ble transformert ved anvend else av den resulterende rekombinant plasmid DNA oppløsning-en. Hvert plasmid DNA ble fremstilt fra transformantklonene og bekreftet ved en restriksjonsenzymbehandling for derved å oppnå et plasmid pKANTEX2160H vist i fig. 16, hvori omtrent 0,44 kb av det ønskede Apal-Noti fragment var blitt innskutt. 3 yg av pKANTEX216 0H og 3 yg av pKM216 0VL61 oppnådd ovenfor ble så tilsatt til en buffer inneholdende 50 mM Tris-HCl (pH 7,5), 100 mM natriumklorid, 10 mM magnesiumklorid, 1 mM DTT og 100 yg/ml BSA, oppløsningen ble innstilt til å gi et totalvolum på 30 yl, 10 enheter av et restriksjonsenzym BsiWI (produsert av New England Biolabs) ble tilsatt dertil, og blandingen fikk reagere ved 55°C i 1 time. Deretter ble et restriksjonsenzym ScoRI (produsert av Takara Shuzo) tilsatt dertil, og blandingen fikk reagere ved 37°C i 1 time. Reaksjonsblandingen ble fraksjonert ved agarose gel elektroforese, og omtrent 13,20 kb og omtrent 0,41 kb ScoRI-BsiWI fragmenter av henholdsvis pKANTEX2160H og pKM2160VL61 ble utvunnet . De således oppnådde to fragmenter ble forbundet ved anvendelse TAKARA DNA Ligation Kit Ver. 2 i overensstemmelse med produsentens instruksjoner og E. coli DH5a (produsert av TOYOBO) ble transformert ved anvendelse av den resulterende rekombinant plasmid DNA oppløsningen. Hvert plasmid DNA ble fremstilt fra transformantklonene og bekreftet ved en restriksjonsenzymbehandling for derved å oppnå et plasmid pKANTEZ216 0 vist i fig. 17, hvori omtrent 0,41 kb av det ønskede ScoRI-BsiWI fragment var blitt innskutt. Når plasmidet ble underkastet reaksjonen ved anvendelse av BigDye Terminator Cycle Sequencing FS Ready Reaction Kit (produsert av PE Biosystems) i overensstemmelse med produsentens instruksjoner, og nukleotidsekvensen ble analysert ved hjelp av en DNA sekvenseringsinnretning ABI PRISM 377 fra den samme produsenten, ble det bekreftet av det ønskede plasmid inn i hvilket cDNA som koder for KM2160 H kjede og L kjede V regionene var blitt klonet, var oppnådd. (2)Stabil ekspresjon av anti-CCR4 kimært antistoff ved
anvendelse av dyrecelle </span>3 µg of the humanized antibody expression vector pKANTEX93 and 3 µg of pKM2160VH41 obtained above were then added to a buffer containing 30 µl of 10 mM Tris-HCl (pH 7.5), 10 mM magnesium chloride and 1 mM DTT, 10 units of a restriction enzyme Apal ( manufactured by Takara Shuzo) was added thereto, and the mixture was allowed to react at 37°C for 1 hour. The reaction solution was subjected to ethanol precipitation, and the resulting precipitate was added to a buffer containing 10 µl of 50 mM Tris-HCl (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, 1 mM DTT, 100 µg/ml BSA and 0 .01% Triton X-100, 10 units of a restriction enzyme Noti (manufactured by Takara Shuzo) were added thereto, and the mixture was allowed to react at 37°C for 1 hour. The reaction mixture was fractionated by agarose gel electrophoresis, and approximately 12.75 kb and approximately 0.44 kb Apal-Noti fragments of pKANTEX93 and pKM2160VH41, respectively, were recovered. The two fragments thus obtained were joined using the TAKARA DNA Ligation Kit Ver. 2 in accordance with the manufacturer's instructions, and E. coli DH5α (manufactured by TOYOBO) was transformed using the resulting recombinant plasmid DNA solution. Each plasmid DNA was prepared from the transformant clones and confirmed by a restriction enzyme treatment to thereby obtain a plasmid pKANTEX2160H shown in fig. 16, into which approximately 0.44 kb of the desired Apal-Noti fragment had been inserted. 3 µg of pKANTEX216 0H and 3 µg of pKM216 0VL61 obtained above were then added to a buffer containing 50 mM Tris-HCl (pH 7.5), 100 mM sodium chloride, 10 mM magnesium chloride, 1 mM DTT and 100 µg/ml BSA, the solution was adjusted to give a total volume of 30 µl, 10 units of a restriction enzyme BsiWI (manufactured by New England Biolabs) was added thereto, and the mixture was allowed to react at 55°C for 1 hour. Then, a restriction enzyme ScoRI (manufactured by Takara Shuzo) was added thereto, and the mixture was allowed to react at 37°C for 1 hour. The reaction mixture was fractionated by agarose gel electrophoresis, and approximately 13.20 kb and approximately 0.41 kb ScoRI-BsiWI fragments of pKANTEX2160H and pKM2160VL61, respectively, were recovered. The two fragments thus obtained were joined using the TAKARA DNA Ligation Kit Ver. 2 in accordance with the manufacturer's instructions and E. coli DH5α (produced by TOYOBO) was transformed using the resulting recombinant plasmid DNA solution. Each plasmid DNA was prepared from the transformant clones and confirmed by a restriction enzyme treatment to thereby obtain a plasmid pKANTEZ216 0 shown in fig. 17, into which approximately 0.41 kb of the desired ScoRI-BsiWI fragment had been inserted. When the plasmid was subjected to the reaction using the BigDye Terminator Cycle Sequencing FS Ready Reaction Kit (manufactured by PE Biosystems) in accordance with the manufacturer's instructions, and the nucleotide sequence was analyzed using a DNA sequencing device ABI PRISM 377 from the same manufacturer, it was confirmed by the desired plasmid into which the cDNA encoding the KM2160 H chain and L chain V regions had been cloned was obtained. (2)Stable expression of anti-CCR4 chimeric antibody by
application of animal cell</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det anti-CCR4 kimære antistoff ble uttrykt i dyreceller som beskrevet nedenfor ved anvendelse av anti-CCR4 kimært antistoff ekspresjonsvektoren pKANTEX 2160 oppnådd i 2(1) i referanseeksempel 2. </span>The anti-CCR4 chimeric antibody was expressed in animal cells as described below using the anti-CCR4 chimeric antibody expression vector pKANTEX 2160 obtained in 2(1) of Reference Example 2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Plasmidet pKANTEX2160 ble omdannet til en lineær form ved digerering med et restriksjonsenzym Aatll (produsert av TOYOBO) og 10 yg derav ble innført i 4xl0&lt;6&gt;celler av rotte-myelomcellelinje YB2/0 (ATCC CRL1662) ved elektroporering ( Cytotechnology, 3_, 133 (1990) ) , og cellene ble suspendert i 40 ml H-SFM (produsert av GIBCO-BRL) medium (supplert med 5% FCS) og dispensert i 200 yl/brønn inn i en 96-brønns mikrotiterplate (produsert av Sumitomo Bakelite). Tjuefire timer etter inkubering ved 37°C i en 5% C02inkubator, ble G418 tilsatt til å gi en konsentrasjon på 1 mg/ml, etterfulgt av dyrking i 1 til 2 uker. En kultur-supernatant ble utvunnet fra en brønn hvori en koloni av G418-resistent transformant kom til syne og ble konfluent, og antigenbindende aktivitet av det anti-CCR4 kimære antistoff i supernatanten ble målt ved hjelp av ELISA vist i 2(3) i referanseeksempel 2 (et peroksidase-merket geit anti-humant IgG(y) antistoff ble anvendt som det sekundære antistoff). </span>The plasmid pKANTEX2160 was converted into a linear form by digestion with a restriction enzyme AatII (manufactured by TOYOBO) and 10 µg thereof was introduced into 4x10&lt;6&gt; cells of the rat myeloma cell line YB2/0 (ATCC CRL1662) by electroporation (Cytotechnology, 3_, 133 (1990) ), and the cells were suspended in 40 ml of H-SFM (manufactured by GIBCO-BRL) medium (supplemented with 5% FCS) and dispensed at 200 µl/well into a 96-well microtiter plate (manufactured by Sumitomo Bakelite) . Twenty-four hours after incubation at 37°C in a 5% CO 2 incubator, G418 was added to give a concentration of 1 mg/ml, followed by cultivation for 1 to 2 weeks. A culture supernatant was recovered from a well in which a colony of G418-resistant transformant appeared and became confluent, and antigen-binding activity of the anti-CCR4 chimeric antibody in the supernatant was measured by ELISA shown in 2(3) of Reference Example 2 (a peroxidase-labeled goat anti-human IgG(γ) antibody was used as the secondary antibody).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For å øke den uttrykte mengden av antistoffet ved anvendelse av et dhfr genamplifikasjonssystem, ble transformanten i en brønn hvor ekspresjon av det anti-CCR4 kimære antistoff ble funnet i kultur-supernatanten suspendert til å gi en densitet på 1 til 2xl0&lt;5&gt;celler/ml i H-SFM medium inneholdende 1 mg/ml G418 og 50 nM metotreksat (i det etterfølgende referert til som "MTX": produsert av Sigma) som er inhibitoren av en dhfr genprodukt-dihydrofolatreduktase, og suspensjonen ble dispensert i 1 ml inn i brønner i en 24-brønns plate (produsert av Greiner) . Blandingen ble dyrket ved 37°C i 1 til 2 uker i en 5% C02inkubator, slik at en transformant som utviser resistens overfor 50 nM MTX ble indusert. Når transformanten ble konfluent i en brønn, ble antigenbindende aktivitet av det anti-CCR4 kimære antistoff i kultur-supernatanten målt ved hjelp av ELISA vist i 2(3) i referanseeksempel 2. Hva angår transformantene i brønner hvor ekspresjon av det anti-CCR4 kimære antistoff ble funnet i kultur-supernatanter, ble MTX-konsentrasjonen økt til 100 nM og deretter til 200 nM på den samme måten for til sist å oppnå en transformant som kan vokse i H-SFM medium inneholdende 1 mg/ml G418 og 200 nM MTX og også kan i høy grad uttrykke det anti-CCR4 kimære antistoff. Den således oppnådde transformant ble underkastet enkeltcelle-isolering (kloning) ved to ganger med begrenset fortynningsanalyse, og en transformantklon som har den høy-este anti-CCR4 kimært antistoff ekspresjon ble betegnet KM2760. Den uttrykte mengden av det anti-CCR4 kimære antistoff ved KM2760 var omtrent 5 ug/10&lt;6&gt;celler/24 timer. I tillegg, tilhører antistoff H kjede C regionen av KM2760 human IgGl underklasse. KM2760 er blitt internasjonalt deponert som FERM BP7054 24. februar 2000 i National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, the Ministry of International Trade and Industry (nåværende navn: International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (Higashi 1-1-3, Tsukuba-Shi, Ibaraki Prefecture, Japan (nåværende adresse: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan)). </span>To increase the expressed amount of the antibody using a dhfr gene amplification system, the transformant in a well where expression of the anti-CCR4 chimeric antibody was found in the culture supernatant was suspended to give a density of 1 to 2x10&lt;5&gt;cells/ ml in H-SFM medium containing 1 mg/ml G418 and 50 nM methotrexate (hereafter referred to as "MTX": manufactured by Sigma) which is the inhibitor of a dhfr gene product dihydrofolate reductase, and the suspension was dispensed in 1 ml into wells in a 24-well plate (manufactured by Greiner). The mixture was grown at 37°C for 1 to 2 weeks in a 5% CO 2 incubator so that a transformant showing resistance to 50 nM MTX was induced. When the transformant became confluent in a well, antigen-binding activity of the anti-CCR4 chimeric antibody in the culture supernatant was measured by ELISA shown in 2(3) of Reference Example 2. As for the transformants in wells where expression of the anti-CCR4 chimeric antibody was found in culture supernatants, the MTX concentration was increased to 100 nM and then to 200 nM in the same way to finally obtain a transformant that can grow in H-SFM medium containing 1 mg/ml G418 and 200 nM MTX and also can highly express the anti-CCR4 chimeric antibody. The transformant thus obtained was subjected to single-cell isolation (cloning) by two-fold limiting dilution assay, and a transformant clone having the highest anti-CCR4 chimeric antibody expression was designated KM2760. The expressed amount of the anti-CCR4 chimeric antibody by KM2760 was about 5 µg/10&lt;6&gt;cells/24 hours. In addition, antibody H chain belongs to the C region of the KM2760 human IgGl subclass. KM2760 has been internationally deposited as FERM BP7054 on 24 February 2000 in the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, the Ministry of International Trade and Industry (current name: International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology (Higashi 1-1-3, Tsukuba-Shi, Ibaraki Prefecture, Japan (current address: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken 305-8566 Japan)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Referanseeksempel 3 </span>Reference example 3</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etablering av hCCR4-høyt-uttrykkende celle: </span>Establishment of hCCR4-high-expressing cell:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1)Konstruksjon av ekspresjonsvektor CAG-pcDNA3 for dyrecelle </span>(1) Construction of expression vector CAG-pcDNA3 for animal cell</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ekspresjonsvektor ble konstruert som beskrevet nedenfor ved å produsere en ekspresjonsvektor (CAG-pcDNA3) hvori promoterregionen av en ekspresjonsvektor for dyrecelle, pcDNA3 (produsert av INVITROGEN), var forandret fra cyto-megalovirus (CMV) promoter til CAG (AG (modifert kylling actin) promoter med CMV-IE enhancer), og å innskyte CCR4 genet i vektoren. </span>An expression vector was constructed as described below by producing an expression vector (CAG-pcDNA3) in which the promoter region of an animal cell expression vector, pcDNA3 (manufactured by INVITROGEN), was changed from the cyto-megalovirus (CMV) promoter to CAG (AG (modified chicken actin) ) promoter with CMV-IE enhancer), and to insert the CCR4 gene into the vector.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">pcDNA3 (5 yg) fikk reagere med et restriksjonsenzym Nrul (produsert av Takara Shuzo) ved 3 7°C i 1 time, og deretter ble DNA fragmenter utvunnet ved etanolpresipitering. De fikk så reagere med et restriksjonsenzym Hindlll (produsert av Takara Shuzo) ved 37°C i 1 time og deretter fraksjonert ved agarose gel elektroforese for å utvinne et DNA fragment på omtrent 5,8 kb som ikke inneholder noen CMV promoterregion. Plasmid CAG-pBluescript IIKS(+) (3 yg) som har CAG promoter ( Nuc. Acid. Res. , 23., 3816 (1995) ) region fikk reagere med et restriksjonsenzym Sali (produsert av Takara Shuzo) ved 3 7°C i 1 time og deretter ble DNA fragmenter utvunnet ved etanolpresipitering. De ble gitt butt ende (blunt-ended) med DNA Blunting Kit (produsert av Takara Shuzo), fikk videre reagere med Hindi 11 ved 3 7°C i 1 time, og deretter fraksjonert ved agarose gel elektroforese for å utvinne et DNA fragment på omtrent 1,8 kb inneholdende CAG promoterregionen. De således utvunnede respektive DNA fragmenter ble ligert ved anvendelse av DNA Ligation Kit (produsert av Takara Shuzo), og E. coli DH5a ble transformert ved anvendelse av det resulterende rekombinante plasmidet DNA for å oppnå plasmid CAG-pcDNA3. </span>pcDNA3 (5 µg) was allowed to react with a restriction enzyme Nrul (manufactured by Takara Shuzo) at 37°C for 1 hour, and then DNA fragments were recovered by ethanol precipitation. They were then allowed to react with a restriction enzyme HindIII (manufactured by Takara Shuzo) at 37°C for 1 hour and then fractionated by agarose gel electrophoresis to recover a DNA fragment of about 5.8 kb containing no CMV promoter region. Plasmid CAG-pBluescript IIKS(+) (3 µg) having the CAG promoter ( Nuc. Acid. Res. , 23., 3816 (1995) ) region was allowed to react with a restriction enzyme Sali (manufactured by Takara Shuzo) at 37°C for 1 hour and then DNA fragments were recovered by ethanol precipitation. They were blunt-ended with a DNA Blunting Kit (manufactured by Takara Shuzo), further reacted with Hindi 11 at 37°C for 1 hour, and then fractionated by agarose gel electrophoresis to recover a DNA fragment on approximately 1.8 kb containing the CAG promoter region. The respective DNA fragments thus recovered were ligated using the DNA Ligation Kit (manufactured by Takara Shuzo), and E. coli DH5a was transformed using the resulting recombinant plasmid DNA to obtain plasmid CAG-pcDNA3.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) Konstruksjon av hCCR4 ekspresjonsvektor </span>(2) Construction of hCCR4 expression vector</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En hCCR4 ekspresjonsvektor ble konstruert som beskrevet nedenfor ved anvendelse av CAG-pcDNA3 oppnådd i 3(1) i referanseeksempel 2 og hCCR4 DNA-innskutt pcDNA3 (CCR4/ pcDNA3). Både CAG-pcDNA3 og CCR4/pcDNA3 fikk reagere med Hindlll ved 37°C i 1 time og DNA fragmenter ble utvunnet ved etanol presipitering. De fikk så reagere med Bglll (produsert av Takara Shuzo) ved 37°C i 1 time og deretter fraksjonert ved agarose gel elektroforese for å utvinne et DNA fragment på omtrent 2,0 kb inneholdende CAG promoterregionen og et DNA fragment på omtrent 5,5 kb inneholdende hCCR4 gen-regionen. Plasmid CAG-CCR4/pcDNA3 ble deretter oppnådd ved anvendelse av begge DNA fragmentene på den sammen måten som i 3(1) i referanseeksempel 2. </span>An hCCR4 expression vector was constructed as described below using CAG-pcDNA3 obtained in 3(1) in Reference Example 2 and hCCR4 DNA-inserted pcDNA3 (CCR4/pcDNA3). Both CAG-pcDNA3 and CCR4/pcDNA3 were allowed to react with HindIII at 37°C for 1 hour and DNA fragments were recovered by ethanol precipitation. They were then allowed to react with BglII (manufactured by Takara Shuzo) at 37°C for 1 hour and then fractionated by agarose gel electrophoresis to recover a DNA fragment of about 2.0 kb containing the CAG promoter region and a DNA fragment of about 5.5 kb containing the hCCR4 gene region. Plasmid CAG-CCR4/pcDNA3 was then obtained by using both DNA fragments in the same way as in 3(1) in reference example 2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3) Ekspresjon av hCCR4 i dyrecelle </span>(3) Expression of hCCR4 in animal cell</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Plasmidet ble innført i dyreceller ved elektroporering på den samme måten som beskrevet i 2(2) i referanseeksempel 2. EL-4 celler (ATCC TIB-39) ble suspendert i PBS(-) (produsert av GIBCO-BRL) til å gi en densitet på lxlO&lt;7&gt;celler/500 yl, 10 yg av CAG-CCR4/pcDNA3 oppnådd i 3(2) i referanseeksempel 2 ble tilsatt dertil, og blandingen ble inkubert i is i 10 minutter og deretter anbrakt i en kyvette for eksklusiv anvendelse (produsert av Bio-Rad) for å bære ut genintroduksjon ved 260 V og 500&lt;y&gt;FD. Etter at blandingen var ytterligere inkubert i is i 10 minutter, ble cellene suspendert i 200 ml 10% FCS-RPMI medium og dispensert ved 200 yl/brønn i en 96-brønns plate for celledyrking. Tjuefire timer etter dyrkingen ble 100 yl av kultur-supernatanten fjernet fra hver brønn, og 10% FCS-RPMI medium inneholdende 1 mg/ml G418 ble dispensert ved 100 yl/brønn til å gi en sluttkonsentrasjon på 0,5 mg/ml. To uker etter dette ble enkeltkloner på mellom 10 og 100 selektert og dyrket igjen. </span>The plasmid was introduced into animal cells by electroporation in the same manner as described in 2(2) of Reference Example 2. EL-4 cells (ATCC TIB-39) were suspended in PBS(-) (manufactured by GIBCO-BRL) to give a density of lx10&lt;7&gt;cells/500 µl, 10 µg of CAG-CCR4/pcDNA3 obtained in 3(2) in Reference Example 2 was added thereto, and the mixture was incubated on ice for 10 minutes and then placed in a cuvette for exclusive use (manufactured by Bio-Rad) to carry out gene introduction at 260 V and 500&lt;y&gt;FD. After the mixture was further incubated on ice for 10 minutes, the cells were suspended in 200 ml of 10% FCS-RPMI medium and dispensed at 200 µl/well into a 96-well plate for cell culture. Twenty-four hours after cultivation, 100 µl of the culture supernatant was removed from each well, and 10% FCS-RPMI medium containing 1 mg/ml G418 was dispensed at 100 µl/well to give a final concentration of 0.5 mg/ml. Two weeks after this, single clones of between 10 and 100 were selected and cultivated again.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(4)Seleksjon av hCCR4-høyt-uttrykkende celle </span>(4) Selection of hCCR4-high-expressing cell</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De ble valgt ved hjelp av en immunfluorescerende metode ved anvendelse av KM2160 fremstilt i (5) i referanseeksempel 1. Inn i en 96-brønns U-form-plate ble det dispensert 2xl0&lt;5&gt;celler av selekterte flere titalls av de geninnførte kloner. </span>They were selected by means of an immunofluorescent method using KM2160 prepared in (5) in Reference Example 1. Into a 96-well U-shaped plate, 2x10&lt;5&gt; cells of selected tens of the reintroduced clones were dispensed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">KM2160 merket med biotin ved hjelp av en kjent metode ( Enzyme Antibody Method, publisert av Gakusai Kikaku) ble fortynnet til 5 yg/ml med en buffer for FACS (1% BSA-PBS, 0,02% EDTA, 0,05% NaN3, pH 7,4), humant IgG (produsert av Welfide) ble fortynnet til 3,75 mg/ml for å hindre ikke-spesifikk farging, hver av den således fortynnede antistoffoppløsning ble dispensert ved 200 yl/brønn, og blandingen fikk reagere i is i 30 minutter. Som en negativ kontroll ble biotinylert anti-IL-5R antistoff (WO 97/10354) anvendt ved den samme konsentrasjon. Etter vasking to ganger med 200 yl/brønn av bufferen, ble streptoavidin-PE (produsert av Becton Dickinson Japan) dispensert ved 2 0 yl/brønn. Tretti minutter etter reaksjonen i is i mørket, ble cellene vasket tre ganger med 200 ul/brønn og til sist suspendert til 500&lt;y&gt;l, og fluorescensintensiteten ble målt ved hjelp av et flow-cytometer for å selektere en cellelinje som har den høyeste fluorescensintensitet. Cellelinjen som har den høyeste fluorescensintensitet ble anvendt som CCR4/EL-4. </span>KM2160 labeled with biotin using a known method (Enzyme Antibody Method, published by Gakusai Kikaku) was diluted to 5 µg/ml with a buffer for FACS (1% BSA-PBS, 0.02% EDTA, 0.05% NaN3 , pH 7.4), human IgG (manufactured by Welfide) was diluted to 3.75 mg/ml to prevent non-specific staining, each of the thus diluted antibody solution was dispensed at 200 µl/well, and the mixture was allowed to react in ice for 30 minutes. As a negative control, biotinylated anti-IL-5R antibody (WO 97/10354) was used at the same concentration. After washing twice with 200 µl/well of the buffer, streptoavidin-PE (manufactured by Becton Dickinson Japan) was dispensed at 20 µl/well. Thirty minutes after the reaction on ice in the dark, the cells were washed three times with 200 µl/well and finally suspended to 500&lt;y&gt;l, and the fluorescence intensity was measured using a flow cytometer to select a cell line that has the highest fluorescence intensity. The cell line with the highest fluorescence intensity was used as CCR4/EL-4.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Industriell anvendelighet </span>Industrial applicability</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som diskutert ovenfor, tilveiebringes det i samsvar med den foreliggende oppfinnelse et rekombinant antistoff og et antistoffragment derav, som binder spesifikt til human CCR4 og inneholder nye CDR-er for CCR4. Antistoffet i henhold til den foreliggende oppfinnelse er anvendbart for diagnose eller behandling av CCR4-relaterte sykdommer. Spesifikt er det anvendbart for immunologisk påvisning av en human Th2-celle ved immunocytt- farging og for diagnose eller behandling av alle Th2-medierte immunsykdommer inkluderende bronkialastma og atopiske hudsykdommer, sykdommer hvori de morbide tilstander skrider frem på grunn av abnorm balanse av Th2-celler og cancertyper inkluderende blodcancertyper slik som levkemi.   </span>As discussed above, in accordance with the present invention there is provided a recombinant antibody and an antibody fragment thereof, which bind specifically to human CCR4 and contain novel CDRs for CCR4. The antibody according to the present invention is useful for diagnosis or treatment of CCR4-related diseases. Specifically, it is applicable for the immunological detection of a human Th2 cell by immunocyte staining and for the diagnosis or treatment of all Th2-mediated immune diseases including bronchial asthma and atopic skin diseases, diseases in which the morbid conditions progress due to abnormal balance of Th2 cells and cancer types including blood cancer types such as leukaemia.</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(40)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Norwegian</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM332723774" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Et humant CDR-podet antistoff eller antistoff fragment derav som spesifikt reagerer med en ekstracellulær region av human CC kjemokinreseptor 4 (CCR4) men ikke reagerer med en human blodplate,og som omfatter hypervariabelt område (CDR) 1. CDR2 og CDR3 av en antistoff tung kjede (H kjede) variabel region (V region) som har aminosyresekvensene representert ved henholdsvis SEQ ID N0:1, 2 og 3, og CDR 1, CDR2 og CDR3 av en antistoff lett kjede (L kjede) V region som har aminosyresekvensene representert ved henholdsvis SEQ ID NO:5, 6 og 7.</span>1. A human CDR-grafted antibody or antibody fragment thereof which specifically reacts with an extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human platelet, and which comprises hypervariable region (CDR) 1. CDR2 and CDR3 of a antibody heavy chain (H chain) variable region (V region) having the amino acid sequences represented by SEQ ID NO:1, 2 and 3, respectively, and CDR 1, CDR2 and CDR3 of an antibody light chain (L chain) V region having the amino acid sequences represented by SEQ ID NO:5, 6 and 7 respectively.</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 1, som har en cytotoksisk aktivitet mot en CCR4-uttrykkende celle.</span>2. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 1, which has a cytotoxic activity against a CCR4-expressing cell.</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 1 eller 2, som spesifikt reagerer med en ekstracellulær region av CCR4 valgt fra gruppen bestående av posisjoner 1 til 39, 98 til 112, 176 til 206 og 271 til 2 84 i aminosyresekvensen representert ved SEQ ID NO:48.</span>3. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 1 or 2, which specifically reacts with an extracellular region of CCR4 selected from the group consisting of positions 1 to 39, 98 to 112, 176 to 206 and 271 to 2 84 in the amino acid sequence represented by SEQ ID NO:48.</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 3,som spesifikt reagerer med en epitop tilstede i posisjonene 2 til 2 9 i aminosyresekvensen representert ved SEQ ID NO:48.</span>4. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 3, which specifically reacts with an epitope present in positions 2 to 29 of the amino acid sequence represented by SEQ ID NO:48.</span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 4, som spesifikt reagerer med en epitop tilstede i posisjoner 13 til 2 9 i aminosyresekvensen representert ved SEQ ID NO:48.</span>5. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 4, which specifically reacts with an epitope present in positions 13 to 29 of the amino acid sequence represented by SEQ ID NO:48.</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 5, som spesifikt reagerer med en epitop tilstede i posisjoner 13 til 25 i aminosyresekvensen representert ved SEQ ID NO:48.</span>6. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 5, which specifically reacts with an epitope present in positions 13 to 25 of the amino acid sequence represented by SEQ ID NO:48.</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 1 eller 2, som spesifikt reagerer med en CCR4-uttrykkende celle.</span>7. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 1 or 2, which specifically reacts with a CCR4-expressing cell.</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 7, som har en høyere cytotoksisk aktivitet mot en CCR4-uttrykkende celle enn et monoklonalt antistoff produsert ved et ikke-humant dyre-hybridom.</span>8. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 7, which has a higher cytotoxic activity against a CCR4-expressing cell than a monoclonal antibody produced by a non-human animal hybridoma.</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 2 til 8, hvori den cytotoksiske aktivitet er en antistoff-avhengig celle-mediert cytotoksisk (ADCC) aktivitet.</span>9. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 2 to 8, wherein the cytotoxic activity is an antibody-dependent cell-mediated cytotoxic (ADCC) activity.</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 9, hvori ADCC aktiviteten er en aktivitet med indusering av apoptose av en CCR4-uttrykkende celle.</span>10. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 9, wherein the ADCC activity is an activity of inducing apoptosis of a CCR4-expressing cell.</span>
    </claim-text>
  </claim>
  <claim num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 10, som har en aktivitet med utarming av en CCR4-uttrykkende celle.</span>11. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 10, which has an activity of depleting a CCR4-expressing cell.</span>
    </claim-text>
  </claim>
  <claim num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 7 til 11, hvori den CCR4-uttrykkende celle er en Th2-celle.</span>12. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 7 to 11, wherein the CCR4-expressing cell is a Th2 cell.</span>
    </claim-text>
  </claim>
  <claim num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 12, som har en aktivitet med inhibering av cytokinproduksjon av en Th2-celle.</span>13. The human CDR-grafted antibody or antibody fragment thereof as stated in one or more of claims 1 to 12, which has an activity of inhibiting cytokine production by a Th2 cell.</span>
    </claim-text>
  </claim>
  <claim num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 13, hvori cytokinet er IL-4, IL-5 eller IL-13.</span>14. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 13, wherein the cytokine is IL-4, IL-5 or IL-13.</span>
    </claim-text>
  </claim>
  <claim num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 14, som tilhører et humant IgG antistoff.</span>15. The human CDR-grafted antibody or antibody fragment thereof as stated in one or more of claims 1 to 14, which belongs to a human IgG antibody.</span>
    </claim-text>
  </claim>
  <claim num="16" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 15, som omfatter rammeverkregioner (FR-er) H kjede V region og L kjede V region av et humant antistoff.</span>16. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 15, comprising framework regions (FRs) H chain V region and L chain V region of a human antibody.</span>
    </claim-text>
  </claim>
  <claim num="17" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">17. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 16, som omfatter FR-er av H kjede V region og L kjede V region av et humant antistoff, og H kjede C region og L kjede C region av et humant antistoff.</span>17. The human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 16, comprising FRs of H chain V region and L chain V region of a human antibody, and H chain C region and L chain C region of a human antibody.</span>
    </claim-text>
  </claim>
  <claim num="18" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18. Det humane CDR-podede antistoff eller antistoffragmentet derav ifølge et hvilket som helst av kravene 1 til 17, som omfatter (a) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:4; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; (b) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:4; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (c) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:4; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:13; (d) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:4; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (e) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:9; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (f) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:9; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (g) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:10; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (h) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:10; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (i) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:11; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (j) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:11; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (k) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:38; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8;</span>18. The human CDR-grafted antibody or antibody fragment thereof according to any one of claims 1 to 17, comprising (a) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:4; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8; (b) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:4; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (c) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:4; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:13; (d) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:4; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (e) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:9; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (f) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:9; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (g) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:10; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (h) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:10; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (i) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:11; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (j) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:11; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (k) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:38; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8;</span>
    </claim-text>
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:38; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (m) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:38; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:13; (n) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:38; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (o) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:39; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; (p) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:3 9; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:12; (q) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:39; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:13; (r) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:39; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (s) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:40; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; (t) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:40; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14; (u) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:41; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:8; eller (v) en antistoff H kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:41; og en antistoff L kjede V region omfattende aminosyresekvensen representert ved SEQ ID NO:14.</span>(1) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:38; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (m) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:38; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:13; (n) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:38; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (o) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:39; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8; (p) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:39; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:12; (q) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:39; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:13; (r) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:39; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (s) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:40; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8; (t) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:40; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14; (u) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:41; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:8; or (v) an antibody H chain V region comprising the amino acid sequence represented by SEQ ID NO:41; and an antibody L chain V region comprising the amino acid sequence represented by SEQ ID NO:14.</span>
    </claim-text>
  </claim>
  <claim num="19" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19. Antistoffragmentet som angitt i ett eller flere av kravene 1 til 18, hvori antistoffragmentet er en antistoffragment valgt fra Fab, Fab&lt;1&gt;, F(ab')2, et enkel kjede antistoff (scFv), et dimerisert V region fragment (Diabody), et disulfid-stabilisert V region fragment (dsFv) og et peptid omfattende CDR.</span>19. The antibody fragment as set forth in one or more of claims 1 to 18, wherein the antibody fragment is an antibody fragment selected from Fab, Fab&lt;1&gt;, F(ab')2, a single chain antibody (scFv), a dimerized V region fragment ( Diabody), a disulfide-stabilized V region fragment (dsFv) and a peptide comprising the CDR.</span>
    </claim-text>
  </claim>
  <claim num="20" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20. Det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i krav 27, som er produsert ved en transformant KM8759 (FERM BP-8129) eller KM8760 (FERM BP-8130).</span>20. The human CDR-grafted antibody or antibody fragment thereof as set forth in claim 27, which is produced by a transformant KM8759 (FERM BP-8129) or KM8760 (FERM BP-8130).</span>
    </claim-text>
  </claim>
  <claim num="21" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">21. Et DNA som koder for det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20.</span>21. A DNA encoding the human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 20.</span>
    </claim-text>
  </claim>
  <claim num="22" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">22. En rekombinant vektor som omfatter DNA-et i samsvar med krav 21.</span>22. A recombinant vector comprising the DNA according to claim 21.</span>
    </claim-text>
  </claim>
  <claim num="23" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">23. En ikke-human transformant som produserer det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 eller som kan oppnås ved innføring av den rekombinante vektor i samsvar med krav 22 i en vertcelle.</span>23. A non-human transformant which produces the human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 20 or which can be obtained by introducing the recombinant vector in accordance with claim 22 into a host cell.</span>
    </claim-text>
  </claim>
  <claim num="24" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">24. Ikke-human transformant som angitt i krav 23, hvori transformanten er KM8759 (FERM BP-8129) eller KM8760 (FERM BP-8130).</span>24. The non-human transformant as set forth in claim 23, wherein the transformant is KM8759 (FERM BP-8129) or KM8760 (FERM BP-8130).</span>
    </claim-text>
  </claim>
  <claim num="25" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25. En fremgangsmåte for fremstilling av et antistoff som er i stand til å produsere det humane CDR-podede antistoff eller antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20, som omfatter dyrking av transformanten i samsvar med krav 23 eller 24 i et medium for å danne og akkumulere det humane CDR-podede antistoff eller antistoffragmentet derav i kulturen; og utvinning av antistoffet eller antistoffragmentet fra kulturen.</span>25. A method for producing an antibody capable of producing the human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 20, comprising culturing the transformant in accordance with claim 23 or 24 in a medium for forming and accumulating the human CDR-grafted antibody or antibody fragment thereof in the culture; and recovering the antibody or antibody fragment from the culture.</span>
    </claim-text>
  </claim>
  <claim num="26" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">26. Et humane CDR-podede antistoff eller antistoffragmentet derav hvori det humane CDR-podede antistoff eller antistoff-fragmentet derav som angitt i ett eller flere av kravene 1 til 20 er kjemisk eller genetisk konjugert med en radioisotop, et protein eller et middel.</span>26. A human CDR-grafted antibody or antibody fragment thereof wherein the human CDR-grafted antibody or antibody fragment thereof as set forth in one or more of claims 1 to 20 is chemically or genetically conjugated with a radioisotope, a protein or an agent.</span>
    </claim-text>
  </claim>
  <claim num="27" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">27. Et medikament som omfatter minst ett valgt fra det humane CDR-podede antistoff og antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 og 26 som en aktiv bestanddel.</span>27. A medicament comprising at least one selected from the human CDR-grafted antibody and the antibody fragment thereof as set forth in one or more of claims 1 to 20 and 26 as an active ingredient.</span>
    </claim-text>
  </claim>
  <claim num="28" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">28. Et terapeutisk middel for behandling av CCR4-relaterte sykdommer, som omfatter minst ett valgt fra det humane CDR-podede antistoff og antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 og 26 som en aktiv bestanddel .</span>28. A therapeutic agent for the treatment of CCR4-related diseases, comprising at least one selected from the human CDR-grafted antibody and the antibody fragment thereof as stated in one or more of claims 1 to 20 and 26 as an active ingredient.</span>
    </claim-text>
  </claim>
  <claim num="29" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">29. Det terapeutiske middel som angitt i krav 28, hvori den CCR4-relaterte sykdom er en cancer eller inflammatoriske sykdommer .</span>29. The therapeutic agent as set forth in claim 28, wherein the CCR4-related disease is a cancer or inflammatory diseases.</span>
    </claim-text>
  </claim>
  <claim num="30" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">30. Det terapeutiske middel som angitt i krav 29, hvori canceren er en blodcancer.</span>30. The therapeutic agent as set forth in claim 29, wherein the cancer is a blood cancer.</span>
    </claim-text>
  </claim>
  <claim num="31" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">31. Det terapeutiske middel som angitt i krav 30, hvori blodcanceren er levkemi eller lymfomatose.</span>31. The therapeutic agent as set forth in claim 30, wherein the blood cancer is leukemia or lymphomatosis.</span>
    </claim-text>
  </claim>
  <claim num="32" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">32. Det terapeutiske middel som angitt i krav 29, hvori den inflammatorisk sykdom er akutt eller kronisk luftveis-over-følsomhet eller bronkialastma, atopisk hudsykdom, allergisk rhinitt eller pollinosis.</span>32. The therapeutic agent as set forth in claim 29, wherein the inflammatory disease is acute or chronic airway hypersensitivity or bronchial asthma, atopic skin disease, allergic rhinitis or pollinosis.</span>
    </claim-text>
  </claim>
  <claim num="33" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">33. Det terapeutiske middel som angitt i krav 28, hvori den Th2-medierte immunsykdom er kronisk luftveis-overfølsomhets-astma, bronkial astma, atopisk hudsykdom, allergisk rhinitt eller pollinosis.</span>33. The therapeutic agent as set forth in claim 28, wherein the Th2-mediated immune disease is chronic airway hypersensitivity asthma, bronchial asthma, atopic skin disease, allergic rhinitis or pollinosis.</span>
    </claim-text>
  </claim>
  <claim num="34" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">34. Et diagnostisk middel for CCR4-relaterte sykdommer eller Th2-medierte immunsykdommer, som omfatter minst ett valgt fra det humane CDR-podede antistoff og antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 og 26 som en aktiv bestanddel.</span>34. A diagnostic agent for CCR4-related diseases or Th2-mediated immune diseases, comprising at least one selected from the human CDR-grafted antibody and antibody fragment thereof as set forth in one or more of claims 1 to 20 and 26 as an active ingredient.</span>
    </claim-text>
  </claim>
  <claim num="35" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">35. Det diagnostiske middel som angitt i krav 34, hvori den CCR4-relaterte sykdom er en cancer eller en inflammatorisk sykdom.</span>35. The diagnostic agent as set forth in claim 34, wherein the CCR4-related disease is a cancer or an inflammatory disease.</span>
    </claim-text>
  </claim>
  <claim num="36" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">36. Det diagnostiske middel som angitt i krav 35, hvori canceren er en blodcancer.</span>36. The diagnostic agent as set forth in claim 35, wherein the cancer is a blood cancer.</span>
    </claim-text>
  </claim>
  <claim num="37" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">37. Det diagnostiske middel som angitt i krav 35, hvori blodcanceren er levkemi eller lymfomatose.</span>37. The diagnostic agent as stated in claim 35, wherein the blood cancer is leukemia or lymphomatosis.</span>
    </claim-text>
  </claim>
  <claim num="38" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">38. Det diagnostiske middel som angitt i krav 35, hvori den inflammatoriske sykdom er kronisk luftveis-overfølsomhets-astma, bronkial astma, atopisk hudsykdom, allergisk rhinitt eller pollinosis.</span>38. The diagnostic agent as set forth in claim 35, wherein the inflammatory disease is chronic airway hypersensitivity asthma, bronchial asthma, atopic skin disease, allergic rhinitis or pollinosis.</span>
    </claim-text>
  </claim>
  <claim num="39" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">39. Det diagnostiske middel som angitt i krav 34, hvori den Th2-medierte immunsykdom er kronisk luftveis-overfølsomhets-astma, bronkial astma, atopisk hudsykdom, allergisk rhinitt eller pollinosis.</span>39. The diagnostic agent as set forth in claim 34, wherein the Th2-mediated immune disease is chronic airway hypersensitivity asthma, bronchial asthma, atopic skin disease, allergic rhinitis or pollinosis.</span>
    </claim-text>
  </claim>
  <claim num="40" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">40. En fremgangsmåte for immunologisk påvisning av CCR4 eller en celle som uttrykte CCR4 på celleoverflaten, som anvender det humane CDR-podede antistoff og antistoffragmentet derav som angitt i ett eller flere av kravene 1 til 20 og 26.</span>40. A method for immunological detection of CCR4 or a cell that expressed CCR4 on the cell surface, using the human CDR-grafted antibody and antibody fragment thereof as set forth in one or more of claims 1 to 20 and 26.</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (15)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000042074A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000042074A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-01-15</span>
                    <span class="td style-scope patent-result">2000-07-20</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Anti-ccr4 antibodies and methods of use therefor 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5608039A/en"><a id="link" href="#" class="style-scope state-modifier">US5608039A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-10-12</span>
                    <span class="td style-scope patent-result">1997-03-04</span>
                    <span class="td style-scope patent-result">The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services</span>
                    <span class="td style-scope patent-result">Single chain B3 antibody fusion proteins and their uses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5914110A/en"><a id="link" href="#" class="style-scope state-modifier">US5914110A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-09-07</span>
                    <span class="td style-scope patent-result">1999-06-22</span>
                    <span class="td style-scope patent-result">Smithkline Beecham Corporation</span>
                    <span class="td style-scope patent-result">Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH0853355A/en"><a id="link" href="#" class="style-scope state-modifier">JPH0853355A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-08-12</span>
                    <span class="td style-scope patent-result">1996-02-27</span>
                    <span class="td style-scope patent-result">Taisho Pharmaceut Co Ltd</span>
                    <span class="td style-scope patent-result">Il-5 production-inhibiting agent 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB9501683D0/en"><a id="link" href="#" class="style-scope state-modifier">GB9501683D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-01-27</span>
                    <span class="td style-scope patent-result">1995-03-15</span>
                    <span class="td style-scope patent-result">Glaxo Group Ltd</span>
                    <span class="td style-scope patent-result">Substances and their uses 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6498015B1/en"><a id="link" href="#" class="style-scope state-modifier">US6498015B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-06-07</span>
                    <span class="td style-scope patent-result">2002-12-24</span>
                    <span class="td style-scope patent-result">Icos Corporation</span>
                    <span class="td style-scope patent-result">Methods of identifying agents that modulate the binding between MDC and an MDC receptor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2205007C/en"><a id="link" href="#" class="style-scope state-modifier">CA2205007C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-09-11</span>
                    <span class="td style-scope patent-result">2010-12-14</span>
                    <span class="td style-scope patent-result">Masamichi Koike</span>
                    <span class="td style-scope patent-result">Antibody against human interleukin-5 receptor .alpha. chain 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL125658A0/en"><a id="link" href="#" class="style-scope state-modifier">IL125658A0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-08-18</span>
                    <span class="td style-scope patent-result">1999-04-11</span>
                    <span class="td style-scope patent-result">Hoffmann La Roche</span>
                    <span class="td style-scope patent-result">Ccr-3 receptor antagonists 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR9814957A/en"><a id="link" href="#" class="style-scope state-modifier">BR9814957A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-11-12</span>
                    <span class="td style-scope patent-result">2000-10-03</span>
                    <span class="td style-scope patent-result">Hoffmann La Roche</span>
                    <span class="td style-scope patent-result">
  Treatment of immune diseases mediated by type 2 "t" helper cell with retinoid antagonists
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6355244B1/en"><a id="link" href="#" class="style-scope state-modifier">US6355244B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-11-17</span>
                    <span class="td style-scope patent-result">2002-03-12</span>
                    <span class="td style-scope patent-result">University Of Kentucky Research Foundation</span>
                    <span class="td style-scope patent-result">Methods and compositions for the treatment of psoriasis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2000000219A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2000000219A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-06-26</span>
                    <span class="td style-scope patent-result">2000-01-06</span>
                    <span class="td style-scope patent-result">Chugai Seiyaku Kabushiki Kaisha</span>
                    <span class="td style-scope patent-result">Remedies for hypercalcemic crisis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6245332B1/en"><a id="link" href="#" class="style-scope state-modifier">US6245332B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-01-15</span>
                    <span class="td style-scope patent-result">2001-06-12</span>
                    <span class="td style-scope patent-result">The Board Of Trustees Of The Leland Stanford Junior University</span>
                    <span class="td style-scope patent-result">Modulation of systemic memory T cell trafficking 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1050307A1/en"><a id="link" href="#" class="style-scope state-modifier">EP1050307A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-05-06</span>
                    <span class="td style-scope patent-result">2000-11-08</span>
                    <span class="td style-scope patent-result">Applied Research Systems ARS Holding N.V.</span>
                    <span class="td style-scope patent-result">CCR4 antagonists in sepsis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6989145B2/en"><a id="link" href="#" class="style-scope state-modifier">US6989145B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-03-03</span>
                    <span class="td style-scope patent-result">2006-01-24</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co., Ltd.</span>
                    <span class="td style-scope patent-result">Recombinant antibody and antibody fragment 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005053741A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005053741A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-12-04</span>
                    <span class="td style-scope patent-result">2005-06-16</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co., Ltd.</span>
                    <span class="td style-scope patent-result">Medicine containing genetically modified antibody against chemokine receptor ccr4 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="nplCitations" class="scroll-target style-scope patent-result">
              Non-Patent Citations (2)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      ANDREW ET AL., J IMMUNOL 2001, 166:103-111, "C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential"., Dated: 01.01.0001
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      IMAI ET AL., INT IMMUNOL, 1999, 11:81-88, "Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine"., Dated: 01.01.0001
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (33)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2420835T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2420835T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-04-09</span>
                    <span class="td style-scope patent-result">2013-08-27</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kirin Co., Ltd.</span>
                    <span class="td style-scope patent-result">
  Procedure to control the activity of immunofunctional molecules
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6989145B2/en"><a id="link" href="#" class="style-scope state-modifier">US6989145B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-03-03</span>
                    <span class="td style-scope patent-result">2006-01-24</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co., Ltd.</span>
                    <span class="td style-scope patent-result">Recombinant antibody and antibody fragment 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6946292B2/en"><a id="link" href="#" class="style-scope state-modifier">US6946292B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-10-06</span>
                    <span class="td style-scope patent-result">2005-09-20</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co., Ltd.</span>
                    <span class="td style-scope patent-result">Cells producing antibody compositions with increased antibody dependent cytotoxic activity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003072134A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2003072134A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-02-28</span>
                    <span class="td style-scope patent-result">2003-09-04</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co., Ltd.</span>
                    <span class="td style-scope patent-result">Diagnostics and remedies for interstitial pneumonia 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7691568B2/en"><a id="link" href="#" class="style-scope state-modifier">US7691568B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-04-09</span>
                    <span class="td style-scope patent-result">2010-04-06</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kirin Co., Ltd</span>
                    <span class="td style-scope patent-result">Antibody composition-containing medicament 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1698640B2/en"><a id="link" href="#" class="style-scope state-modifier">EP1698640B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-10-01</span>
                    <span class="td style-scope patent-result">2019-06-19</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kirin Co., Ltd.</span>
                    <span class="td style-scope patent-result">Method of stabilizing antibody and stabilized solution-type antibody preparation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPWO2005035582A1/en"><a id="link" href="#" class="style-scope state-modifier">JPWO2005035582A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-10-08</span>
                    <span class="td style-scope patent-result">2007-11-22</span>
                    <span class="td style-scope patent-result">協和醗酵工業株式会社</span>
                    <span class="td style-scope patent-result">
  Antibody composition that specifically binds to CCR4
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2005053741A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2005053741A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-12-04</span>
                    <span class="td style-scope patent-result">2005-06-16</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co., Ltd.</span>
                    <span class="td style-scope patent-result">Medicine containing genetically modified antibody against chemokine receptor ccr4 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PT2805728T/en"><a id="link" href="#" class="style-scope state-modifier">PT2805728T</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-12-23</span>
                    <span class="td style-scope patent-result">2020-04-08</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">Novel anti-il 13 antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20060034841A1/en"><a id="link" href="#" class="style-scope state-modifier">US20060034841A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-06-07</span>
                    <span class="td style-scope patent-result">2006-02-16</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co., Ltd.</span>
                    <span class="td style-scope patent-result">Method of depleting regulatory T cell 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8329178B2/en"><a id="link" href="#" class="style-scope state-modifier">US8329178B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-02-18</span>
                    <span class="td style-scope patent-result">2012-12-11</span>
                    <span class="td style-scope patent-result">Dana-Farber Cancer Institute, Inc.</span>
                    <span class="td style-scope patent-result">Antibodies against CXCR4 and methods of use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007013627A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2007013627A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-28</span>
                    <span class="td style-scope patent-result">2007-02-01</span>
                    <span class="td style-scope patent-result">Kyowa Hakko Kogyo Co., Ltd.</span>
                    <span class="td style-scope patent-result">Therapeutic agent for b-lymphoma and hodgkin lymphoma 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20080118978A1/en"><a id="link" href="#" class="style-scope state-modifier">US20080118978A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-04-28</span>
                    <span class="td style-scope patent-result">2008-05-22</span>
                    <span class="td style-scope patent-result">Takashi Sato</span>
                    <span class="td style-scope patent-result">Anti-tumor agent 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0718167D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0718167D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-09-18</span>
                    <span class="td style-scope patent-result">2007-10-31</span>
                    <span class="td style-scope patent-result">Cancer Rec Tech Ltd</span>
                    <span class="td style-scope patent-result">Cancer marker and therapeutic target 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8962806B2/en"><a id="link" href="#" class="style-scope state-modifier">US8962806B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-12-28</span>
                    <span class="td style-scope patent-result">2015-02-24</span>
                    <span class="td style-scope patent-result">Dana-Farber Cancer Institute, Inc.</span>
                    <span class="td style-scope patent-result">Humanized monoclonal antibodies and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5552630B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5552630B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-10-24</span>
                    <span class="td style-scope patent-result">2014-07-16</span>
                    <span class="td style-scope patent-result">学校法人  聖マリアンナ医科大学</span>
                    <span class="td style-scope patent-result">
  Medicament for treating or preventing HTLV-I related myelopathy and method for testing the effect of antibody therapy on patients with HTLV-I related myelopathy
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0909906D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0909906D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-06-09</span>
                    <span class="td style-scope patent-result">2009-07-22</span>
                    <span class="td style-scope patent-result">Affitech As</span>
                    <span class="td style-scope patent-result">Antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2010293383B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2010293383B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-09-10</span>
                    <span class="td style-scope patent-result">2014-12-18</span>
                    <span class="td style-scope patent-result">Kyowa Kirin Co., Ltd.</span>
                    <span class="td style-scope patent-result">Medicament including antibody composition specifically bound to human CC chemokine receptor 4 (CCR4) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN102863533B/en"><a id="link" href="#" class="style-scope state-modifier">CN102863533B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-06-21</span>
                    <span class="td style-scope patent-result">2013-12-11</span>
                    <span class="td style-scope patent-result">中国科学技术大学</span>
                    <span class="td style-scope patent-result">Method for humanized reform for antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EA201370030A1/en"><a id="link" href="#" class="style-scope state-modifier">EA201370030A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-08-10</span>
                    <span class="td style-scope patent-result">2013-06-28</span>
                    <span class="td style-scope patent-result">Амген Инк.</span>
                    <span class="td style-scope patent-result">
  BIFUNCTIONAL QUANTITATIVE IN VITRO ANALYSIS OF BINDING TARGETS FOR DETECTING NEUTRALIZING ANTIBODIES TO TARGET ANTIBODIES
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201020738D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201020738D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-12-07</span>
                    <span class="td style-scope patent-result">2011-01-19</span>
                    <span class="td style-scope patent-result">Affitech Res As</span>
                    <span class="td style-scope patent-result">Antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10266599B2/en"><a id="link" href="#" class="style-scope state-modifier">US10266599B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-12-07</span>
                    <span class="td style-scope patent-result">2019-04-23</span>
                    <span class="td style-scope patent-result">Cancer Research Technology Limited</span>
                    <span class="td style-scope patent-result">Antibodies which bind to the human CC chemokine receptor 4 and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR101615474B1/en"><a id="link" href="#" class="style-scope state-modifier">KR101615474B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-12-16</span>
                    <span class="td style-scope patent-result">2016-04-25</span>
                    <span class="td style-scope patent-result">제넨테크, 인크.</span>
                    <span class="td style-scope patent-result">Diagnosis and treatments relating to th2 inhibition 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2723380B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2723380B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-06-24</span>
                    <span class="td style-scope patent-result">2019-08-21</span>
                    <span class="td style-scope patent-result">Stephen D. Gillies</span>
                    <span class="td style-scope patent-result">Light chain immunoglobulin fusion proteins and methods of use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX365592B/en"><a id="link" href="#" class="style-scope state-modifier">MX365592B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-07-06</span>
                    <span class="td style-scope patent-result">2019-06-07</span>
                    <span class="td style-scope patent-result">Univ School St Marianna Medicine</span>
                    <span class="td style-scope patent-result">Therapeutic method and remedy for htlv-1-associated myelopathy patients. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/SG11201601823TA/en"><a id="link" href="#" class="style-scope state-modifier">SG11201601823TA</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-09-13</span>
                    <span class="td style-scope patent-result">2016-04-28</span>
                    <span class="td style-scope patent-result">Genentech Inc</span>
                    <span class="td style-scope patent-result">Methods and compositions comprising purified recombinant polypeptides 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2016107435A/en"><a id="link" href="#" class="style-scope state-modifier">RU2016107435A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-09-13</span>
                    <span class="td style-scope patent-result">2017-10-18</span>
                    <span class="td style-scope patent-result">Дженентек, Инк.</span>
                    <span class="td style-scope patent-result">
  COMPOSITIONS AND METHODS FOR DETECTING AND QUANTITATIVE DETERMINATION OF THE PROTEIN OF CELLS-OWNERS IN CELL LINES AND RECOMBINANT POLYPEPTIDE PRODUCTS
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015179236A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015179236A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-05-21</span>
                    <span class="td style-scope patent-result">2015-11-26</span>
                    <span class="td style-scope patent-result">Pfizer Inc.</span>
                    <span class="td style-scope patent-result">Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20180025897A/en"><a id="link" href="#" class="style-scope state-modifier">KR20180025897A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-07-14</span>
                    <span class="td style-scope patent-result">2018-03-09</span>
                    <span class="td style-scope patent-result">교와 핫꼬 기린 가부시키가이샤</span>
                    <span class="td style-scope patent-result">
  A tumor treating agent comprising an IDO inhibitor administered in combination with an antibody
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2756236C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2756236C2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-06-20</span>
                    <span class="td style-scope patent-result">2021-09-28</span>
                    <span class="td style-scope patent-result">Кимаб Лимитед</span>
                    <span class="td style-scope patent-result">Pd-l1 specific antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2020006155A/en"><a id="link" href="#" class="style-scope state-modifier">MX2020006155A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-12-12</span>
                    <span class="td style-scope patent-result">2020-08-13</span>
                    <span class="td style-scope patent-result">Macrogenics Inc</span>
                    <span class="td style-scope patent-result">Bispecific cd 16-binding molecules and their use in the treatment of disease. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN108250290B/en"><a id="link" href="#" class="style-scope state-modifier">CN108250290B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-02-23</span>
                    <span class="td style-scope patent-result">2024-03-12</span>
                    <span class="td style-scope patent-result">上海捌加壹医药科技有限公司</span>
                    <span class="td style-scope patent-result">N-terminal recombinant protein of CCR4 and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN116731186B/en"><a id="link" href="#" class="style-scope state-modifier">CN116731186B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-07-07</span>
                    <span class="td style-scope patent-result">2023-12-26</span>
                    <span class="td style-scope patent-result">武汉爱博泰克生物科技有限公司</span>
                    <span class="td style-scope patent-result">Anti-human IgG-Fc rabbit monoclonal antibody and preparation method thereof, polynucleotide molecule, expression vector and host cell 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party, ‡ Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10590203B2/en"><a id="link" href="#" class="style-scope state-modifier">US10590203B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-03-17</span>
                    <span class="td style-scope patent-result">Human CDR-grafted antibody and antibody fragment thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3504242B1/en"><a id="link" href="#" class="style-scope state-modifier">EP3504242B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-06-24</span>
                    <span class="td style-scope patent-result">Anti-ox40 antibodies and their uses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3926153B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3926153B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-06-06</span>
                    <span class="td style-scope patent-result">
  Recombinant antibody and antibody fragment thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6215707B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6215707B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-10-18</span>
                    <span class="td style-scope patent-result">
  Anti-CCR4 antibody and use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003072134A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2003072134A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-09-04</span>
                    <span class="td style-scope patent-result">Diagnostics and remedies for interstitial pneumonia 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN116997571A/en"><a id="link" href="#" class="style-scope state-modifier">CN116997571A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-11-03</span>
                    <span class="td style-scope patent-result">Therapeutic binding molecules that bind CCR9 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (2)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        JP2001265144<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2001-08-31</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2003018635A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/JP2002/008828</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2002-08-30</span>
                    <span class="td style-scope patent-result">Human cdr-grafted antibodies and antibody fragments thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2019-12-23</span>
                    <span class="td nowrap style-scope patent-result">CHAD</span>
                    <span class="td nowrap style-scope patent-result">Change of the owner's name or address (par. 44 patent law, par. patentforskriften)</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Owner name</strong>: KYOWA KIRIN CO., JP</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2022-09-12</span>
                    <span class="td nowrap style-scope patent-result">MK1K</span>
                    <span class="td nowrap style-scope patent-result">Patent expired</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu">·</span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Anatomy</div>
          
            <div class="item style-scope dropdown-menu">Chemical class</div>
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          
            <div class="item style-scope dropdown-menu">Chemical group</div>
          
            <div class="item style-scope dropdown-menu">Diseases</div>
          
            <div class="item style-scope dropdown-menu">Drugs</div>
          
            <div class="item style-scope dropdown-menu">Effects</div>
          
            <div class="item style-scope dropdown-menu">Human genes</div>
          
            <div class="item style-scope dropdown-menu">Inorganic materials</div>
          
            <div class="item style-scope dropdown-menu">Methods</div>
          
            <div class="item style-scope dropdown-menu">Natural products</div>
          
            <div class="item style-scope dropdown-menu">Nutrition</div>
          
            <div class="item style-scope dropdown-menu">Polymers</div>
          
            <div class="item style-scope dropdown-menu">Proteins</div>
          
            <div class="item style-scope dropdown-menu">Species</div>
          
            <div class="item style-scope dropdown-menu">Substances</div>
          
            <div class="item style-scope dropdown-menu">Toxicity</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Immunoglobulin Fragments</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">100</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Immunoglobulin Fragments</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">100</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drug</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">therapeutic agent</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">diagnostic agent</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">16</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">diagnostic agent</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">16</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">method</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">90</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vector</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">31</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">immune effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">14</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">detection method</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drug</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">preparation method</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">therapeutic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">active ingredient</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">CCR4 Receptors</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">CCR4 Receptors</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">149</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">effects</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">70</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fragment</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">63</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">proteins and genes</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">63</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">processed proteins &amp; peptides</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">58</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">proteins and genes</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">46</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytokines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">27</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytokines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">27</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Th2 cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">asthma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cytotoxic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mediated effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">21</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">treatment</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">21</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">19</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">diseases, disorders, signs and symptoms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">19</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">immune system disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">19</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">manufacturing process</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Hypersensitivity</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">15</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chemical substances by application</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">15</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">inherited susceptibility to asthma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">15</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">allergic disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">13</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Atopy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Rhinitis allergic</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">allergic rhinitis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chronic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">hypersensitivity</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">skin disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Allergic Seasonal Rhinitis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Interleukin-4</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Seasonal allergy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">hematologic cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">hematopoietic and lymphoid system neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">hybridoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">inflammatory disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">leukemia</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Interleukin-13</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Interleukin-13</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Interleukin-5</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">inhibitory effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cytokine production</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">dependent effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">acute effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Toxicity style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cytotoxic</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">apoptotic process</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">culturing</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">NSP3 Papain-like protease domains</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">inductive effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">depleting effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical group style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">alpha amino acid group</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims</span>
                        <span class="td nowrap style-scope patent-result">50</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">reactivity</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">18</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cytotoxicity</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Toxicity style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cytotoxicity</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.125168989" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.125168989" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=898771286" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>